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A b s tra c t
Squamous intraepithelial neoplasia can develop at several sites in the lower 
genital tract and is associated w ith a risk of malignant progression. W omen 
w ith vulval intraepithelial neoplasia (VIN) usually undergo treatment, not only 
to reduce the risk of subsequent carcinoma but also in an attem pt to alleviate 
symptoms. Current therapies are often unpleasant and frequently ineffective, 
w ith many patients requiring m ultiple treatm ents for recurrent, recalcitrant 
disease. The central role of hum an papillomaviruses (HPVs) in the pathogenesis 
of cervical squam ous neoplasia is now accepted. However, the potential 
mechanisms underlying disease progression in VIN are poorly understood 
m aking it difficult to define a high-risk group of patients in w hom  treatm ent 
w ould be most urgent.
In the work presented in this thesis, viral and genetic events of potential 
importance in the pathogenesis of vulval neoplasia have been identified. Using 
polymerase chain reaction (PCR) oncogenic HPVs were found w ithin pre- 
invasive VIN lesions often, but not exclusively, as viral integrants. It w ould 
appear that viral integration m ight therefore be an early event in vulval 
oncogenesis. RNA in situ hybridisation has shown that the HPV is 
transcriptionally active and could therefore contribute to the subversion of 
normal cellular growth control mechanisms. Comparative genomic 
hybridisation (CGH) has identified chromosomal alterations occurring in a non- 
random  fashion within VIN lesions. Several of these aberrations show striking 
similarities to those seen in invasive disease of both the vulva and cervix and 
m ay help to define a high-risk group of patients. Finally, the use of a novel viral 
vector vaccine to induce cell-mediated immune responses to non-structural 
HPV proteins in women with VIN is described. Vaccination can be associated 
w ith disease regression suggesting that development of effective 
im m unostim ulation could become an additional therapy for wom en w ith VIN.
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Chapter 1 Vulval intraepithelial neoplasia
Intraepithelial neoplasia can develop in several anatomical sites in the lower 
genital tract and carries w ith it the risk of progression to malignancy. Squam ous 
intraepithelial neoplasia of the vulva is difficult to treat and often causes 
troublesome symptoms for the patient. There is a need both to try to 
understand the pathophysiology of this disease as well as to develop new 
treatm ent modalities, thereby providing patients with the possibility of 
individualised management w ith treatm ents that are both more acceptable and 
effective.
1.1 Clinical aspects
1.1.1 Classification of intraepithelial disease of the Vulva
The first description of intraepithelial neoplasia of the vulval skin appears to 
have been in the early 1920's (Hudelo et al, 1922). Since this time the condition 
has been described w ith a som ewhat bewildering variety of terms, some of 
which are listed below.
-  Bowen's disease of the vulva
-  Bowenoid atypia & dysplasia
-  Bowenoid papulosis
-  Erythroplasia of Querat
-  Carcinoma in situ of the vulva
-  Hyperplastic dystrophy with severe atypia
In an effort to reduce clinical confusion, the Terminology Committee of the 
International Society for the Study of Vulvar Disease (ISSVD) recom m ended a 
standardised classification for intraepithelial neoplasia of the vulva (Wilkinson 
et al., 1986). This classification is detailed in (Table 1-1). This thesis will be 
confined to intraepithelial neoplasia of the squam ous type known as vulval 
intraepithelial neoplasia.
The classification for squamous intraepithelial neoplasia of the vulva is 
analogous in terminology to the 'three-tier' (cervical intraepithelial neoplasia or
17
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CIN) system employed by some countries for disease of the uterine cervix 
(Richart, 1973). Some investigators have extrapolated this similarity, referring to 
VIN 2 /3  as 'high-grade7 disease in a similar fashion to the 'tw o tier' Bethesda 
classification (Solomon et al., 2002) for cervical disease. In contrast to disease in 
the cervix, the majority of preinvasive lesions diagnosed are high-grade lesions, 
usually VIN 3. Although progression from VIN 1 to VIN 3 / SCC has been 
documented (Barbero et al., 1990), clear evidence for a stepwise progression is 
lacking and the relevance of a diagnosis of VIN 1 therefore rem ains 
controversial. This may reflect the heterogeneous nature of disease that falls 
w ithin this classification. Difficulties in the histological grading of lesions will 
be discussed in detail (section 1.1.1.1)
a. Squamous b. Non-squamous
VIN 1 Paget’s disease
VIN 2 Melanoma in situ
f  High-grade
VIN 3
Table 1-1 -  1986 ISSVD classification of intraepithelial neoplasia of the vulva with 
additional annotation showing so-called ‘high-grade* disease 
1.1.1.1 Histological subtypes of VIN
In addition to the histological grading system described above, VIN may be 
subdivided on a morphological basis into similar categories to vulval SCC. The 
majority of cases show classic features of lower genital tract intraepithelial 
neoplasia, w ith immature cells showing a high nuclear to cytoplasmic ratio, 
hyperchrom atic nuclei and occasional mitotic figures extending most of the way 
through the epithelium. The strong association of this type of VIN w ith hum an 
papillom avirus (HPV) infection will be discussed later (section 1.1.4.1). This 
group has been further divided into 'basaloid' (undifferentiated) and 'w arty ' 
(Bowenoid) sub-types (Park et a l, 1991a) dependent on the degree of 
differentiation, koilocytosis and surface contour. There would appear to be 
considerable overlap between these two sub-types with many lesions show ing a 
'm ixed' histological picture (Hording et al., 1995).
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a) b)
Figure 1-1. 'Classical* or 'undifferentiated' vulval intraepithelial neoplasia
a) H/E section seen  at low power showing normal stratified squam ous epithelium on the left
adjacent to full thickness VIN (VIN 3) on the right of the image
b) Adjacent section stained with the proliferation marker MIB1. In the normal vulval skin 
proliferation is confined to the basal layer of the epidermis. In contrast, within the a reas  of 
VIN 3, proliferation is seen  throughout the full thickness of skin.
c) High-grade VIN (VIN 3) - immature cells showing a high nucleancytoplasm ic ratio,
hyperchromatic nuclei and occasional mitotic figures extending the whole way through the 
epidermis. This type of VIN shows a strong association with human papillomavirus infection, 
notably by the oncogenic type 16.
(Images a) and b) courtesy of Dr R. Moseley, Addenbrooke's Hospital, Cambridge)
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Figure 1-2. 'Differentiated' VIN
a)Low power view of H/E section. Normal vulval skin evident on the right hand side of the 
image. Left hand sides shows 'differentiated' VIN. The diagnosis of 'differentiated' VIN may 
be difficult.
b) Area indicated by box at higher magnification to show features of ’differentiated’ VIN. 
Preservation of epithelial maturation in upper layers with atypia limited to basal cell layers 
(indicated by arrows). Abnormal keratinisation seen  in lower layers of epiderm is (K). 
'Differentiated' VIN accounts for <5% prospectively identified VIN and is commonly 
associa ted  with non-neoplastic epithelial disorders or keratinising SCC. Unlike 'classical' 
VIN, ’differentiated' VIN is commonly HPV-negative.
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A second, less common morphological subtype has also been described and is 
referred to as 'differentiated' or 'sim plex-type' VIN. In contrast the 'classic' or 
'undifferentiated' type of VIN, these lesions show minimal atypia of the upper 
cell layers w ith proliferation accompanied by preservation of epithelial 
m aturation and atypia limited to basal cell layers. Differentiated VIN rarely 
occurs in isolation and is usually associated with non-neoplastic epithelial 
disorders (NNED) such as lichen sclerosus and squam ous cell hyperplasia 
(Leibowitch et al, 1990; Rouzier et a l, 2001) or the keratinising form of vulval 
SCC. Differentiated VIN is difficult to diagnose and accounts for <5% of 
prospectively identified VIN (Haefner et a l, 1995). Cases tend to be negative for 
HPV and show increased suprabasal expression of p53, which is of potential 
use in establishing the diagnosis (Yang et a l, 2000; Al-Ghamdi et a l, 2002). The 
different types of VIN are illustrated in Figure 1-1 and Figure 1-2.
1.1.2 Epidemiology
VIN has an incidence of 2.1/100,000 w om an years (Sturgeon et a l, 1992). 
Originally considered an uncom m on disease of the older woman, several 
authors have recently reported an increasing incidence particularly in younger 
women. In their retrospective study of 113 wom en with VIN, Jones and Rowan 
found a fall in the mean age of affected women from 52.7 years for the period 
1961-80 to 35.8 years for the period 1981-93 (Jones et al, 1994). This finding has 
recently been confirmed by other investigators in the southern hemisphere 
(Thuis et al, 2000), whilst data from European institutions have shown a three- 
to fourfold increase in the incidence of VIN (Herod et al, 1996; Joura et al, 
2000). The result of an institutional retrospective study comparing the incidence 
of VIN 2 /3  for two four year periods in consecutive decades (1985-88 and 1994- 
97) dem onstrates the dramatic increase for the younger age group (Joura et al, 
2000 - illustrated in figure 1-3).
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Figure 1-3. Incidence of h igh-grade VIN from  tw o four year p erio d s in c o n se c u tiv e  
d e c a d e s . Arrow indicates dramatic increase in younger age group (Joura e t al., 2000)
Population data from Norway has also demonstrated an increase in the 
incidence of intra-epithelial neoplasia over the last 40 years (Iversen et al., 1998). 
In contrast to the institutional studies already discussed, the authors found this 
increase to be spread across all age groups. They therefore suggest that the 
increase in incidence may simply represent increased awareness and 
subsequent diagnosis of VIN. Whilst institutional studies are particularly prone 
to observer and referral bias, such criticisms do not readily explain the 
preponderance of younger cases found in these studies. Furthermore, 
additional population data from the Surveillance, Epidemiology and End 
Results (SEER) program in the USA not only reveals a doubling in the rate of 
VIN but confirms that the largest (threefold) increase was seen for those women 
under the age of 35 years (Sturgeon et al, 1992).
An increase in pre-invasive disease might be expected to be accompanied by a 
subsequent rise in the incidence of invasive squamous cell carcinoma (SCC) of 
the vulva. Until recently this effect had not been observed (Sturgeon et al, 1992; 
Iversen et al, 1998), lending further support to the view that the 'reported' rise 
in VIN was artefactual. Although latency could delay the appearance of such an 
effect, progression from VIN to carcinoma appears to be faster than for SCC of 
the cervix, usually occurring in less than eight years (Jones et al, 1994; Herod et 
al, 1996; Thuis et al, 2000). A retrospective study (Jones et al, 1997) comparing
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the rates of SCC of the vulva between two cohorts two decades apart (1965-74 
and 1990-94) showed a significant increase in the proportion of SCC cases 
younger than 50 years of age (1 of 56 vs. 12 of 57; p<0.001). Although this data 
is institutional, the geography and provision of services of the country 
concerned (New Zealand) would support a true increase in incidence. 
Population data from the USA (1973-98) is now available to support this early 
study (Howe et al, 2001). Vulval carcinoma is one of only twelve cancers whose 
incidence rates have increased from 1992-98. In contrast to the usual older age 
group for this carcinoma, the increase was predominantly in wom en under 65 
years of age. More recently still, a retrospective Canadian study confirmed a 
significant rise in vulval SCC affecting young women (<40years) over the study 
period 1975-1998 (Al-Ghamdi et al., 2002).
1.1.3 VIN as a precursor of malignancy
The natural history of VIN is controversial. There seems little doubt that high- 
grade disease represents a true pre-invasive lesion but the quoted risk of 
progression varies greatly between studies (Table 1-2).
Study Progression 
(Number o f  cases/cohort)
% Mean age Interval
/years
Comment
(Buscema et al., 1980) 2/102 2.0 19 n/a immunosuppressed
(Crum et al., 1984) 5/39* 12.8 55 <1-10* median < 1 year
(H erding et al., 19 9 1) 3/19 15.8 n/a 3-5
(Jones et al., 1994) 11/113 9.7 53 2-18 median 5 years
(Herod et a t,  1996) 9/133 6.8 49 2-9 median 4.5yr
(Kuppers et al., 1997) 4/59 6.8 n/a n/a
(Thuis et al., 2000) 1/40 2.5 30 4
(M cNally et al., 2002) 3/101 3.0 n/a 6-7
Overall 7.4 %
Table 1-2. Varying rates of progression for high-grade VIN. * It should be noted that 
progression within a year may imply poor initial treatment or a missed diagnosis and that 2/41 
patients in this study were lost to follow-up.
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W hat is not apparent from this data are that most studies involved populations 
of treated individuals and that progression in these studies therefore represents 
a risk of malignancy despite treatment. Data from untreated populations are 
scarce and unlikely to be acquired in the future. Jones et al provide an insight 
into the possible true natural history of disease (Jones et a l, 1994). Their study 
includes eight untreated individuals. When these patients are considered as a 
separate group, the risk of m alignant progression appears rather more alarm ing 
at 87.5% (7/8 patients progressed to malignancy, six within 8 years). This 
com pared to a figure of 3.8% in the treated group. Caution m ust be used w hen 
interpreting this difference as half the untreated group had previously been 
treated w ith pelvic radiotherapy and could be regarded as being at increased 
risk for lower genital tract malignancy. However, it remains likely that the true 
rate of progression of untreated VIN will be considerably in excess of the oft- 
quoted risk of 5-10%. Others have estimated the relative risk of developing 
anogenital carcinoma following a diagnosis of VIN to be as high as 29.8 (95%CI 
7.3-263.4) (Sherman et a l, 1988).
The hypothesis that aggressive treatm ent of VIN may be reducing the apparent 
risk of vulval SCC is supported by studies of excisional biopsy specimens. 
Detailed histopathological assessment of specimens from lesions thought pre- 
operatively to be clinically intraepithelial (ie. VIN) has shown invasive 
carcinoma to be present in 16.4 to 22% of cases (Chafe et al, 1988; H ording et al, 
1995; Modesitt et al, 1998; Husseinzadeh et al, 1999; Thuis et al, 2000). The 
majority of invasive lesions found represent superficial invasion (<lm m , FIGO 
stage 1A) and would be expected to have been cured by excisional treatm ent 
alone. Attempts to selectively demonstrate invasive areas using 
imm unohistochemistry for Ki-67 (a proliferation marker) have so far been 
unsuccessful (Modesitt et al, 2000).
The incidence of SCC of the vulva in younger women is increasing (section
1.1.2). In the cohort study already described (Jones et al, 1997), wom en below 
the age of 50 years were significantly more likely to have VIN associated with 
their tum our than women over 50 years (10/13 vs. 13/100; p<0.001). Tum ours
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w ith adjacent VIN are usually 'basaloid' or 'w arty7 in type and frequently 
associated with HPV infection (Toki et al., 1991; H ording et ah, 1993; Kurm an et 
ah, 1993; Al-Ghamdi et al, 2002). W hen taken together, these findings support a 
role for undifferentiated VIN in the development of SCC of the vulva in the 
younger patient. Even stronger evidence of VIN as a precursor lesion is now 
available from molecular genetic studies. X-chromosome inactivation analysis 
(Tate et al, 1997; Rosenthal et a l, 2002) and microsatellite markers (Rosenthal et 
al., 2002) have been used to dem onstrate the clonal nature of VIN and SCC 
associated with VIN in both contiguous and multifocal disease (section
1.2.3.2).
1.1.3.1 Spontaneous regression of high-grade disease
The recognition that 'severe atypia' could be reversible led to the use of 
separate descriptions such as 'Bowenoid papulosis' (Wade et al., 1979) and 
'Reversible vulval atypia' (Friedrich, 1972). Concern regarding the risk of 
malignant progression has led to aggressive intervention with many clinicians 
choosing to treat high-grade disease surgically (either by ablative or excisional 
methods). Limited data therefore exists regarding the rate of spontaneous 
regression of high-grade disease. In early studies of 'VIN' (Friedrich et al., 1980; 
Bernstein et al, 1983), spontaneous regression was surprisingly common (5/9  
and 5/13 untreated individuals respectively) although investigators were still 
unable to predict those cases in w hom  regression was most likely (Bernstein et 
al., 1983). The results m ust be interpreted with some caution given the 
inconsistent classifications used at the time, but in retrospect these individuals 
share many of the characteristics (Table 1-3) identified in a more recent review 
of 14 cases of VIN 2-3 in which spontaneous regression occurred (Jones et al., 
2000). Despite the lack of a histological endpoint in this study (regression was 
'confirm ed' by vulvoscopy alone), it is interesting to note the timescale for 
regression in these cases. The m edian time from diagnosis to complete 
disappearance of the lesions was 9.5 months.
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Common features of high-grade disease 
associated with spontaneous regression
Young (*median age 19.5 -21 years)
Non-white
Associated with pregnancy/recent pregnancy 
Atypical condyloma/recent condyloma 
Multifocal 
Papular
Hyperpigmented lesion
Table 1-3. Clinical features assosciated with disease regression.
(‘ median age from Friedrich etal., 1980; Jones etal., 2000)
Given the increasing incidence of VIN am ongst younger women and the 
m orbidity (physical and psychosexual) associated w ith surgical treatm ents, 
these features are especially relevant. It w ould seem appropriate to consider a 
period of 1-2 year's observation (by an experienced clinician) for such a patient. 
The discovery that cytological regression in CIN is preceded by clearance of 
HR-HPV infection types (Nobbenhuis et a l, 2001), would suggest that HPV 
testing (qualitative or quantitative) may be prognostically useful, at least for 
multifocal undifferentiated VIN.
1.1.4 Aetiology and pathogenesis of VIN
It is likely that 'VIN' may actually encompass at least two pathological entities 
(section 1.1.1.1). The vast majority of studies involve 'classical' or 
undifferentiated VIN. In this section, aetiological factors and aspects of disease 
pathogenesis will be considered further.
1.1.4.1 Human papillomavirus infection and VIN
In common with intra-epithelial neoplasia at other ano-genital sites, 'classical' 
VIN shows a strong association w ith HPV infection. The potential mechanisms 
of HPV oncogenesis will be discussed at a later point (section 1.2.1). Before 
considering the reported association of VIN and HPV, it is im portant to
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understand that the reported incidence of HPV infection will vary with the 
method chosen to make this diagnosis.
1.1.4.1.1 The detection o f HPV infection
In the simplest studies HPV infection was assumed from the finding of 
koilocytes on histological examination of lesional tissue. Histological 
assessment of VIN lesions suggests that 31-78% of lesions are associated with 
HPV infection (Herod et al., 1996; I.S.G.V.D., 1996; McNally et al, 2002).
Figure 1-4. K oilocytes. Hyperchromatic, irregular nuclei and vacuolated cytoplasm giving the 
classical ‘halo’ type appearance to the cell. The appearance of koilocytes on a biopsy from the 
lower genital tract is highly suggestive of human papillomavirus infection.
Although koilocytosis is still taken by many to be pathognomonic of HPV 
infection, studies relying on this feature may be misleading. With the advent of 
more sensitive molecular biological techniques e.g. PCR, it has been shown that 
this feature does not accurately allow the clear distinction of the subset of HPV 
positive VIN lesions (Haefner et al, 1995).
The understanding of DNA structure provided the opportunity for the 
development of more sensitive and specific methods of HPV detection. In the 
Southern hybridisation technique, crude or extracted DNA is transferred to a 
membrane and probed with HPV specific probes, whilst DNA:DNA in situ 
hybridisation provided a means to directly demonstrate viral DNA in clinical 
tissue specimens. However, both these techniques demand the use of type- 
specific probes and studies were therefore often limited to the detection of only
4
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a few virus types. Nevertheless, early investigation of VIN still dem onstrated a 
high rate (75%) of HPV infection in VIN. If analysis was limited to VIN 3 lesions 
this rate increased further to 84% (Buscema et al, 1988).
For m any years the preferred technique to detect HPV infection has been the 
polymerase chain reaction or PCR (Mullis et al., 1987; Saiki et al, 1988). This 
technique is associated with a m uch greater sensitivity than those already 
detailed (Table 1-4).
Technique__________________ Approximate sensitivity
In situ hybridisation >25 viral copies / cell
Southern blot >1 viral copies /100 cells
Polymerase chain reation >10 viral copies / 106 cells
Table 1-4. Comparative sensitivities of HPV detection techniques (Nuovo, 1990)
PCR primers can be constructed using low annealing tem peratures and 
degenerate base sites to perm it mismatch pairing of bases, thereby enabling one 
set of primers to amplify m ultiple different HPV types. Two main degenerate 
prim er systems are currently in use for genital HPV typing, namely the 
MY09/11 primers (Manos et al, 1989) and GP5+/6+ primers (de Roda H usm an 
et a l, 1995). Both target regions w ithin the LI open reading frame (ORF) of 
genital HPV types (section 1.2.1.2). The MY09/11 system was developed first 
and amplifies a region of -450 base pairs, enabling the detection of <100 copies 
of the HPV genome for a broad range of genital HPV types. The GP5+/6+ 
system amplifies a shorter -150 base sequence, localised within the sequence 
amplified by the MY09/11 primers. Both primer sets have been widely used in 
genital HPV identification and typing and have been shown to be both reliable 
and reproducible (Jacobs et al., 1999). The GP5+/6+ system has a potential 
advantage in that reducing the size of the target sequence should lead to 
im proved sensitivity. This may be of particular importance if the target DNA 
has been poorly preserved following formalin fixation. A recently designed 
PCR system (short-fragment PCR, or SF-PCR) has taken this strategy even 
further, utilising a target of only 66 bases (Kleter et al, 1999). An alternative
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means to increase the sensitivity for HPV detection is the use of a two-step 
nested-PCR. The design of the MY09/11 and GP5+/6+ primers allows for a 
nested reaction of MY09/11 followed by GP5+/6+ and a single tube real-time 
system using these pairs has been described (Strauss et al, 2000). The problem  
of contamination (common to all PCR systems) is of particular relevance w hen 
using nested-PCR.
The identification of specific HPV types amplified by degenerate PCR systems 
can be achieved in a variety of ways including: direct sequencing (Smits et al., 
1992); restriction-enzyme digestion (Adams et al, 1996); type-specific PCR (van 
den Brule et a l, 1990) and type-specific oligonucleotide hybridisation (Ylitalo et 
al, 1995). In this thesis direct sequencing was employed. The sequence obtained 
from the PCR product was com pared against all known HPV sequences 
available on-line from the Los Alamos National Laboratory Bioscience Division, 
USA (http://hpv-w eb.lanl.gO v/V  Direct sequencing is not limited by the 
availability of type-specific probes or prim ers and provides for accurate 
identification of whichever HPV type has been amplified. However, the 
alternative m ethods have the advantage of facilitating detection of infection 
w ith m ultiple HPV types. Sequencing the PCR product will miss such infections 
as the sequence obtained represents the predom inant PCR product present 
following the reaction. An attractive option for typing multiple infections is the 
reverse line blot method. In this technique the biotinylated PCR product is 
hybridised to an array of immobilised type specific probes, before detecting 
bound probe with a streptavidin-conjugated enzyme (Gravitt et a l, 1998). A 
recent developm ent combines this technique with the SF-PCR described earlier, 
perm itting the simultaneous detection of 16 different HPV types from the 22 
base inter-prim er region of the PCR product. Although not widely available, 
this technology is extremely promising. The application of microarray 
technology to HPV typing may also be of relevance (Cho et al, 2003).
A commercially available alternative to PCR detection is the Hybrid-capture II 
system (HCII). HCII is based on chemiluminescent detection of hybrids, 
between RNA probes and target DNA that have been antibody-captured
29
Introduction
(Clavel et al, 1998). HCII differentially detects a group of 13 high-risk and 5 
low-risk HPV. Precise viral typing is not possible, although contamination is 
less of a problem than w ith PCR. The HCII system does however require test 
specific equipment.
1.1.4.1.2 HPV infection and VIN: PCR-based and immunological evidence
Estimates of the prevalence of HPV infection in high-grade VIN based on PCR 
m ethodology vary between 72 and 100% (Haefner et al, 1995; H ording et a l, 
1995; van Beurden et al., 1995; Madeleine et al, 1997; van Beurden et a l, 1998a) 
and indeed some investigators have claimed that "VIN 3 always reflects 
underlying HPV infection" (Hording et a l, 1993). The virus also appears to be 
transcriptionally active with mRNA from the major oncoproteins being 
detected using reverse-transcriptase PCR (RT-PCR) (van Beurden et a l, 1995). 
Although initially believed that HPV-associated VIN was confined to the 
'younger' age group, Haefner and colleagues dem onstrated HPV positive cases 
in the eighth decade of life (Haefner et al, 1995).
The association between VIN and HPV infection is similar to that seen for 
cervical disease (CIN). There are, however, some im portant differences. VIN 3 
is usually associated w ith infection by a single HPV type, namely the oncogenic 
type 16. This type appears to account for ~86% of infections (Haefner et a l, 1995; 
H ording et al, 1995; van Beurden et al, 1995; van Beurden et a l, 1998a; 
Rosenthal et al, 2001), with HPV types 18, 31 and 33 making up the rem ainder 
(Haefner et al, 1995; Hording et a l, 1995; Rosenthal et al, 2001). Infection with 
m ultiple HPV types is uncommon in VIN (Hording et al, 1995; Madeleine et al, 
1997). In contrast, studies of cervical disease have demonstrated a w ide variety 
of HPV types and have shown m ultiple infections to be common (Bosch et al, 
1995; Chang et al, 1997; Kleter et al, 1999). It is also interesting to note that one 
PCR-based study failed to demonstrate infection with the common HPV types 
in 101 normal vulval biopsies (Hording et al, 1993). In cervical specimens 
transient HPV infection often in the absence of dysplasia is a common 
occurrence, particularly in young women (Ho et al, 1998; W oodman et a l, 2001).
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W hether these differences reflect variations in the m icroenvironment or host 
imm une response between cervix and vulva remains to be seen.
Serological evidence from case controls also lends support to the role of HPV 
infection in the pathogenesis of VIN. Although the low participation rates for 
studies is a source of potential bias, seropositivity for HPV 16 is associated w ith 
an increased risk of VIN with odd ratios of 3.6-13.4 (Hildesheim et a l, 1997; 
Madeleine et al, 1997).
A causal relationship between HPV infection and cervical neoplasia is now 
accepted (Bosch et al, 2002). Despite the evidence of a strong association 
between VIN 3 and oncogenic HPV infection, there are currently insufficient 
data to support HPV infection as a necessary cause of vulval neoplasia.
1.1.4.1.2.1 HPV and differentiated VIN’
In contrast to 'classical' VIN, differentiated VIN is rarely associated w ith HPV 
infection (Haefner et al, 1995; Yang et a l, 2000). The role of HPV in the 
pathogenesis of neoplasia will be discussed in detail later, but it is interesting to 
note that this form of VIN is associated with increased suprabasal p53 protein 
detected by immunohistochemistry (Yang et a l, 2000). Such expression may be 
taken as circumstantial evidence of m utations in the p53 gene, w ith the 
resultant production of a m utant p53 protein that is more stable than w ild-type 
p53 (Baas et al, 1994). Inactivation of p53 function is certainly a potentially 
im portant step in carcinogesis. In vitro studies of cervical carcinoma cell lines 
suggest that p53 mutations are only found in HPV-negative cells lines, arising 
as an alternative to the effects of high-risk HPV oncoproteins on p53 (section 
1.2.1.4). This evidence would therefore further support differentiated VIN as a 
separate entity to 'classical' VIN.
1.1.4.2 Other factors
1.1.4.2.1 Other anogenital intraepithelial neoplasia (AGIN)
In a retrospective review of 133 patients w ith VIN, up to half were found to 
have coexistent or previous AGIN (Herod et al, 1996). When VIN 3 alone is 
considered this proportion may increase further to 66% (van Beurden et al,
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1995). Such a high incidence of multicentric disease favours the possibility of 
HPV infection being the common cause for such lesions. Indeed, HPV infection 
is significantly (p=0.01) more common in multicentric intra-epithelial neoplasia, 
as opposed to unicentric VIN3 (van Beurden et al., 1995). Infection is not, 
however, always with the same HPV type. In one fifth of wom en w ith 
multicentric disease, van Beurden and colleagues found differing HPV types at 
the various affected sites (van Beurden et a l, 1998a).
Patients with CIN are also at an increased risk of subsequently developing VIN. 
Following an analysis of nearly four and a half thousand patients treated for 
CIN 3 w ith cold-knife cone excision and reviewed for 18 years, Reich and 
colleagues estimated that VIN may develop in 0.3% of cases (Reich et al, 2001).
1.1.4.2.2 Immunosuppression
The increasing incidence of im m unosuppression following allogenic organ 
transplantation has highlighted the influence of host immune response in the 
genesis of intraepithelial neoplasia of the lower genital tract. Such patients are 
often younger than usual with multifocal, multicentric disease (Leckie et al., 
1977). Idiopathic isolated CD4 cell deficiency can also occur and may be 
associated w ith recurrent VIN (Park et al., 1994a). More recently patients w ith 
the hum an immunodeficiency virus (HIV-1) have been shown to have a 
significantly increased risk of vulval neoplasia (condylomata, intra-epithelial 
and invasive disease) (Conley et ah, 2002). Defects in cellular immune responses 
may predispose such individuals to HPV infection and subsequent AGIN. The 
host immune response to HPV will be considered in more detail later in this 
chapter (section 1.2.2).
1.1.4.2.3 Smoking
The incidence of smoking in association with VIN varies between studies but 
can be as high as 82% (Modesitt et al., 1998). Jones et al found 60% of VIN 3 
patients in their study to be smokers, a figure which was twice the background 
population rate at the time (Jones et al., 1994). The role of smoking in the 
aetiology of VIN is supported by case control studies of HPV seroprevalence
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(Hildesheim et al., 1997; Madeleine et al., 1997). The effect of smoking on the risk 
of vulval neoplasia appears to be additive to that of HPV infection (Madeleine 
et al., 1997).
1.1.5 The presentation of VIN
Most women (~45-65%) with VIN suffer from pruritus or irritation (Bernstein et 
al., 1983; Barbero et al, 1990; Jones et al., 1994; Herod et al., 1996). The reporting 
of an atypical area on the vulva is another common presentation, occurring in 
up  to one third of cases (Buscema et al., 1980; Herod et al., 1996). It is im portant 
to note that up  to one fifth of cases may be asymptomatic (Buscema et al., 1980; 
Bernstein et al., 1983; Chafe et al., 1988) and are diagnosed by chance during 
clinical examination for another purpose, e.g. at the time of cervical screening. 
The high incidence of multicentric disease means that particular attention 
should be paid to those patients referred for the assessment of intraepithelial 
neoplasia at other sites. Many patients are embarrassed to discuss genital 
symptoms and a delay in presentation to an appropriate clinic is commonplace. 
In their small study of 65 patients, Bernstein et al. found that 40% of patients 
had had symptoms for > 2 years (Bernstein et al., 1983). The reticence of patients 
is not the only cause for delay in diagnosis and appropriate treatment. Almost 
three-quarters of women may have seen more than one physician prior to an 
appropriate diagnosis being m ade (Bernstein et al., 1983) and 18% of patients 
w ait more than 6 months for referral to a specialist (Jones et al., 1994). Many 
vulval lesions are treated w ithout a histological diagnosis being m ade e.g. 
condylomata, lichen sclerosus. VIN should be considered where such lesions 
fail to respond to conventional therapy.
1.1.6 Making the diagnosis of VIN
1.1.6.1 Vulvoscopy
Inspection of the vulva under magnification (vulvoscopy) is the cornerstone of 
diagnosis for VIN. Almost one half of cases will show white lesions on the 
vulva (Barbero et al., 1990) but in practice the appearance of VIN is extremely 
variable. Red, pigmented, pale, flat, raised, warty or eroded lesions have all
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been described (Ridley et al., 1992). The application of 5% acetic acid to the 
vulva has been advocated in an attem pt to improve detection of VIN lesions. In 
contrast to the cervix, application of acetic acid to the vulva m ust be prolonged 
-  for as long as 5 minutes -  and is probably more useful for those lesions 
lacking in surface keratin. The incidence of acetowhite lesions in cases of VIN 
varies considerably (10-40%) between studies (Barbero et al., 1990; H erod et al.,
1996). Care m ust be taken w hen using this technique both as m any patients 
w ith soreness/fissures may find the acid extremely uncomfortable and because 
the technique has limitations in its specificity. In a study of 40 healthy female 
volunteers, it was noted that the vestibule became acetowhite in all cases (van 
Beurden et al., 1997). Twelve patients showed acetowhite change outside the 
vestibule. These areas showed a weak association with HPV DNA as detected 
by PCR (p=0.055) but were otherwise normal. Failure to appreciate this lack of 
specificity may lead to unnecessary and uncomfortable biopsies being 
performed.
W hen considering the diagnosis of VIN it is helpful to remember that 
approximately two-thirds of cases have lesions that affect non-hair bearing skin 
and a similar proportion are unifocal (I.S.G.V.D., 1996). Multifocal lesions are 
m ore common in young (< 40years) patients (Bernstein et al., 1983) in w hom  the 
disease is often associated w ith HPV infection. The posterior third of the vulva 
is commonly affected, with the inferior border of the right labium majus 
reported as the most frequent site for VIN (Bernstein et al., 1983). Particular care 
should be taken when inspecting the periurethral and perianal regions. Failure 
to recognise a n d /o r  treat disease in these areas may account for the apparent 
excess risk of progression to malignancy reported for these sites (Jones et al.,
1994).
1.1.6.2 Outpatient biopsy
At present, a suspicious lesion identified at vulvoscopy will usually prom pt a 
biopsy from the attendant clinician. The vast majority of specimens are obtained 
under local anaesthesia with a punch biopsy (illustrated overleaf).
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Figure 1-5. Keyes punch used to obtain vulval biopsy. Circular cutting punch available in a 
variety of sizes but usually used at 4-5mm diameter. After infiltration with local anaesthetic, 
punch is inserted perpendicular to lesion and with rotating motion. Punch does not need to be 
used to full depth, a s  biopsy only needs to include epiderm is and dermo-epidermal junction.
Local anaesthesia can be achieved by infiltration, often using a mixture of local 
anaesthetic and vasoconstrictive agents. The use of topical anaesthetics (such as 
EMLA cream) alone is rarely sufficient to allow the biopsy to be performed, but 
makes infiltration of this well-innervated area far more acceptable to the 
patient. Although this technique has largely replaced excision biopsy in the 
initial diagnosis of vulval neoplasia, care must still be taken when clinically 
suspicious lesions are subsequently found to be histologically negative on 
punch biopsy. False negative biopsies of frankly invasive lesions have been 
reported (Crawford et al., 1995) and excisional biopsy should therefore be 
considered where there is a marked discrepancy between clinical and 
histological specimens obtained at punch biopsy.
1.1.6.3 Alternative techniques for the diagnosis of vulval neoplasia
1,1.6.3.1 Vulval cytology
The potential to obtain a diagnosis without biopsy is attractive to all clinicians 
who look after women with vulval disease. However, the role of vulval 
cytology remains controversial. Whilst undoubtedly a successful tool for 
detecting premalignancy of the uterine cervix, increased keratinisation of the
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vulval skin makes obtaining a representative sample more difficult than  at 
other sites. New developments in cytological techniques such as the use of 
cytobrushes and liquid-based cytology (LBC) may help to overcome such 
difficulties in the future. In a small study of 23 patients, Levine and colleagues 
(Levine et al., 2001) prepared Papanicolaou stained slides from LBC specimens 
obtained from vulval lesions using a cytobrush. All subjects subsequently 
underw ent vulval biopsy. Vulval LBC detected all cases of known dyskaryosis. 
However, 2 of 28 samples (7.1%) were inadequate for assessment and over one 
third of dyskaryotic lesions differed by more than one grade from the 
subsequent histological specimens. Interestingly, the two inadequate specimens 
were from patients with lichen sclerosus and lichen simplex, two conditions 
that are frequent differential diagnoses in suspected cases of VIN. For cytology 
to have an impact on current clinical practice the negative predictive value of a 
'vulval smear' will have to improve.
7. L 6.3.2 5-aminolevulinic acid
Photodynamic therapy is commonly used in the field of dermatology and has 
recently been described as a treatm ent for VIN (section 1.1.7.3.2). It involves the 
use of 'photosensitising agents', which may either be applied topically or 
adm inistered systemically. The agent of choice is 5-aminolevulinic acid (5- 
ALA), which induces the production of protoporphyrin IX, a precursor of 
porphyrin. Optim um  ratios of photosensitiser in tum our versus normal tissue 
are achieved at approximately four hours post administration (independent of 
the route of administration). W hen viewed under blue light (380-440nm), 
neoplastic tissue exhibits pronounced red fluorescence, which may enable 
enhanced detection and localisation of neoplastic disease. Indeed, for the 
detection of bladder cancer, this technique appears to be more sensitive that 
conventional white light cystoscopy (Koenig et al., 1999). This concept has 
undergone limited evaluation for vulval neoplasia. Fluorescence is not 
exclusive to areas of vulval neoplasia and is also seen in normal introital skin as 
well as the distal vagina when observed 4-5 hours after topical application 
(Hillemanns et al., 2000). The accurate identification of VIN 3 is still possible
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w hen the interval post-application of 5-ALA is reduced to 2-3 hours (Fehr et al., 
2001) and this may help to reduce such 'false-positive7 background 
fluorescence. Pigmented or hyperkeratotic lesions may not be suitable for 
assessment by this technique as they are associated w ith reduced levels of 
fluorescence (Hillemanns et al., 2000). More recently, oral 5-ALA has been 
evaluated in the assessm ent/treatm ent of cervical neoplasia (Duska et al., 2002). 
This route of administration has potential advantages with regard to cost and 
patient convenience but has yet to be studied in vulval disease.
1.1.633 Toluidine blue test
Toluidine blue is a nuclear stain that has been used to allow the detection of 
nuclei at the skin surface. In normal vulval skin the surface cells lack nuclei, 
whilst in VIN 3 surface cells w ould be expected to have retained their nuclei. 
The use of Toluidine blue in the identification of vulval neoplasia is not a new 
technique (Collins et al., 1966; Broen et al., 1971). Recently, a small retrospective 
study has suggested that the technique may be of particular use in 
distinguishing VIN from NNED flour a et al., 1998). However, the technique 
requires the use of a subjective classification of the staining pattern and, in 
order to achieve clinically acceptable sensitivities for neoplastic disease, the 
positive predictive value may be as low as 24% floura et al., 1998). The 
Toluidine blue test is not in w idespread use in current clinical practice.
1.1.63.4 Serum tumour markers
Squamous cell carcinoma antigen is a glycoprotein with a molecular weight of 
approxim ately 45kDa that was originally identified as a possible tum our 
m arker in cervical SCC (Kato et al., 1977). SCC antigen may be useful in the 
follow-up of patients with vulval cancer, but the overlap in values between VIN 
cases and the normal population means that this m arker is of no clinical use for 
pre-invasive disease (Hefler et al., 1999). Tissue polypeptide antigen has also 
been investigated with similar findings (Hefler et al., 2000). A lthough an 
attractive goal, a reliable serum marker for pre-invasive disease has yet to be 
established.
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1.1.7 Current treatment options for VIN
VIN presents a therapeutic challenge and a wide variety of medical and surgical 
treatm ents have been attempted.
1.1.7.1 Surgical management -  excisional techniques
In the UK the principle management of high-grade disease is surgical. Initially, 
such treatm ent was extensive, w ith skinning vulvectomy and skin-grafting 
advocated for multifocal in situ disease (Rutledge et al., 1968). The principle 
behind this technique is to excise multifocal disease, replacing the 'vulnerable' 
vulval skin with skin from an ectopic donor site. However, in some individuals 
even vulvectomy fails to prevent the subsequent development of invasive 
disease (Hording et al., 1991). Furthermore, both 'skinning' or 'sim ple' 
vulvectomy (primary closure) are extensive surgical procedures requiring 
general or regional anaesthesia. Both techniques have a risk of significant 
complications, both local (eg. w ound breakdown/infection) and systemic (eg. 
deep vein thrombosis /  pulm onary embolism), as well as the prospect of 
dam aging psychosexual morbidity and sexual dysfunction. For these reasons 
surgical excision is now usually restricted to local superficial excision w herever 
possible. Guidelines as to the extent of macroscopic surgical margins required 
are inconsistent. It would seem unreasonable to insist on similar m argins to 
invasive disease (1-2 cm) for preinvasive lesions but standard gynaecological 
reference texts usually suggest margins of > 5mm (DiSaia et al., 1997). However, 
even with histologically clear margins, recurrence may occur in almost one fifth 
of cases (Modesitt et al., 1998) and this risk appears highest for those w ith 
multifocal disease. In this study margins of l-2cm were advocated. Despite 
adopting this aggressive strategy, histological assessment revealed two-thirds 
of m argins to be involved with disease suggesting that microscopic disease is 
commonly more extensive than visible acetowhite change at vulvoscopy w ould 
suggest.
The major advantage of excisional techniques is the availability of the 
subsequent specimen for complete histological assessment. As discussed earlier, 
occult invasion occurs in 15-22% of cases (Chafe et al., 1988; Hording et al., 1995;
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Modesitt et al, 1998; Husseinzadeh et al, 1999; Thuis et al, 2000). W hilst 
superficial invasion (<lm m, FIGO stage 1A) is readily treated by local excision 
w ith appropriate margins, SCC w ith a depth of invasion of > lm m  carries a 
significant risk of lymph node metastasis and is routinely treated w ith radical 
surgery involving wide local excision and inguinofemoral lym ph node 
dissection (Hacker et al, 1984). The proportion of cases where invasion has 
already passed undetected through this critical threshold appears to be betw een 
33 and 57% (Chafe et al, 1988; Husseinzadeh et al, 1999). W ithout full 
histopathological assessment, these cases w ould have been missed, increasing 
their chance of 'recurrent' nodal disease w ith its associated poor long-term 
prognosis (Simonsen, 1984).
1.1.7.1.1 Biopsy-directed conservative surgical management
Given the high risk of recurrence associated w ith surgical excision, a m ore 
conservative strategy for the surgical treatm ent of VIN has been advocated (van 
Beurden et al, 1998b). In this technique lesions are m apped out w ith m ultiple 
punch biopsies and excisional treatm ent (with a 5mm margin) is only utilised 
for those areas subsequently diagnosed as VIN 3. There are however concerns 
regarding this methodology. Firstly, the extensive 'm apping' biopsies used for 
multifocal disease required general as opposed to local anaesthesia. Secondly, 
this technique assumes that punch biopsies will exclude the presence of 
invasion and that the areas chosen for biopsy are representative of the most 
severe changes to be found within the lesion. Lesions containing areas of occult 
invasion are more likely to be exophytic/raised (Chafe et al, 1988 ) and unifocal 
(Modesitt et a l, 1998). It would, however, be difficult to exclude sam pling error 
for larger areas of multifocal disease. A punch biopsy may also provide a false 
negative histopathological result (Crawford et al, 1995). Furthermore, occult 
invasion occurred in only 9% of cases in this study, almost half as frequent as 
the studies mentioned previously (Chafe et al, 1988; Hording et a l, 1995; 
M odesitt et a l, 1998; Husseinzadeh et al, 1999; Thuis et al, 2000). This finding 
could indicate significant differences in the study population and makes it hard
39
Introduction
to apply the conservative m anagem ent strategies advocated by the authors to 
patients w ith VIN in general.
1.1.7.2 Surgical management - Laser ablation
The use of lasers has been suggested for both excisional and ablative treatm ent 
of high-grade VIN. Ablative therapy w ith lasers may be advantageous in that 
the fine beam size of the carbon-dioxide laser allows treatm ent to be delivered 
precisely to the intended area, w ith m inim um  effect to the surrounding norm al 
skin. The depth of treatment can also be limited with a resultant reduction of 
scarring and a potentially better cosmetic result. Vaporisation appears to be 
well tolerated and small studies have suggested a cure rate after one treatm ent 
of ~75% (Hoffman et al., 1992; Sideri et al., 1999). Care m ust be taken to continue 
treatm ent to an appropriate depth of tissue for the area of vulval skin being 
treated. Early investigation suggested that vaporisation to a depth of 5mm was 
required (Mene et al., 1985). More recently it has been suggested that such 
extensive treatm ent is unnecessary w ith 3mm depth being sufficient to ensure 
the treatm ent of involved skin appendages in > 95% of cases (Baggish et al., 
1989). Although it had been thought that even less radical treatm ent m ight be 
appropriate for non-hairy skin (Wright et al., 1987), this study does not support 
such a stance, as involvement of sebaceous gland ducts to a depth of 1.27mm 
and deep hair follicle involvement of > 2.4mm were found in macroscopically 
non-hairy skin. However, over aggressive vaporisation should be avoided as 
destruction of the dermal layer may result in increased bleeding, pain and delay 
in healing w ith scar formation. In particular, it has been recommended that 
vaporisation of the labia minora should be limited to a depth of 1mm 
(providing treatm ent to 1.5 mm due to additional thermal damage) (Baggish et 
al., 1989). Reduced operative margins of 3-4mm may also be safe for laser 
therapy (Baggish et al., 1989).
Despite the potential benefits of laser vaporisation as a treatm ent there are 
disadvantages: the cost of laser equipm ent may limit its use and operating staff 
require additional safety training; recognition of the surgical planes (Reid, 1985) 
required for effective treatm ent requires additional surgical training;
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vaporisation does not provide a histological specimen and it is therefore 
m andatory to ensure the area to be treated has been adequately biopsied prior 
to ablative treatment; and finally, there may be an increased risk of recurrent 
disease associated with ablative, as opposed to excisional, treatm ent (Herod et 
a l , 1996).
1.1.7.2.1 Cavitronic surgical aspiration
Cavitronic surgical aspiration (CUSA) uses the properties of ultrasound to 
achieve tissue destruction. At an appropriate frequency ultrasound induces 
cavitations and disruption of tissue, which can then be aspirated, providing a 
specimen for histopathological assessment. Evidence for the use of CUSA in the 
treatm ent of VIN is limited. One study of 37 patients reported 'excellent' long 
term  functional and cosmetic results. However, CUSA for VIN requires regional 
or general anaesthesia and has only been used to treat to a depth of 1.5mm, 
which will be insufficient in some cases due to the involvement of skin 
appendages already described (Baggish et a l, 1989).
1.1.7.3 Alternatives to surgery
1.1.7.3.1 Topical Chemotherapy -  5 Fluorouracil
Topical 5-Fluorouracil (5-FU) has been used in the treatment of AGIN. 5-FU is a 
pyrim idine analogue that functions as a competitive inhibitor of DNA 
synthesis, blocking the conversion of uracil deoxyribonucleotide to thym idine 
deoxyribonucleotide. An additional mode of action is direct interference on 
RNA synthesis and function. Topical 5-FU usually produces erythema and 
oedema within 48 hours followed by necrosis and ulceration of neoplastic 
tissues with prolonged use. Neoplastic skin is preferentially affected but normal 
skin will still demonstrate inflammatory changes. Limited penetration of the 
drug  means that its effects are only reliable in the upper 2mm of skin 
(Klostermann, 1970).
Although the use of topical 5-FU is potentially attractive in that treatm ent may 
be patient-led and healing of the treated areas is usually complete and w ithout 
scarring, its use on the vulva is not ideal. The keratinised nature of the vulval
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skin and the depth to which skin appendage involvement may occur m ean that 
treatm ent of VIN with 5-FU may well be ineffective. Furthermore, the 
bystander effect of inflammation of normal adjacent vulval skin frequently 
limits the dose that can be applied. In their review, Sillman and colleagues 
report results from seventeen studies (involving a total of 68 patients) w here 5- 
FU was used to treat VIN 3 (Sillman et al, 1985). Remission was achieved in 
only 34% of cases whilst treatm ent failed in 59%, usually because patients were 
unable to tolerate the severe local tissue reaction beyond the first two weeks. 
The authors propose the alternative of chemosurgery, where a short course of 
treatm ent (5% 5-FU applied twice daily for ten days) is followed by physical 
removal of the partially detached epithelium. This technique has not been 
widely adopted and data on its efficacy are limited.
1.1.7.3.2 Photodynamic therapy
Photodynamic therapy (PDT) has recently been described as a treatm ent for 
VIN. The principle steps of PDT are show n in Figure 1-6. As previously 
described (section 1.1.6.3.2) the photosensitising agent of choice in the treatm ent 
of VIN is 5-ALA, which induces the accumulation of the photosensitiser 
protoporphyrin IX preferentially in neoplastic tissue. Four hours after topical 
application the neoplastic areas exhibit red fluorescence under 'blue light' and 
can be treated by applying non-thermal light with a spectrum that includes 
635nm, usually generated by a laser. Irradiation of porphyrin-sensitised skin 
causes erythema and is accompanied by burning and pain, which may last for 
hours after therapy. Crusting of the skin is common and the treated area 
usually heals w ith 10-14 days. Experience of PDT in the treatm ent of VIN is 
limited but disease clearance is reported to occur in 37-53% of treated wom en 
(Martin-Hirsch et al, 1998; Hillemanns et al, 2000; Fehr et a l, 2001). 
Unfortunately, the response rate for multifocal high-grade VIN may be as low 
as 27% (Hillemanns et al, 2000). In addition, a small study found that PDT was 
unsuccessful in treating of six cases of VIN 3 that had proved resistant to other 
treatm ent modalities (Kurwa et al, 2000) and PDT is of limited efficacy in the 
treatm ent of hyperkeratotic or pigmented lesions (Hillemanns et a l, 2000). The
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optimum PDT regime for VIN has yet to be established but it would appear 
unlikely that PDT will solve the problem of treating this difficult disease.
Figure 1-6. P ho todynam ic therapy , a) Photosensitising agent may be applied topically or 
given systemically. b) Preferential accumulation of agen t in dysplastic cells over the subsequen t 
4 hours c) Irradiation with non-thermal light induces of porphyrins with d) subsequen t 
destruction of dysplastic epithelium, e) As tissue dam age is limited to epithelium, healing 
without scarring usually occurs over the next 10-14 days.
1.1.7.3.3 Topical immunotherapy
Boosting local immunity in an attempt to induce cytotoxic cellular activity 
against dysplastic cells (often infected by HPV) is a reasonable strategy for 
immunocompetent patients. A prospective randomised trial of topical 
interferon-a (IFNa) for the treatment of high-grade VIN demonstrated a 
complete response, lasting one year, in nine of eighteen patients (50%) (Spirtos 
et al., 1990). Given this encouraging early evidence it is therefore both 
disappointing and surprising that there are no other data available regarding 
this potential therapy.
More recently a novel topical immune modulator been employed to treat high- 
grade VIN. Imiquimod is an imidazoquinoline that binds the toll-like receptor 
TLR-7, activating the nuclear factor kappa-B (Hemmi et al., 2002) w ith the
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resultant production of inflammatory cytokines including IFNa and 
interleukin-12 (IL-12) (Wagner et al., 1999). The consequences of cytokine 
production are complex, but in particular, these cytokines induce cellular 
immune responses against both virus-infected cells and tumour cells.
IMIQUIMOD
/  \
DENDRITIC 
CELL 'MACROPHAGE
Am iviral effect 
in uninfected 
neighbouring
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cell Tumour cell
Figure 1-7. Major routes of action of Imiquimod. Imiquimod acts on m acrophages and 
dendritic cells with resultant production of cytokines. IL-12 induces both T-helper 1 cells (Th1) 
and natural killer cell (NK) activation. Th1 cells subsequently produce interleukin-2 (IL-2) which 
in turn activates cytoxic T-cells (CTL). In addition to the direct activation of NK, IFNa ap p ears  to 
have a protective effect against subsequent viral infection. Both NK and CTL are involved in 
cell-mediated immune responses against both tumour and virally infected epithelial cells.
Initial success with Imiquimod in the treatment of condyloma accuminata 
(Tyring et al, 1998) prompted case reports suggesting that the compound might 
be of use in the treatment of VIN (Davis et al, 2000; Petrow et al, 2001). These
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early reports have subsequently been followed by two small studies of high- 
grade VIN treated with 5% Imiquimod used in a 3-times per week regime for 
12-16 weeks. Whilst a retrospective review of 13 patients suggested that a 
complete response rate of 62% was possible (Jayne et al., 2002), a similar sized 
(n=15) prospective study showed a much lower complete response rate of 20% 
(Todd et al., 2002). Both studies contained patients who found the side effects of 
local inflammation so severe that they were unable to complete the prescribed 
course of topical therapy. Indeed, the low response rate of the latter study may 
reflect the fact that 11/13 patients in this trial were unable to tolerate the 
prescribed regime of 3-times per week application. For those who are able to 
tolerate such a regime, disease that shows an incomplete response may indicate 
foci of occult invasion (Jayne et al., 2002).
1.1.7.3.4 Antiviral therapy
The strong association between basaloid VIN and HPV infection has lead to the 
trial of antiviral agents in the treatm ent of this disease. Cidofovir is a 
deoxycytidine monophosphate analogue that exhibits potent antiviral activity 
against a range of DNA viruses. Although usually prescribed intravenously for 
the treatm ent of cytomegalovirus retinitis in patients with HIV, the use of 
topical cidofovir in the treatm ent of VIN has been described (Koonsaeng et al., 
2001). Further data are required before this drug can be considered as a 
therapeutic option for clinical practice, but its efficacy in the 
immunocompromised patient is particularly attractive.
The developm ent of an effective HPV-vaccination has been a goal of HPV- 
researchers for many years. The major drive behind such research has been the 
global burden of carcinoma of the uterine cervix, which currently kills almost
250,000 wom en every year (Ferlay et al., 2001), mainly in the developing world. 
Although cervical screening has been effective for developed countries 
(Vizcaino et al., 2000), the lack of resources in developing countries makes 
primary prevention an im portant goal. Compelling data exist to support the 
development of prophylactic vaccines and a recent study of a viral-like particle 
(VLP) vaccine (Koutsky et al., 2002) suggests that an effective prophylactic
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vaccine should be available for routine use in the next 5-10 years. However, 
prophylaxis will not affect those wom en who are already infected w ith HPV 
and there is a pressing need to develop effective therapeutic vaccines. Viral 
targets for therapeutic vaccination and the immune responses required to treat 
HPV related pathology will be considered at a later stage of this thesis (Chapter 
5). Research on VIN has an im portant role to play in the development of such 
vaccines. Unlike CIN, the current treatm ent options for VIN are rather 
ineffective and often unpleasant for a n d /o r  unacceptable to the patient. The 
preponderance of HPV 16 infection in high-grade VIN means that therapeutic 
vaccines may therefore focus on this HPV type alone. Advances in therapeutic 
HPV vaccination and the use of a novel vaccinia-based therapeutic vaccine in 
the treatm ent of VIN will be considered in Chapter 5 of this manuscript.
1.1.7.4 Symptom relief
As ~70% of patients with VIN will suffer pruritus and others soreness or 
discomfort, symptom control is an im portant part of the m anagement of this 
condition. Many patients will have been prescribed topical steroids, either as 
empirical treatm ent or for sym ptom  control following a known diagnosis of 
VIN. Whilst steroids are effective in the relief of itching and soreness, there are 
certainly concerns regarding the application of an immunosuppressive agent to 
w hat is often a virus-associated premalignancy. The association between 
im m unosuppression and the development of high-grade VIN has already been 
described (section 1.1.4.2.2). Molecular studies have suggested at least one 
mechanism by which steroid administration may affect immune surveillance of 
HPV-related tumours. In vitro experiments suggest that whilst glucocorticoids 
lead to upregulation of hum an leucocyte antigen (HLA) class I molecules in 
HPV-negative cells, the exact opposite occurs in HPV-positive cells. This effect 
appears to be dependent on viral integration and the transcription of viral genes 
and can be blocked by the use of steroid receptor antagonists (Bartholomew et 
al., 1997). HLA class I molecules are crucially involved in the presentation of 
viral peptides to T-cells and their downregulation following the application of 
steroids may contribute to immune evasion by HPV. Steroids are therefore
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inappropriate in the long-term treatm ent of VIN. Symptom relief m ay be 
obtained by the application of simple agents such as cooled aqueous cream. 
Silver sulfadiazine (flamazine) has also proved useful as a soothing agent.
1.1.8 Recurrent disease and need for follow-up
The risk of recurrent VIN following treatm ent may be as high as 50% (Herod et 
al., 1996; Thuis et al, 2000), and is highest for those with multifocal VIN 
(Kuppers et al, 1997; Thuis et al, 2000) or multicentric AGIN (Hording et al,
1995). Pathological grading also appears to be of importance with an increased 
risk of recurrence evident in those patients w ith high-grade disease (Kuppers et 
al, 1997). W hen excisional treatm ent is employed, pathological assessment of 
the margins of the specimen may provide further information as to the 
likelihood of recurrent VIN. In their study of 73 patients with VIN 3, M odesitt 
and colleagues found those w ith histologically involved margins to be at 
significantly increased risk of disease recurrence when compared to those in 
whom  disease excision appeared complete (46% vs. 17%; p=0.03) (Modesitt et 
al, 1998). Although this finding was in agreem ent with an earlier study 
(Andreasson et al, 1985), other authors have reported high (50%) recurrence 
rates despite seemingly adequate surgical treatm ent (Kuppers et a l, 1997). 
Resorting to extensive local excision, such as vulvectomy, fails to prevent 
recurrent disease and invasive carcinoma may still develop in patients who 
have undergone this procedure (Hording et al, 1991). It therefore seems likely 
that whilst recurrent disease commonly represents persistent or incompletely 
treated disease, in some individuals new disease does occur. Regular 
surveillance of patients who have been treated for VIN is therefore essential and 
m ost authorities advocate six-monthly to yearly follow-up after treatment. The 
majority of recurrences will occur in the first four years after treatm ent (Herod 
et a l, 1996) and it may be possible to safely reduce the frequency of follow-up at 
this stage. Immunocompromised individuals represent a group at particular 
risk of recurrence (Park et al, 1994a; Korn et al, 1996). Follow-up for such 
patients should be long-term at increased frequency e.g. six-monthly for life.
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1.2 The multistep process of carcinogenesis in the female 
lower genital tract
There seems little doubt that the development of carcinoma is usually a 
m ultistep process with tum our developm ent occurring as a result of complex 
interplay between genetic and environmental factors, coupled w ith the 
response of the host organism to these stimuli. Three stages in the developm ent 
of a cancer have been classically described, namely initiation, prom otion and 
progression. Tumour initiation often involves mutational damage to somatic 
DNA. Subsequent progression is characterised by the expansion of initiated 
cells with the development of a chronic state of cellular proliferation. At this 
stage the cells are usually diploid but may show altered differentiation. A 
benign outgrowth such as a papilloma may then develop. The first stage of 
tum our progression is the developm ent of a pre-invasive lesion that usually 
demonstrates further loss of differentiation with aneuploidy and loss of 
heterozygosity. Lesions that progress further develop an invasive phenotype 
and commonly demonstrate gene amplification as well as loss of know n 
tum our suppressor genes e.g. p53 mutation.
1.2.1 HPV and lower genital tract neoplasia
The role of HPV infection in the pathogenesis of carcinoma of the uterine cervix 
has now been clearly established. Persistent infection with HR-HPV is a 
"necessary cause of cervical carcinoma" (Bosch et al., 2002) and HPV DNA can 
be isolated from almost all cases of this cancer using PCR (Walboomers et ah, 
1999). However, although strong associations have been described, firm 
evidence establishing causality is lacking for HPV at other anogenital sites.
1.2.1.1 HPV classification
Papillomaviruses are small, double stranded DNA viruses of the papovavirus 
family, which show both species- and tissue-specificity, infecting only stratified 
epithelia. H um an papillomaviruses also show a degree of site specificity, 
whereby they produce lesions only at certain anatomical sites. This site-
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specificity has led to the division into those HPV types that affect skin 
(cutaneous HPV) and those that affect mucosal surfaces (mucosal HPV). HPV 
types are assigned on the basis of the genotype of the virus. Since 1995 this 
typing has been made on the basis of the LI gene or open reading frame (ORF) 
alone. To classify an HPV sequence as representing a new HPV type, the virus 
sequence should show >10% difference in the amplified LI ORF from its m ost 
similar known type. More than 130 types have been identified on the basis of 
the LI ORF sequence, but the full sequence is currently only available for 
around 85 of these. Computer analysis of the genetic sequences allowed the 
construction of phylogenetic trees for HPV. This has shown the genomic 
classification system to correlate closely with the clinical classification.
The study of cervical cancer has allowed the subdivision of mucosal HPV into 
high- and low-risk types (HR-HPV and LR-HPV) on the basis of those types 
most likely to be associated w ith the developm ent of malignancy and those 
which are associated with benign lesions such as warts. This classification was 
originally proposed in the 1980's (zur Hausen, 1986) but a recent study has 
reaffirmed the validity of such a division (Munoz et al, 2003). Examples of both 
groups are shown in the table below.
Mucosal HPV group HPV types identified
High-risk 16,18,31,33,35,39,45,51,52,56,58,59,68,73 and 82
Low-risk 6,11,40,42,43,44,54,61,70,72,81 and CP6108
Table 1-5. High-risk and low-risk HPV types (Muftoz ef al., 2003). Types 26,53 and 66 
should be classed as probable HR-HPV.
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Figure 1-8. Phylogenetic similarities between papillomaviruses. Note subdivision of 
mucosal types into high and low risk. Reproduced from Van Ranst et al., 1992.
1.2.1.2 HPV structure
The HPV vim s particle measures 55nm in diameter and comprises an 
icosahedral protein coat enveloping the double-stranded DNA (Williams et al, 
1961). The genome is approximately 8000 base pairs in length and encodes eight 
genes. In contrast to other papovaviridae, HPV have all ORF (sequences 
encoding the genes) arranged on one strand. The genes are divided into early 
and late genes (denoted by the prefix 'E' or 'L') on the basis of their role in the 
virus life cycle. In addition to the ORFs, there is a non-coding region (NCR) also 
known as the long control region (LCR) or upstream  regulatory region (URR). 
This regions varies between 0.5-lkb and is rich in motifs that bind cellular 
transcription factors (including API and NF1) as well as binding sites for the El
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and E2 proteins that allow for feedback control from viral transcription 
(O'Connor et al, 1995). The organisation of the HPV 16 genome is show n as an 
example of a genital HPV type and it is these types that will be considered in 
further detail within the scope of this thesis.
1E7 ] ESI L2 |
E6 E2 | L1
URR
p97 p670 pA(4213) pA(7260)
1 i i i i I 1 1
0 1000 2000 3000 4000 5000 6000 7000
Figure 1-9. Linearised HPV 16 genome showing ORFs. Genome comprises 7905bp 
arranged in a circular fashion. ‘E’ denotes early genes whilst ‘L’ denotes late genes. Positions of 
early gene promoter (p97) and differentiation dependent late gene promoter (p670) are 
indicated. The polyadenylation signals for both early and late transcripts are shown (pA). In 
addition to ORFs the non-coding upstream regulatory region (URR) or long control region (LCR) 
is shown.
1.2.1.3 Virus life cycle
H um an papillomaviruses are thought to enter through 'microlesions' in 
stratified squamous epithelium. Recent evidence has suggested a6 integrin as a 
potential receptor for virus entry (Evander et al, 1997). Virus entry may then be 
followed by a period during which there is no overt evidence of infection. 
Indeed, studies looking at the possibility of using HPV testing to screen for 
cervical neoplasia have shown a high incidence of transient infection often with 
high-risk types, particularly in younger women (Ho et al, 1998). It may be that 
such individuals undergo abortive sub-clinical infections but the possibility of 
latent HPV infection must be considered. Many investigators consider the 
increased incidence of AGIN in imm unocompromised patients to represent the
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reactivation of latent HPV infection rather than the acquisition of new  HPV 
infection.
HPVs exhibit a differentiation-dependent life cycle, following the keratinocyte 
in its passage from basal layer tow ards the surface of the stratified squam ous 
epithelium. Initial infection of the basal epithelium occurs at a level of ~10 
copies per cell. The HPV genomes rem ain episomal (or extra-chromosomal) and 
copy num ber is rapidly increased to about 50-100 copies per cell (Stubenrauch 
et al., 1999). As basal cells divide to replace the more superficial cells, viral 
genomes are shared between daughter cells. HPV production requires 
differentiation and does not therefore occur in the basal cells. These cells are 
therefore spared a potentially lytic viral infection and can remain present as a 
source of virus for prolonged periods. The need to complete a life cycle in 
differentiating cells poses a potential problem  to HPV. The virus is dependent 
on the cellular machinery to replicate, but differentiating cells have usually 
exited the cell cycle. The transcripts from the early ORFs function to overcome 
this quiescent environment. The E6 and E7 proteins are the major transform ing 
proteins of genital HPV types and serve to induce the differentiated 
keratinocytes to enter S-phase, whilst at the same time preventing the apoptotic 
response that is usually associated w ith inappropriate DNA synthesis in normal 
cells. The details of this process will be considered in the following section.
Transcription of the early ORFs is initiated from the early promoter located 
upstream  of the E6 ORF -  known as p97 in HPV16 (Smotkin et ah, 1986). 
Effective viral replication appears to be dependent on the interplay of several 
early proteins. Whilst transient viral replication requires only El and E2 
expression (Del Vecchio et al, 1992), in vitro studies using m utant E6 and E7 
constructs have demonstrated that these proteins appear to be essential for the 
maintenance of stable replication in hum an foreskin keratinocytes (Thomas et 
ah, 1999). The El and E2 proteins have a complex interaction with one another 
and appear to exert a controlling influence on the process of early replication. 
Whilst E2 is able to undergo high affinity binding to E2-specific sequences in 
the URR, El binds adjacent A /T  rich sequences in the replication origins (ori)
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w ith low affinity. Complex formation between El and E2 alters both the target 
and affinity of this binding and may allow for a means of influencing the 
replication of viral episomes (Frattini et al, 1994).
Full length E2 may cause both transcriptional activation and repression via a 
variety of different mechanisms (Table 1-6). In a fashion analogous to the 
oncoproteins E6 and E7, DNA binding and hence transcriptional effects appear 
to vary between HR- and LR-HPV types, w ith HPV 16 E2 dem onstrating the 
strongest effects in vitro (Hou et a l, 2002). The major action of HPV 16 E2 has 
been thought to be to repress the transcription of E6 and E7 in the basal 
epithelial cells. However, recent w ork w ith cell lines containing both integrated 
and episomal HPV 16 has suggested that such transcriptional regulation m ay be 
a secondary effect, with the main mechanism of E2 control being directly on 
viral replication itself (Bechtold et al, 2003). Whilst E2 has no enzymatic 
activity, El has been shown to have both ATPase and helicase activity (Hughes 
et a l, 1993). El also facilitates viral replication by recruiting cellular replication 
enzymes such as DNA polymerase a  to the viral ori (Park et al, 1994b).
Activation Repression
Recruitment of general transcription Displacement of cellular transcription
machinery factors
Interaction with nuclear factors eg. Spl Prevention of pre-initiation complex
formation
Remodelling of DNA structure
Table 1-6. Mechanisms of E2 transcriptional effects (Hou etal., 2002)
As has been stated previously, the virus life cycle is differentiation dependent. 
As the keratinocyte moves toward the epithelial surface the differentiation 
dependent prom oter (known as p670 in HPV 16 (Grassmann et al, 1996)) is 
activated with the subsequent expression of HPV late genes. E l and E2 
production are also enhanced following activation of this promoter (Klumpp et 
al, 1999).The increased levels of these proteins is thought to lead to a m arked
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increase in viral copy number, at least in part by interference with the usual 
mitotic checkpoints (Frattini et al., 1997).
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Figure 1-10. Productive HPV infection demonstrates a differentiation dependent virus life 
cycle
Differential splicing accounts for the production of at least three transcripts 
from the late promoter. Despite the 'early' prefix, E4 production is largely 
under the control of this promoter. The major transcript demonstrated in the 
upper two-thirds of the epithelium is the E1A4 transcript (Iftner et al, 1992). The 
fusion protein from this transcript is predominantly from E4, with just five 
amino acids from the C terminus of El. The protein associates with cellular 
cytokeratin networks and in cell culture, this association appears to result in 
collapse of such networks (Doorbar et al, 1991). This process may allude to a 
role for the E1AE4 fusion protein in preparation for virus exit but more recently 
it has been shown that the protein provides the virus with yet another way of 
interfering with the host cell cycle. HPV 16 E1AE4 induces G2 arrest in HeLa 
cells (Davy et al., 2002). This strategy has been used by other virus e.g. 
baculovirus, parvovirus and HIV, to enhance virus production in the late stages 
of the viral life cycle, and may explain the widespread distribution of this 
protein in the upper epithelial layers described earlier.
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In productive HPV infections, the appearance of the E4 protein precedes that of 
the LI and L2 structural proteins (Doorbar et al., 1997). These proteins are 
translated in a differentiation-dependent m anner from messages that encode 
E1AE4 upstream, passing through the inefficient early polyadenylation (polyA) 
site at the end of El to use the polyA site at the end of LI (Terhune et al., 1999). 
LI and L2 are known as the major and minor capsid proteins respectively. L2 is 
not essential for capsid formation in vitro but virus capsid assembly appears 
more efficient in the presence of both proteins (Kirnbauer et al., 1993). 
Maintenance of viral episomes is essential for late gene synthesis and the 
assembly of the virus capsid (Frattini et al., 1996).
1.2.1.4 The major viral oncoproteins
Although evidence is accumulating for the role of other early proteins in the 
subversion of the host cell cycle, the major transforming abilities of the HR- 
HPV are thought to be conferred by the E6 and E7 oncoproteins. Together these 
proteins combine to induce the differentiated keratinocyte into S-phase and 
allow the cell to avoid the usual apoptotic response to such an event. The major 
effects of these proteins are discussed below and are summarised in Table 1-9.
1.2.1.4.1 The E7 oncoprotein
The E7 oncoprotein is a small protein of approximately 100 amino acids, which 
shares structural similarities w ith both the adenovirus 5 El A and SV 40 large T 
oncoproteins. Like these proteins, HR-HPV E7 is able to bind to the 
retinoblastoma protein (pRb) (Dyson et al., 1989) and associated pocket proteins 
p i  07 and p i 30 (Dyson, 1998). This binding is dependent upon homologous 
motifs within the amino-terminal of the protein. These proteins all function as 
regulators of cell growth, at least in part by their interaction with the E2F family 
of transcription factors. Both phosphorylated and non-phosphorylated forms of 
pRb exist at various stages of the cell cycle. The non-phosphorylated form of 
pRb binds E2F. Phosphorylation of pRb by cyclin dependent kinases (CDKs) 
serves to drive cell cycle progression by releasing E2F. HR-HPV E7 binds non- 
phosphorylated pRb, p i 07 and p i  30, releasing E2F with the resultant increase 
in E2F inducible genes, including cyclin E (Ohtani et al., 1995) and cyclin A
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(Yam et al., 2002). This transcriptional activation allows the cell to overcome 
both the Gl-S and G2-M checkpoints and is a major mechanism by which HR- 
HPV E7 contributes to oncogenesis.
The carboxy-terminus of HR-HPV E7 contains two cysteine-X-X-cysteine 
repeats, which have several functions. Acting via this domain HR-HPV E7 can 
trans-activate the AP-1 family of transcription factors (Antinore et al., 1996), 
which participate in the transforming effects of E7. Another contribution of this 
term inus of the oncoprotein is to further encourage cell cycle progression by 
inhibiting the CDK inhibitors (CKIs) WAF1 (p21) (Funk et al., 1997) and KIP1 
(p27) (Zerfass-Thome et al., 1996). Although these inhibitors are themselves 
induced by E7-mediated increases in E2F, E7 is able to prevent regulation of the 
cell cycle by directly inhibiting these CKIs. It is w orth noting that in productive 
infections both cyclin E and WAF1 are co-stabilised with KIP1 in some 
keratinocytes containing HR-HPV E7, apparently as a host mechanism to 
suppress S-phase entry and viral replication (Noya et al., 2001).
1.2.1.4.2 The E6 oncoprotein
The E6 protein is approximately 150 amino acids in length. A major effect of 
this protein is to interfere w ith the function of the cellular tum our suppressor 
gene (TSG) p53. The p53 protein is induced by a variety of cellular 'stress7 
signals and acts to protect the cell against inappropriate DNA synthesis by 
prom oting growth arrest (Gl-S arrest) and apoptosis. As HPVs rely on cellular 
DNA replication machinery for their life cycle this protein poses a threat to viral 
replication. HR-HPV E6 is able to counteract p53 function by both direct and 
indirect methods. E6 leads directly to the breakdown of p53 by ubiquitin- 
dependent proteolysis (Scheffner et al., 1990). This interaction is m ediated by a 
cellular protein E6AP (Huibregtse et al., 1991) which functions as a ubiquitin 
ligase, the E6-E6AP complex targeting p53 for ubiquitination and subsequent 
degradation. In intro work suggests that a polymorphism at codon 72 (arginine 
replacing proline) of the p53 TSG may increase the susceptibility of p53 to E6 
m ediated degradation for individuals homozygous for the arginine allele
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(Storey et al, 1998). However, epidemiological studies of HPV-associated 
neoplasia, including a study of cervical carcinoma patients in the UK (Rosenthal 
et al, 1998), do not support a role for this polymorphism in vivo. Furthermore, in 
a small study of HPV associated vulval neoplasia, arginine homozygotes were 
significantly less common in cases as compared to control subjects, suggesting 
that in vivo this polymorphism may actually confer some form of protection 
against the development of HPV-associated vulval neoplasia (Rosenthal et a l,
2000). HR-HPV E6 can also indirectly inhibit p53 action by binding and 
inhibiting the transcriptional coactivator CBP/p300. In addition to its effects on 
p53, HR-HPV E6 acts to prevent apoptosis induced by the Bak protein, which is 
highly expressed in differentiating keratinocytes (Thomas et al, 1998). These 
two mechanisms are crucial in allowing the infected keratinocyte to escape the 
normal protective responses to the proliferative signals induced by the E7 
oncoprotein.
In addition to its anti-apoptotic effects, HR-HPV E6 activates telomerase. This 
RNA-dependent DNA polymerase serves to correct the shortening of the 
telomeres that usually occurs w ith each round of cell division. Telomeric length 
is a crucial determ inant of cell life. Telomerase activity is necessary for the 
immortalisation of cells and can be demonstrated in more than 90% of hum an 
cancers (Kim et al, 1994). However, telomerase induction alone is insufficient 
to immortalise hum an keratinocytes. Once again, it would appear that there is a 
synergistic effect with the oncoprotein E7, whereby both E7-induced 
inactivation of the Rb pathway and E6 induction of telomerase are required to 
achieve the immortalisation of keratinocytes in vitro (Kiyono et al, 1998).
Finally, HR-HPV E6 may be able to reduce cell-cycle control effected by the 
CDKIs. Recent work has shown that HPV 16 E6 can bind the coactivator of the 
retinoic X receptor alpha (Zeng et al, 2002). This interaction may enhance S- 
phase progression by reducing transactivation of the CDKI WAF1 (p21).
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1.2.1.43 The role of HPV E5
Although a major oncoprotein in bovine papillomaviruses (reviewed in DiMaio 
et a l, 2001), the exact role of the E5 protein in HPV infection remains uncertain. 
In vitro work has shown that the protein forms stable complexes w ith a variety 
of growth factors (Hwang et al, 1995) and a membrane-bound ATPase which 
forms part of the gap junction complex (Conrad et al, 1993). These studies 
provide possible mechanisms by which HPV E5 may contribute to cellular 
transformation and interfere w ith normal cellular communication. More 
recently, E5 from the HR-HPV type 16 has been shown to protect keratinocytes 
from ultraviolet radiation-induced apoptosis (Zhang et al, 2002). In contrast to 
the p53 mediated anti-apoptotic effects of HPV 16 E6, E5 achieves this 
protection at least in part by interference w ith the caspase family of cysteine 
proteases. However, early evidence suggested that in cervical carcinomas the 
gene is frequently deleted or simply not expressed (Schwarz et al, 1985). It is 
most likely that the role of E5 w ould therefore be at an early stage of viral 
infection.
1.2.1.5 The physical state of the virus
The role of viral integration in the development of vulval carcinoma has not 
been studied but it has been investigated for carcinoma of the cervix. The 
frequency of integration appears to increase with the severity of cellular 
dysplasia. In early pre-malignant lesions (LSIL -  low grade squam ous intra- 
epithelial lesions) the virus usually exists in its episomal form. As has already 
been described, this form of the viral genome is essential to allow completion of 
the virus life cycle with synthesis and assembly of the capsid proteins (Frattini 
et a l, 1996). For more advanced high-grade squamous intraepithelial lesions 
(HSIL) there have been estimates of the percentage of lesions that contain 
integrated forms of HPV ranging from 6% to 90% (Daniel et al, 1995; Kalantari 
et al, 2001). Analysis of cervical SCC has shown the vast majority (90 -100%) of 
tum ours to contain HPV in the integrated form (Park et al, 1997; Kalantari et al,
2001). Integration would appear to have effects on both host and viral gene
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expression. Early evidence suggested that disruption of the E2 region during 
integration resulted in increased expression of the E6 and E7 oncogenes 
(Schwarz et al, 1985; Cripe et al, 1987) leading to an increased capacity to cause 
immortalisation and hence malignant progression (Romanczuk et al, 1992).
Figure 1-11. Integration of viral genome into host DNA. Integration typically occurs within the 
E2 ORF, which may reduce the negative transcriptional regulation of the high-risk oncoproteins 
E6 and E7 (shown in red).
The increase in E6/E7 activity may in part be mediated by an increase in 
transcript stability due to transcription of 'fused' viral and cellular sequences 
(Jeon et al, 1995). In carcinomas where the virus remains in its episomal form, 
mutations in putative binding sites for known cellular transcriptional repressors 
(such as YY1 (May et al, 1994)) have been shown. This finding supports the 
hypothesis that it is the loss of E6/E7 transcriptional control following E2 
disruption that is the crucial event in developing malignancy following 
integration. There is however, some evidence to support a direct role for E2 loss 
in oncogenesis. The HPV 16 E2 protein can induce apoptosis in intro in both 
HPV-transformed and non-HPV-transformed cell lines (Webster et al, 2000), 
probably via a p53-dependent pathway. The disruption of the E2 gene at
LCR
L1
E1
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integration might therefore lead to reduced apoptosis via this pathway, further 
allowing the E6/E7 stimulated cells to escape the usual control mechanisms for 
cellular growth.
Although the study of transcripts derived from integrated HPV 16 E6/E7 DNA 
suggests that almost all chromosomes are potential sites for integration 
(Wentzensen et al., 2002), investigators agree that such integration often occurs 
at common fragile sites (CFS) (Wentzensen et al., 2002; Thorland et al., 2003)]. 
These sites are chromosomal loci, which are prone to chrom atid or 
chromosomal breaks and subsequent recombination events (Glover et al., 1988). 
Other work has suggested that integration may occur close to areas of highly 
transcribed genes, which may simply reflect the fact that DNA in these regions 
remains 'decondensed' and more accessible to viral DNA integration (Klimov et 
al, 2002).
Viral integration may have a direct effect on host gene expression. HPV 
integration in cervix cancer cell lines has been shown to activate proto­
oncogenes and oncogenes (Diirst et al., 1987) and more recently the application 
of array technology has identified altered expression of groups of genes 
including increased expression of the IFN-responsive genes (Alazawi et al.,
2002). Viral integration may therefore directly enhance the progression tow ards 
malignancy or simply facilitate immune evasion by the dysplastic, virally- 
infected cells. The further application of new technology and the increased 
understanding of the hum an genome may provide more detailed insight into 
both the site and consequences of viral integration and its role in m alignant 
progression.
1.2.1.6 HPV and vulval carcinoma
Vulval carcinoma is uncommon affecting approximately 800 women in England 
and Wales every year (incidence 2.4 per 100,000 population). Most carcinomas 
are squamous cell carcinomas and these can further be classified into 
keratinising and non-keratinising subtypes. The strong association between 
HPV infection and undifferentiated VIN has been described in section 1.1.4.1.
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However, studies investigating its invasive counterpart have consistently 
shown a lower incidence of HPV detection, w ith rates of between 30 and 50% 
commonly reported. These figures m ust be interpreted w ith some caution. 
Some of the early studies used histological markers or in situ hybridisation to 
detect HPV infection rather than the more recently developed and more 
sensitive PCR based techniques, which may under-represent the true incidence 
of HPV infection. Furthermore, the relative infrequency of this cancer makes it 
hard to draw  strong conclusions from the limited num ber of cases available for 
analysis. However, it would appear that much of the variance in the rates of 
HPV infection is likely to reflect the heterogeneous nature of the populations 
studied. Kurman and colleagues classified one hundred vulval SCC into 
basaloid, warty and keratinising cell types (Kurman et al., 1993). Keratinising 
tum ours account for approximately two-thirds of vulval SCC. The rem ainder fit 
into either basaloid (28%) or warty (7%) subtypes. HPV typing studies, which 
have used this histological classification, tend to support at least two 
aetiological subgroups of vulval SCC, namely HPV-related and HPV- 
independent. The results from two such PCR-based studies are detailed in the 
following table:
Incidence of HPV infection
Study Number Overall Keratinising Basaloid/Warty
of subtype (non-keratinising)
subjects Subtypes
(Nuovo et al., 1991) 23 30% 0% 70%
(Hording et al., 1994) 78 31% 4% 81%
Table 1-7. Varying incidence of HPV infection in SCC vulva with histological subtype
Basaloid and warty SCC are more commonly found in younger (<60yrs) wom en 
and are associated with undifferentiated VIN of the corresponding subtype in 
over three-quarters of cases (Kurman et al, 1993). In common with 
undifferentiated VIN, HPV 16 accounts for the vast majority of HPV infections 
(88%) associated with SCC of the vulva (Hording et al, 1994), but HPV 18 (Al- 
Ghamdi et al, 2002) and HPV 33 (Hording et al, 1994) infections have also been
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reported. The evidence for an increasing incidence of vulval SCC in younger 
wom en has already been discussed (section 1.1.2). When women under 40 years 
of age are considered, the association w ith undifferentiated VIN (95%) and HPV 
infection (85%) appears stronger still (Al-Ghamdi et al., 2002).
Whilst HPV may well be responsible for the suggested increase in both VIN and 
subsequently SCC of the vulva in younger women, there is debate as to the 
impact of HPV infection on the prognosis in vulval cancer. In their small (n=23) 
series of vulval SCC, Nuovo and colleagues (Nuovo et al., 1991) found an 
increased rate of lymph node metastasis w ith HPV-positive tum ours (3 /7  vs 
4/16). This is in direct contrast to the finding in a Dutch study in which 
m ultivariate analysis suggested an improved disease prognosis for HPV- 
positive tum ours (Ansink et al., 1994). H ording and colleagues were unable to 
demonstrate any difference in prognosis between HPV-positive and HPV- 
negatives SCC (Hording et al., 1993) and it would seem likely that the small 
num bers of cases available for analysis will make the detection of significant 
differences in outcome difficult.
Keratinising SCCs of the vulva are usually described as affecting older wom en 
and are associated w ith adjacent differentiated VIN, squamous hyperplasia or 
epithelial dystrophies such as lichen sclerosus (Hording et al., 1994). Many feel 
these precursors are rarely found in association with HPV infection and use this 
statement to support two entirely distinct aetiologies for vulval carcinoma, one 
HPV-related and one HPV-independent. Differentiated VIN does indeed show 
a strong negative association w ith HPV infection (Haefner et al., 1995). 
However, when lichen sclerosus is considered the evidence is less convincing. 
Although studies have shown no HPV in areas of lichen sclerosus associated 
w ith carcinoma (Leibowitch et al., 1990; Neill et al., 1990), other authors have 
found HPV in between 22 and 50% of cases (Kiene et al., 1991; Ansink et al, 
1994; Haefner et al, 1995). It would therefore appear that HPV and lichen 
sclerosus are not mutually exclusive and may act as cofactors in the 
development of vulval carcinoma.
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1.2.2 The immune response to human papillomaviruses
HPV infection of the lower genital tract is a common event in young wom en 
(Ho et al, 1998). The vast majority of wom en do not develop overt clinical 
disease and this fact, coupled w ith the transient nature of most infections, 
suggests a central role for the imm une system in the control and clearance of 
genital HPV infection.
1.2.2.1 The typical response to viral infection
Both humoral and cellular immunity typically have roles in the defence against 
viral infection. Cell mediated immune responses (CMI) are necessary for the 
clearance of virally-infected cells and antibody responses help to clear free virus 
particles and prevent subsequent re-infection by the virus.
Viral antigens are presented to T-lymphocytes by antigen presenting cells 
(APC) in conjunction with major histocompatibility complex (MHC) molecules. 
The surface markers CD4 and CD8 define two broad categories of T-cell. CD4+ 
T-cells recognise exogenous antigen that has been processed by specialised APC 
and presented on the cell-surface in conjunction with MHC class II molecules 
(HLA -DP, -DQ and -DR). Activation of CD4+ cells requires a second signal 
m ediated via the interaction of CD80 on the APC and CD28 on the T cell. In 
contrast CD8+ cells have highly specific receptors that recognise endogenous 
antigen presented in association with MHC class I antigens. CD4+ cells are 
further divided into T-helper (Th) 1 and 2 cells. These cells exhibit different 
cytokine production profiles enabling them to influence different immune 
effector cells. Thl cells secrete IFNy and are able to activate macrophages, 
natural killer (NK) cells and cytotoxic T-cells involved in CMI. In contrast, Th2 
cells secrete IL-4, -5 and -10 which activate B-cells and generate a hum oral 
imm une response. Which T-cell response arises may well be determined early 
on in immune activation at the time of antigen presentation by the APC and 
will be of crucial importance to the nature and effectiveness of the subsequent 
immune response.
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1.2.2.2 The role of cell-mediated immunity in HPV infection
The precise nature of the immune response to HPV has yet to be established, 
but it would appear that CMI is central to the effective control of HPV infection. 
The study of genital warts has shown persistent lesions to be characterised by 
an absence of immune effector cells, whilst regressing warts show a 
mononuclear cell infiltrate. The infiltrating lymphocytes are largely CD4+ 
although CD8+ cells are also present in the epithelium (Coleman et a l, 1994). 
Both morphological data and cytokine profiling suggest that the CD4+ response 
is Thl biased. In addition, the fact that individuals in whom CMI is reduced are 
particularly prone to genital HPV infection supports the central role of CMI in 
combating HPV infection.
1.2.2.3 HPV-specific immunological responses in AGIN
Studying 'natural' immunity to HPV is essential if effective im m unotherapies 
are to be developed. Once again, the majority of experience has been obtained 
from the study of cervical disease. Serial biopsies of genital lesions are difficult 
to obtain and research has therefore focussed on systemic rather than local 
immune responses to HPV-associated AGIN. The limitations of studying such 
responses will be considered at a later point in this thesis (sections 1.2.2.3.3 and 
5.4)
1.2.2.3.1 Humoral immune responses
HPV 16 infections in young women induce seroconversion after a m edian time 
of 8.3 months (Carter et al, 1996). Variations in rates of seropositivity are found 
for HPV16 DNA positive cancers at different anogenital sites, suggesting that 
imm une responses may vary by cancer site (Carter et al., 2001). Although some 
wom en fail to m ount a humoral response despite persistent viral DNA, 
persistent HPV 16 infection (as assessed by PCR based detection of viral DNA) 
is associated with an increased chance of seroconversion1. Comparisons of 
mucosal versus systemic antibody responses assessed by capsomere-based 
ELISA suggest that mucosal IgA responses occur over a similar timescale to
1 Galloway et al. Personal communication, HPV Vaccines and Immunotherapies, July 2003, Cambridge.
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serum  IgG responses. However, the duration of the IgA response (both in 
mucosal secretions and serum) is significantly shorter (Onda et al., 2003). This 
feature of the humoral immune response to HPV m ust be considered w hen 
interpreting the encouraging results of a prophylactic virus-like particle (VLP) 
vaccination study (Koutsky et al, 2002). In this study, vaccination w ith an HPV 
16 VLP provided protection against both persistent HPV infection and the 
development of CIN over a m edian follow-up of 17.4 months. Whilst this 
duration of follow-up exceeds the mean time for both local and systemic IgA 
reversion (12.0 and 13.6 months respectively; (Onda et al, 2003)), the long-term 
benefit for this cohort of women may be less dramatic. It remains to be seen 
whether therapeutically induced antibody responses will have any effect on the 
natural history of established HPV infections.
1.2.2.3.2 Cell mediated immunity
Most work to date concerns systemic im m unity assessed by testing peripheral 
blood mononuclear cells (PBMC). Such responses are often small and difficult 
to detect. The current evidence for Th-cell reactivity in man is som ewhat 
contradictory. In a study of wom en w ith CIN, HPV 16 E7 reactivity appeared 
strongest in those patients w ith persistent or progressive disease (de Gruijl et al., 
1998), possibly reflecting the increased availability of viral antigen in such 
subjects. In contrast, Kaddish and colleagues report Th reactivity to be 
enhanced amongst those women who clear HPV infection and in whom  CIN 
regresses (Kadish et a l, 1997). Using the sensitive ELISPOT technique (section
2.2.5.3) a more recent study has confirmed the presence of memory Th 
responses in over 50% of apparently 'healthy' individuals (Welters et a l, 2003). 
It is interesting to note that this study found immune responses predom inantly 
to HPV16 E6 epitopes, with little response detected to HPV16 E7. These 
findings led the authors to conclude that T-cell reactivity against HPVI 6 E7 was 
suboptimal during infection and that IFNy-producing T-cells directed against 
HPV16 E6 may offer protection against persistent viral infection and the
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development of neoplasia. In a recent update of their data2, the authors 
reported a reduced proliferative response in those individuals w ith CIN or 
carcinoma when compared to the healthy volunteers. Moreover, the responses 
that were induced appeared to be deficient in effective cytokine production.
The eradication of virally-infected cells requires cell-mediated cytotoxicity and 
is dependent on the CD8+ cytotoxic T-cells (CTL) and Natural Killer cells (NK). 
Following the discovery that peptides binding class I MHC antigens shared 
common motifs (Falk et al., 1991), HPV16 E 6/7  imm unostimulatory peptides 
have been designed for the common HLA-A*0201 haplotype (Ressing et al., 
1995), which is found in about 40% of the Caucasian population. Such peptides 
were then used to demonstrate HPV specific CTL in blood samples (Ressing et 
ah, 1996) and subsequently within cervical tum ours and the locoregional lym ph 
nodes from such patients (Evans et al., 1997). Whilst initial work focussed on 
HPV16 E7 peptides, recent studies have lent further weight to the importance of 
the HPVE6 CTL response in determ ining viral persistence and possibly 
malignant progression. In one such study, an E6 specific CTL response was 
significantly more likely in wom en who cleared their HPV16 infection as 
opposed to those w ith persistent disease (22/40 vs. 0/9; p=0.003). There was no 
significant difference when an HPV16 E7 specific response was considered 
(Nakagawa et al., 2000a). Furthermore, an in vitro study of cervical cancer cell 
lines suggests that these cells may escape a CTL response to E6 by defective 
antigen presentation, mediated in part by decreased expression of MHC class I 
molecules and transporter associated with antigen processing (TAP) proteins 
(Evans et al., 2001).
1.2.2.3.3 Improving the detection o f CTL responses
There have been concerns that studies using immunostimulatory peptides may 
fail to detect memory CTL responses, as the peptides may not be appropriate 
epitopes for all subjects. A variety of strategies have been developed to improve 
the detection of HPV-specific CTL. Initial attem pts to mimic 'natural' antigen
2 Van der Burg et al. Personal communication, HPV Vaccines and Immunotherapies, July 2003, 
Cambridge.
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presentation involved stimulation of PBMC using CaSki cells (Evans et al., 1996) 
or full length proteins expressed using viral vectors (Nimako et al., 1997). More 
recently sensitive quantitative techniques have been developed which allow 
HPV-specific CTL responses to be m easured directly from clinical blood 
samples. Tetramers are soluble, fluorogenic MHC-peptide complexes that can 
be used to stain specific CD8+ cells. Such tetramers have been constructed 
using HLA-A*0201 and the well characterised, immunogenic HPV16 E7n-2o 
peptide (Youde et al, 2000) and these tetramers were able to detect memory T- 
cell responses from patients with CIN 3.
An alternative technique is the ELISPOT technique (Figure 1-12). ELISPOT is a 
microtitre-plate-based enzyme-linked immunoassay used to detect cytokines, 
commonly IFNy, produced by antigen specific T-cells following isolation of 
PBMC from blood and stimulation w ith the appropriate antigen. By knowing 
the concentration of PBMC seeded in each well, the concentration of antigen 
specific T-cells in the blood can be estimated. This technique has been used 
successfully to show HPV16 E7-directed T-cell immunity in subjects w ith 
HPV16 positive cervical lesions (van der Burg et al., 2001b). The quantitative 
nature of this technique allows the detection of an increased response following 
therapeutic intervention in a patient w ith a degree of pre-existing T-cell 
immunity to HPV.
1.2.2.3.4 Cytokines
The fundamental role of cytokines in the development of an appropriate 
imm une response has already been highlighted (sectionl.2.2.3.4). Cytokines can 
be broadly divided into immunostimulatory (typel eg. IFN, IL-2) or 
immunoinhibitory (type 2 eg. IL-4, IL-10). Following work suggesting that IL-2 
responses were greatest in healthy individuals and decreased with increasing 
disease severity (Tsukui et al, 1996), Clerici and colleagues went on to suggest 
that production of immunoinhibitory cytokines was enhanced in those 
individuals w ith 'extensive7 HPV related disease (Clerici et al, 1997). This 
pattern of cytokine production might reflect a defective immune response in 
such individuals. However, a subsequent study found increasing production of
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IL-2 with disease persistence or progression (de Gruijl et al, 1998). These results 
relate to cytokine production from PBMC and a small study of local cytokine 
production measured from CIN explants cultured in vitro found even more 
heterogeneity in local cytokine responses (Mota et al, 1999). Undoubtedly the 
local cytokine milieu will be crucial to the outcome for virus-associated 
neoplastic lesions. Influencing cytokine production has proved useful in benign 
viral warts and encouraging early results have been seen with VIN (section
1.1.7.3.3). At present the specific cytokine profile associated with spontaneous 
regression of HPV-associated AGIN remains uncertain.
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Figure 1-12. The ELISPOT technique. A microtitre plate-based technique to detect cytokine 
release from activated T-cells isolated from peripheral blood. Central illustration show s typical 
appearance of ‘sp o ts’ within well, indicating cytokine production by specifically activated T-cells. 
Addition of a known quantity of PBMCs allows for a quantitative assessm en t of the immune 
response. Control experiments allow establishm ent of thresholds to allow the identification of 
both boosted and de novo immune responses.
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1.2.2.4 Genetic determinants of the host immune response to HPV
HLA polymorphism may have a central role in determining the response to 
HPV-associated AGIN. For class I MHC molecules, the HLA B*44 genotype has 
been implicated in disease progression for HPV-positive CIN (Bontkes et al., 
1998a), possibly due to specific downregulation of this allele in neoplastic cells 
(Bontkes et al., 1998b). More recently, population data has suggested a single 
protective HLA-C allele (Wang et al., 2002). For class two alleles, HLA DRB1*13 
has been negatively associated w ith cervical cancer (Apple et al, 1994; Sastre- 
Garau et al., 1996; Lin et al., 2001) and may confer some form of protection 
against this disease. Conversely, HLA DRB1*15 is increased amongst cervical 
cancer cases (Maciag et al., 2000; Ghaderi et al, 2002). Recent work on the 
DRBI*1501-DQB1*0602 haplotype (Beskow et al., 2001; Beskow et al., 2002) has 
suggested that these alleles may have an indirect effect on the development of 
neoplasia, by interfering w ith the ability to clear HPV, with resultant 
development of persistent infections and high viral loads. We have recently 
published data from a small (n=42) group of patients with high-grade VIN, 
which has shown similar associations w ith HLA polymorphism. In particular, 
HLA-A2, HLA-B7, HLA-DRB1*11 and HLA-DQB1*03032 are associated w ith an 
increased probability of HPV16- positive high-grade VIN. Conversely, 
individuals of type HLA-DRB1*01, HLADQB1*05 and HLA-DRB1*13 are less 
likely to have the condition (Davidson et al., 2003b).
In addition to congenital variation, acquired genetic variation may potentially 
influence the host immune response to HPV infection. The expression of 
immune relevant genes may be influenced by the genetic instability arising 
from the expression of HR-HPV oncoproteins (section 1.2.3). Furthermore, viral 
integration may influence the response to anti-viral cytokines such as IFN 
(Alazawi et al, 2002).
1.2.2.5 Immune evasion by HPV
Our understanding of the immune response to HPV has allowed progress in the 
development of both prophylactic and therapeutic vaccines (Chapter 5). 
However, the possible shortcomings of such immunotherapies m ust be
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considered. As a virus, HPV is particularly effective at avoiding an appropriate 
immune response. This immune evasion accounts for the lag time between 
primary infection and the development and progression of clinical lesions. 
Immune evasion is achieved at various different levels within the im m une 
response and some of these mechanisms are outlined in Table 1-8. The success 
of immunotherapy for HPV-associated AGIN will depend in part on 
overcoming such immune evasion by the virus.
Level of 
Immune
Possible
mechanism
Comment
evasion
Antigen
presentation
Tropism for 
keratinocytes 
Antigen 
threshold
MHC expression
APCs
-  Low levels of HLA molecules may induce 
non-responsiveness (Bal et al., 1990)
-  Murine model shows non-responsiveness at 
low levels of E7 exposure (Chambers et al., 
1994)
-  HPV integration may reduce MHC class I 
expression (Bartholomewsal., 1997)
-  Reduced Langerhans cells in dysplasia and 
HPV infection (Connor et al., 1999)
Cytokines IL-10
Loss/gain of 
immune 
response genes
-  Increased immunoinhibitory cytokines 
associated with HPV (Clerici et al., 1997)
-  HPV-induced genetic instability associated 
with HPV may alter expression of immune 
relevant genes
-  HPV-integration associated with altered 
expression IFN-responsive genes (Alazawi et 
al., 2002)
Effector cells NK inactivation
Reduced CTL 
signalling
-  In vitro expression of oncogenic E7 blocks 
NK cell mediated lysis of HPV-transformed 
cells (Routes et al., 1995)
-  CD3 zeta chain expression reduced in CIN 
and cervical carcinoma. (Kono et al., 1996)
Table 1-8. Possible mechanisms of immune evasion by human papillomaviruses
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1.2.3 Genetic events in female lower genital tract malignancy
1.2.3.1 The genetic basis of malignancy
The transformation of normal epithelium  to carcinoma occurs w ith increasing 
morphological and cellular alterations. In colonic carcinoma it w ould appear 
that tum our progression occurs w ith the progressive and apparently sequential 
acquisition of genetic change (Fearon et al, 1990). Indeed, genetic alterations are 
common to many solid tum ours and progression is associated w ith increasing 
frequency of copy number alterations per case (Ried et al, 1999). The recurrent 
nature of such changes supports the existence of genes whose functions are 
central to the development of cancer, namely proto-oncogenes and tum our 
suppressor genes (TSG). Proto-oncogenes usually promote cell proliferation. 
Gain of function mutations in cancer cells create versions of these genes w ith 
excessive proliferative activity know n as oncogenes. Oncogenes behave in a 
dom inant fashion such that m utation of a single allele may affect the phenotype 
of the cell. In contrast, TSG produce products whose activity limits progression 
towards carcinoma. W ork on familial retinoblastoma led to the proposal of a 
'two-hit' hypothesis for TSG, whereby two successive mutations of a TSG are 
required to turn  a normal cell into a cancer cell (Knudson, 1971). An individual 
who is already heterozygous at a TSG locus (due to a hereditary or acquired 
mutation) therefore only requires inactivation of the remaining wild-type allele 
- known as loss of heterozygosity (LOH) - for tum our formation to occur. 
Mutations that commonly 'activate' oncogenes or TSGs include translocations, 
point mutations, gene amplifications and gene deletions.
Genetic instability may occur at either chromosomal or nucleotide level 
(Lengauer et al, 1998). The low rate of spontaneous mutations (2xl0*7 /  cell 
division) contrasts dramatically with the high incidence of mutations found in 
tum our cells. This discrepancy has led some authors to postulate the existence 
of a 'm utator phenotype' in cancer (Loeb, 2001). This phenotype is proposed to 
arise as a result of mutations in genes whose products that are crucial to the
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maintenance of genomic stability e.g. DNA repair enzymes such as polymerases 
and helicases. However, such a phenotype is not essential as m utations may 
provide a selective growth advantage with resultant rounds of clonal expansion 
at exponential rates (Cairns, 1975). At a chromosomal level, aneuploidy may 
serve to drive genetic instability (so-called "chromosome error propagation") 
(Holliday, 1989; Duesberg et a l, 1998). Indeed, aneuploidy has been 
demonstrated in LSIL of the cervix and can therefore be a relatively early step 
in the development of lower genital tract cancer. Carlson and colleagues used 
fluorescence in situ hybridisation (FISH) to demonstrate a significant 
progression of chromosome 17 polysomy through the histological spectrum  of 
normal vulvar skin to vulval SCC (Carlson et al, 2000). Normal skin found in 
association w ith vulval SCC showed higher rates of chromosome 17 aneusomy 
than control skin, lending support to the notion of aneuploidy as a driving force 
at an early stage of vulval carcinogenesis.
1.2.3,1.1 The role o f HPV infection in the development o f genetic instability
Infection with genital HPV is a common and often transient event in young 
women (Ho et al, 1998). Only a fraction of infected individuals develop SIL and 
even when HSIL are considered, only a minority of lesions will progress to 
invasive disease. Thus, it would appear that HPV infection alone is insufficient 
for malignant progression. Before an invasive tum our will develop, the 
normally tight control of viral gene expression (section 1.2.1.3) m ust be 
disrupted to allow the expression of early genes in proliferating epithelial cells. 
Following such disruption, HR-HPV E6 and E7 cooperate to overcome the 
usual cellular controls on DNA synthesis; to promote aneuploidy and genomic 
instability; and to prevent the usual apoptotic response to such aberrations 
(Table 1-9 and section 1.2.1.4).
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High-risk HPVE6________________ High-risk HPVE7
Inhibits p53 function directly by Binds and inactivates pRb, p i07 and p i30 
degradation (Scheffner et al., 1990) and (Dyson, 1998), with resultant increase in 
indirectly by binding the transcriptional E2F inducible genes, including cyclin E 
coactivator CBP/p300 (Zimmermann et (Ohtani et al., 1995) and cyclin A (Yam et 
al., 1999). a/., 2002).
Inhibits Bak induced apoptosis (Thomas Transactivates API transcription factors 
A ction  et al., 1998) (Antinore et al., 1996).
Reduced transactivation o f cyclin- Inhibits CKIs WAFl(Funk et al., 1997) 
dependent kinase inhibitor (CK.I) WAF1 and KIPl(Zerfass-Thome et al., 1996). 
(Zeng et al., 2002).
Telomerase activation (Klingelhutz et Induces abnormal centrosome synthesis 
al., 1996). (Duensing et al., 2001 a).
H # ; , Promotes ; . genomic iastabHhy Prom pts f*
eflect 5 2001a).
V .. ■ ’m * .«•.:* ' .v.'.:--' >-/•' t *„ , -
Prevents agtoptosis *.
Table 1-9. Contribution of high-risk HPV oncoproteins to genetic abnormalities in lower 
genital tract malignancy
1.2.3.2 Genetic alterations in squamous cell neoplasia of the vulva and 
cervix
The combination of a long natural history, well-defined morphology and 
relative ease of access to tissue specimens lends itself to the study of the role of 
genetic change in squamous neoplasia of female lower genital tract. Cervical 
neoplasia is the most common form of lower genital neoplasia and has the 
additional advantage that well characterised cell lines exist to allow in vitro 
studies to be performed. For this reason, most evidence for recurrent genetic 
alterations has been gained from the study of CIN and cervical SCC. However, 
limited data also exist to support recurrent genetic change in both VIN and 
vulval SCC.
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1.2.3.2.1 Classical cytogenetics
Classical cytogenetics involves the study of metaphase chromosomes, which 
can be identified by their unique banding pattern w ith certain stains. Karyotype 
analysis is routinely performed using Giemsa (G-banding) although m any other 
stains have been used e.g. 4,6-Diamidino-2-phenylindole (DAPI). G-banding 
produces a pattern of three to four hundred alternating light and dark bands 
along the chromosome length. Giemsa preferentially stains gene poor areas 
containing repeat-rich sequences (usually A-T repeats) that replicate late during 
S-Phase. Since its inception in I960, the International System for H um an 
Cytogenetic Nomenclature (ISCN) has been used to allow the description of a 
diseased karyotype from the study of metaphase chromosomes. The 
classification was most recently revised in 1995 (Mitelman, 1995). Although 
staining techniques allow the identification of alterations > 4000 kb, there are 
problems with such an approach. Accurate classification will depend on 
subjective variables such as operator experience. The resolution of staining is 
crucially dependent on chromosomal condensation and the physical 
accessibility of the staining agent. Although improved results may be obtained 
by the use of proteolytic enzymes such as trypsin, the technique is inherently 
variable. Furthermore, solid tum ours often contain sparse metaphases, 
exhibiting m arked aneuploidy and heterogeneity, which are frequently 
unsuitable for such assessment. Despite these difficulties karyotypic 
abnormalities have been reported in a small study of six vulval carcinomas 
(Worsham et al, 1991). Frequent abnormalities seen included both losses (3p, 
8p, 22q, Xp) and gains (3q, llq ) .
In view of the difficulties in standard karyotype analysis, many early studies 
focussed on ploidy. In the 1960s aneuploidy was documented in cervical HSIL, 
then known as carcinoma in situ (Spriggs et al, 1962). Cellier et al subsequently 
defined two groups of HSIL of the cervix, those with a peritetraploid cell 
population and those with a peridiploid/peritriploid population (Cellier et al., 
1970). In this study no invasive carcinoma with an exclusively peritetraploid 
population was found, leading to the suggestion that only those HSIL w ith a
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peridiploid/peritriploid cell population would progress to malignancy. More 
recently high rates of aneuploidy have been dem onstrated in both vulval SCC 
(72%) and VIN (80%) (Lerma et al., 1999). The authors' data support an earlier 
report that used regression analysis to suggest that ploidy was an independent 
prognostic parameter in vulval carcinoma (Kaem et al, 1992). This view has 
been challenged by a smaller study of 43 carcinomas, where ploidy status was 
not found to be of prognostic importance (Ballouk et al, 1993).
1.2.3.2.2 Molecular genetic techniques
Advances in recombinant DNA technology and our understanding of the 
hum an genome have allowed investigation of the genetic changes associated 
w ith carcinogenesis at a molecular level. Initially genetic polymorphisms were 
studied by labour intensive restriction enzyme digestion of large am ounts of 
DNA followed by Southern blotting and hybridisation with a radiolabelled 
probe (restriction fragment length polymorphisms or RFLP). Developments in 
PCR technology have improved the sensitivity of DNA analysis. The more 
commonly employed techniques will be described in the following sections.
1.2.3.2.2.1 Loss of heterozygosity studies using microsatellites
Loss of heterozygosity (LOH) studies are normally used to suggest the presence 
of putative TSG. Microsatellites (MS) are short (1-4 bp) repetitive sequences 
(often (CA)n) that are interspersed throughout the genome, usually in 
intergenetic DNA. The length of the repetitive sequence may be highly variable 
or polymorphic. This feature is used to identify potential TSG by screening 
paired normal (e.g. blood or stroma) and tum our samples for such sequences. 
The sequence is amplified using PCR and the products are resolved on an 
appropriate gel. For a marker to be useful or 'informative', the normal tissue 
should be heterozygous for the marker polymorphism -  indicated by the 
presence of two bands on the gel, representing alleles of two different lengths. 
Should a deletion occur within a tum our this will be seen as loss of one of the 
bands from the tumour specimen - LOH. In practice, many pathological 
specimens contain a certain am ount of normal stroma. As such, LOH often 
shows as a decrease in the relative intensity of one or other band -  also term ed
75
Introduction
"allelic imbalance" (Al). MS screening for LOH may also suggest the presence of 
Microsatellite instability (MI), which may reflect the "mutator phenotype" 
w ithin an individual tumour. In MI, the gel reveals additional novel bands that 
are present in the tum our specimen but not in the normal control. Although 
informative polymorphic MS m arkers have been identified at approximately 
lOOkb intervals throughout the genome, studying tum ours in a global fashion 
w ould be a massive undertaking. LOH is therefore usually performed in a more 
focussed fashion, concentrating on regions of the genome where other evidence 
has suggested the presence of a potentially im portant locus. To obtain 
meaningful results from such studies, ideally a large panel of tum ours should 
be screened w ith closely spaced MS markers. LOH occurring at a specific locus 
in > 20 % of cases has been suggested to support the presence of a TSG 
(Hampton et al, 1994).
a) LOH b) MSI
N T  N T
Figure 1-13. Schematic illustration to show loss of heterozygosity (LOH) and 
microsatellite instability (MSI). Diagram represents bands seen on gel following PCR for an 
informative MS marker. The normal (N) tissue is heterogygous for the MS marker and therefore 
shows two products/bands, a) LOH is seen as loss of one of the allelic bands in the tumour 
specimen (missing band indicated by an arrow) b) In MSI, the tumour specimen shows 
additional bands (indicated by arrows) that are distinct from the two alleles seen in the normal 
specimen.
Recurrent LOH at high incidences has been demonstrated in SCC of the cervix 
for a variety of loci, including 3pl4.1-22, 4pl6, 4q21-35, 6p21.3-22, l lp l5 ,  and 
llq 2 3  (for review see Lazo, 1999). LOH may accumulate in a sequential pattern. 
Larson and colleagues studied a small group of 42 women with varying grades
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of CIN for AI/LOH at selected loci on four of the chromosomal arms identified 
as commonly affected in cervical cancer. Allelic loss at one or m ore locus 
increased in frequency with increasing histology grade of lesion (Larson et al., 
1997). A comparison of LOH between invasive carcinomas and concurrent CIN 
3 revealed high incidences of LOH at 3pl4.1-12 and 6p23, suggesting that these 
loci may be important early in tumorigenesis (Rader et al., 1998). The concept of 
progressive loss of genomic material is further supported by data from 
comparative genomic hybridisation (CGH -  section 2.2.4). Specific patterns of 
allelic loss may influence both prognosis in SCC (Kersemaekers et al., 1998) and 
disease recurrence following cervical conisation in cases of CIN (Lin et al., 2000).
The first study to document LOH in SCC of the vulva and associated VIN was 
extremely small preventing any meaningful conclusions from being draw n (Lin 
et al., 1998). Since this report, several investigators have demonstrated LOH in 
VIN (Pinto et al., 2000; Rosenthal et al., 2001; Rosenthal et al., 2002) a n d /o r  
vulval SCC (Flowers et al., 1999; Pinto et al., 1999; Rosenthal et al, 2001; 
Rosenthal et al., 2002). Indeed, Rosenthal et al. found LOH for at least one of the 
six loci studied to be a common event for both VIN (53%) and vulval SCC 
(81%). LOH is not unique to neoplasia and can be demonstrated in non­
neoplastic vulval dermatoses such as lichen sclerosus (Pinto et al., 2000). 
However, data from X-chromosome inactivation studies (Tate et al., 1997; 
Rosenthal et al., 2002) coupled w ith shared patterns of LOH between SCC and 
associated VIN (Rosenthal et al, 2002) provides molecular evidence suggesting 
that VIN is indeed a true precursor lesion for vulval SCC and that the 
progressive acquisition of genetic damage may be crucial to carcinogenesis. The 
loci that have been demonstrated to be affected in vulval neoplasia are similar 
to those found at high prevalence in SCC of the cervix and include 3p, 4q21, 
5pl4 and l lp l5  (Pinto et al., 1999; Rosenthal et al., 2001).
Several known TSG loci have been studied in more detail. Both Flowers and 
Rosenthal used MS markers to investigate LOH at 13ql4, the Rb locus (Flowers 
et al., 1999; Rosenthal et al., 2001). The authors concluded that LOH for Rb 
occurred at relatively low frequency and that loss of Rb did not appear to be
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im portant in vulval carcinogenesis. Rosenthal and colleagues also considered 
the p l6  locus (9p21). Whilst LOH at this locus did occur more frequently in VIN 
associated with carcinoma than VIN occurring in isolation, the fact that the p l6  
loss occurred at reduced frequencies in the associated carcinomas w ould 
suggest that p l6  is probably not involved in disease progression (Rosenthal et 
al., 2001). LOH at the p53 locus (17pl3.3) is more common in HPV negative 
vulval SCC than in HPV positive vulval SCC (Flowers et ah, 1999; Rosenthal et 
al, 2001). As HPV-positive tum ours can abrogate p53 function by their high-risk 
E6 oncoprotein, there is unlikely to be a selection pressure for m utation of the 
p53 gene within these tumours. O ther loci on 3p, 5q, lOp and lOq also show 
significantly higher rates of LOH in HPV-negative carcinomas (Flowers et ah, 
1999; Pinto et al., 1999; Rosenthal et al., 2001). These findings may provide an 
insight into distinct pathways for the development of HPV-negative vulval 
SCC.
1.2.3.2.2.2 Fluorescence in situ hybridisation
FISH techniques rely on the fact that, under appropriate conditions, a DNA 
probe will bind to the complementary DNA sequence on a chromosome. The 
probe can be labelled either directly by incorporation of a fluorescent-labelled 
nucleotide precursor, or indirectly by incorporation of a reporter molecule 
(such as biotin or digoxigenin) which can then be detected using a specific, 
fluorescent-labelled antibody. Large DNA probes are used to improve the 
intensity of the hybridisation signal and the addition of a large excess of 
genomic DNA to the probe prior to the hybridisation will saturate repetitive 
elements within the probe, preventing them from masking the signal generated 
by unique sequences (Lichter et al., 1990). Molecular genetic techniques based 
on FISH have improved the resolution of chromosome mapping beyond that 
afforded by conventional banding analysis and overcome some of the 
limitations associated with variation in metaphase chromosome preparation 
(Trask, 1991). Multiplex-FISH, spectral karyotyping and interphase FISH 
involve the hybridisation of a known probe to target chromosomes in either 
m etaphase spreads or interphase nuclei. Comparative genomic hybridisation
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(CGH) reverses this strategy, using a probe constructed from the tum our DNA 
and hybridising it to normal metaphase chromosomes in competition with 
normal reference DNA. The technique of CGH will be discussed in detail in the 
following section.
1 .2 .3 .2 .2 .3  C o m p a ra t iv e  g en o m ic  h y b r id is a t io n
CGH permits the rapid and detailed detection of both gains and losses across 
the whole genome within the confines of a 'single7 hybridisation experiment. 
The technique was first described in the early 1990's (Kallioniemi et al., 1992; du 
Manoir et al, 1993) and requires relatively small amounts of DNA which can be 
obtained from either fresh or archival material. The methodology is illustrated 
in the following diagram.
Figure 1-14. Comparative Genomic Hybridisation. DNA from subject and normal reference 
are  differentially labelled (conventionally test DNA is labelled green, control DNA is labelled 
red). Equal am ounts are then used in a competitive hybridisation against normal male 
m etaphase chrom osom es on a g lass slide. Copy number gains will be indicated by a 
predominantly green fluorescent signal from that region, whilst losses will give a predominantly 
red signal.
Equal amounts of 'test' DNA (from the tumour to be investigated) and 'control' 
normal reference DNA (e.g. WBC from a karyotypically normal individual) are 
differentially labelled, using either digoxygenin-conjugated or biotinylated 
nucleotides. The mixture is then used as a probe in a competitive hybridisation
DOP PCR
‘ t
Meta phase 
spreads
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against normal metaphase chromosomes on a glass slide. An excess of 
repetitive, unlabelled Cot-1 placental DNA is used to suppress the signal from 
highly repetitive sequences (see above). Following stringency washes the bound 
DNA is detected by using antibodies directed against the incorporated haptens, 
each labelled with a different fluorochrome. Conventionally, test DNA is 
labelled with a green fluorochrome and control DNA with a red fluorochrome. 
DAPI counterstaining facilitates chromosomal identification. An image of the 
hybridisation pattern is captured using a fluorescence microscope w ith a 
cooled, charged coupled device camera and selective filters and analysed w ith 
the aid of appropriate software. The green:red intensity ratio is calculated along 
the entire axis of each chromosome within a metaphase. The data is converted 
to a graphical format, generating a fluorescence intensity ratio profile for each 
chromosome within the karyotype. Losses of DNA sequence within the test 
DNA are detected as an increased red fluorescent signal of the control DNA on 
the chromosomal region from which the sequence was derived (shown 
graphically as a deviation to the left). Conversely gains within the test sample 
are shown by increased green fluorescence (ratio profile deviated to the right).
Criteria have been established to ensure that the hybridisation is suitable for 
such quantitative analysis (Kallioniemi et al, 1994 - see table 1-10). Analysing 
multiple metaphases provides a mean ratio profile for each hybridisation and 
reduces the possibility of background noise influencing the result. 
Com puterised standardisation of fluorescent signals from each metaphase 
allows for meaningful comparisons between each experiment. The technique 
has limits of resolution of 10-12 Mb for deletions (Bentz et al, 1998). The lower 
limit of detection for copy num ber increase is dependent on the size of the 
amplicon and the excess copy num ber (Piper et al, 1995), but is likely to be 
between 2-5Mb. Contamination of the tum our sample with normal DNA may 
mask a real gain or loss and should be minimised by microdissection of the 
tum our sample where appropriate.
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2)
3)
Figure 1-15. S ta g es  of classica l CGH analysis
1) Images of suitable m etaphases captured using filters to allow visualisation of DAPI staining 
(blue) and red/green fluorescence respectively. Once captured, a composite image is created.
2) M etaphase displaying DAPI banding pattern
3) Individual chrom osom es outlined (blue) to allow sampling of fluorescence ratio along the 
long axis of the chromosome. Sampling axis shown in green
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4 )
5)
6)
Figure 1-15 cont.) Stages of classical CGH analysis
4) Manual karyotyping performed using DAPI banding pattern
5) Colour image showing chromosome pairs. 'Green' X chromosom e and 'red' Y chrom osom e 
serve a s  internal controls for hybridisation reaction.
6) Karyogram showing mean fluorescence ratio profile for each chromosome pair with 95% 
confidence limits. Threshold for copy num ber gains (green) and losses (red) se t at 1.15 and 0.85 
respectively. P rocess repeated for approximately ten m etaphases in each case.
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Criteria Note
Even hybridisation across Hybridisation should be smooth and of high
metaphase intensity. Granularity should be avoided.
Fluorescence distributions Both green and red fluorescence should
are similar between sister chromatids, chromosome 
homologues and identical chromosomes from 
other metaphases should be similar.
Background fluorescence low Although standardisation will be performed.
Adequate suppression of Binding of labelled DNA centromeres and
heterochromatin heterochromatic regions should be low.
Appropriate metaphases Intense DAPI staining, adequate length and 
minimal overlapping.
Table 1-10. Criteria to ensure quality of hybridisation is appropriate for quantitative 
analysis of CGH
1.2.3.2.2.3.1 Degenerate oligonucleotide-primed PCR
In the original descriptions of CGH, nick translation was used to create labelled 
probe DNA (Kallioniemi et ah, 1992; du Manoir et al, 1993). However, the 
potential applications of CGH were greatly enhanced with the development of 
novel PCR methodology. Degenerate oligonucleotide-primed PCR (DOP-PCR, 
Telenius et al., 1992) allows the general amplification of target DNA and 
provides the opportunity to perform CGH studies in situations where little 
tum our material is available. The technique can be used on archival paraffin 
embedded specimens (Speicher et al, 1993) and has been used successfully to 
perform  CGH from as little as three cells (Aubele et al, 1998).
DOP-PCR relies on multiple locus priming to achieve generalised amplification 
of target DNA. The PCR uses a partially degenerate primer, 6MW (Figure 1-16). 
Starting at the 5' end, the primer consists of a standard 3 base linker, followed 
by a hexanucleotide restriction enzyme site (Xhol) and a degenerate m iddle 
section. 6MW relies initially on priming at low annealing tem peratures from 
short sequences at the 3' end of the oligonucleotides used. These short
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sequences will occur frequently and facilitate prim er annealing at 
approximately 4Kb intervals throughout the genomic template. The 3' end of 
the primer contains an anti-codon for methionine, followed by glycine. Glycine 
is believed to be the most frequently occurring amino acid to follow the 
initiating methionine in eukaryotic proteins and these bases therefore 
preferentially direct annealing tow ards gene rich regions of the genome. The 
consistent 5' sequence allows for efficient annealing of the primer to previously 
amplified DNA at higher annealing tem peratures used in later PCR cycles.
Figure 1-16. Sequence of 6MW primer used in DOP-PCR
5' CCG ACT CGA GNN NN N  NAT GIG G 3'
N = any base in an equal ratio.
1.2.3.2.2.3.2 CGH studies o f vulval and cervical neoplasia
CGH has been applied to a wide variety of hum an tumours (summarised in 
(Struski et ah, 2002) including tum ours at a variety of sites in the female genital 
tract. Studies of SCC of the cervix have shown a consistent pattern of copy 
num ber imbalances (CNI). Common losses have been shown to affect 2q, 3p, 
4p, 4q, 5q, 6q, 13q and Xq. Chromosomes demonstrating consistent copy 
num ber increases include lq , 3q, 5p, 6p, 8q, 17p, 17q and 20 (Heselmeyer et al, 
1996; Heselmeyer et al., 1997b; Dellas et al, 1999; Kirchhoff et al., 1999; Kirchhoff 
et al., 2001). Analysis of preinvasive lesions has shown that CNI do occur, albeit 
at lower frequencies (Heselmeyer et al., 1996; Kirchhoff et al., 2001; Umayahara 
et al., 2002). The presence of non-random aberrations in preinvasive lesions 
may point towards potentially important genes in the development of 
carcinoma. Heselmeyer and colleagues found gain in 3q to be present in 1/13 
cases of CIN 3 (Heselmeyer et al., 1996). As such this abnormality might define 
the transition to invasive disease, but others have found this aberration in CIN2, 
an earlier stage of preinvasive disease (Kirchhoff et al., 2001).
Three recent studies have used CGH to study SCC of the vulva (Jee et al., 2001; 
Allen et al., 2002; Micci et al., 2003). The num ber of cases studied is small (36 in
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total) but recurrent CNI were found in all studies. The pattern of CNI was 
similar to that found in SCC of the cervix. The most common losses affected 3p, 
4p, 5q and l lq .  In keeping w ith the cervical SCC, gain of 3q was the most 
frequent amplification seen. Allen and colleagues found this change to be 
limited to HPV-positive tum ours and suggested 3q may harbour genes that act 
in synergy with HPV to cause anogenital carcinomas (Allen et al., 2002). To date 
no CGH studies of vulval pre-malignancy have been performed.
In addition to understanding the critical steps in carcinogenesis, the study of 
CNI may provide useful prognostic information. In endometrioid 
adenocarcinoma of the uterine corpus the average num ber of CNI was 
significantly greater in those patients who died from their disease than for those 
patients who were disease free after treatm ent (Suehiro et al, 2000). In addition, 
Suehiro and colleagues showed that the specific pattern of CNI could predict 
the likelihood of cervical involvement, lym ph node spread and even death from 
the disease. More recently, Kiechle et al. showed a correlation between the 
pattern of CNI and the degree of differentiation for ovarian carcinoma (Kiechle 
et al., 2001), itself a known prognostic variable.
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1.3 The aims of this thesis
Vulval intraepithelial neoplasia is increasing in incidence, particularly amongst 
younger women. The rate of disease progression remains uncertain w ith 
estimates varying from 5-10% in treated patients to as high as 85% in untreated 
individuals. VIN shows a strong association with HR-HPV types that have 
already been linked with the m alignant progression of other genital epithelial 
tumours. Current therapeutic options for affected individuals are 
unsatisfactory, often m utilating and carry disappointingly high recurrence 
rates. There is a pressing need to improve the understanding of the disease at a 
molecular level and to develop novel therapeutic options.
The research presented in this thesis aims to investigate viral and genetic factors 
that contribute to pathogenesis in VIN. It is hoped that this work will facilitate 
the identification of markers of disease progression, which might be used to 
identify women with a high or even inevitable risk of progression to invasive 
disease. In addition, a possible im m unotherapy will be assessed in a phase II 
open-labelled clinical trial.
W ithin the confines of this project the following hypotheses will be tested:
• W ithin HPV positive disease the pattern of viral gene expression may 
influence disease progression
• In common with its cervical counterpart, VIN will exhibit non-random  
chromosomal alterations (both losses and gains).
• The degree and site of these abnormalities are crucial for containment of 
the lesion w ithin the epithelium
• These abnormalities may differ between HPV positive and negative 
women
• Stimulating cell-mediated immunity against the most common HR-HPV 
genes may cause regression of clinical disease.
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Chapter 2 Materials and Methods
2.1 Equipment and reagents
This sections lists equipment, reagents and suppliers used for this research.
2.1.1 General laboratory equipment
Specialised equipm ent will be discussed in the appropriate section of the 
methods.
Equipment Manufacturer
Pipettes (2-1 OOOpl) Gilson
Pipette (large volume) Integra Biosciences Ltd.
Bench top vortex Chiltem Scientific
Bench top centrifuge Heraeus
Centrifuge Beckmann
Water baths Grant
UV Spectrophotometer Beckman Coulter
Hot block Techne
Water purification -  ElixlO Millipore
Water purification -  Milli-Q Millipore
PCR thermal cycler Techne
PCR thermal cycler Hybaid
Gel Imaging system/software Flowgen
Laminar flow cabinet (class II) Envair
CO2 incubator Heraeus
Dissecting microscope Kyowa
Phase contrast microscope Nikon
Microscope Leitz
Microscope image capture system Olympus
Table 2-1. General laboratory equipment.
2.1.2 Reagents and plasticware
General laboratory reagents were supplied by BDH laboratory supplies. Table 
2-2 lists specific additional reagents, proprietary kits and plasticware used 
during the research project. Unless certified clean, plasticware was steam- 
autoclaved prior to use.
Name Supplier
Reagents Amberlite IRN-150L BDH Laboratory Supplies
Anti-Digoxigenin-AP Fab Roche Diagnostics Ltd.
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Name Supplier
fragments (sheep)
Anti-digoxigenin-fluoroscein Fab Roche Diagnostics Ltd.
fragments (mouse)
Biotin 16-dutp Roche Diagnostics Ltd.
Block Roche Diagnostics Ltd.
Bovine Serum Albumin Sigma-Aldrich
CGH Metaphase Target Slides Abbott Diagnostic Division
dATP PCR grade Roche Diagnostics Ltd.
Depex BDH Laboratory Supplies
Denhardts solution Sigma-Aldrich
Diaminobenzidine (DAB) Sigma-Aldrich
Dig-RNA labeling mix Roche Diagnostics Ltd.
Dig- RNA labelling kit Roche Diagnostics Ltd.
Dig-11-dUTP Roche Diagnostics Ltd.
lKb+ DNA Ladder Invitrogen Life Technologies
DNAZap Ambion (Europe) Ltd.
DOP PCR master Roche Diagnostics Ltd.
dTTP PCR grade Roche Diagnostics Ltd.
Far amount aqueous mountant Dako Ltd.
Ficoll-Paque PLUS Amersham Biosciences Ltd
Fluorolink Cy3 streptavidin Amersham Biosciences Ltd
Goat anti-mouse biotinylated Dako Ltd.
antibody
Goat Anti-Rabbit biotinylated Dako Ltd.
antibody
HotStar Taq. DNA polymerase Qiagen Ltd.
Human Cot 1-DNA Invitrogen Life Technologies
Hybridisation Buffer Sigma-Aldrich
Lymphoprep Nycomed Pharma
B-mercaptoethanol Sigma-Aldrich
NBT/BCIP Stock Solution Roche Diagnostics Ltd
Normal Goat Serum Dako Ltd.
NTP Mix (lOmM each NTP) Roche Diagnostics Ltd
OCT Compound Agar Scientific Ltd
Optimised-200 Buffer Kit D Invitrogen Life Technologies
Orthoboric Acid Merck Ltd
Paraformaldehyde Sigma-Aldrich
Polyoxyethylene ether W1 Sigma-Aldrich
Proteinase K Sigma-Aldrich
Set of deoxynucleotides-PCR Roche Diagnostics Ltd
Streptavidin-biotin antibody Dako Ltd.
complex (SABC)
Super Taq (HC) HT Biotechnology Ltd.
N-Tris(hydoxymethyl)-3- Sigma-Aldrich
aminopropanesulphonic acid
(TAPs)
Taq DNA Polymerase Amersham Biosciences Ltd
Trizma base Sigma-Aldrich
Tween-20 (Polyoxyethlenesorbitan Sigma-Aldrich
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Name Supplier
monolaurate)
Vectashield (with DAPI) mountant 
Water -DNase/RNase free
Vector Laboratories 
Sigma-Aldrich
Plasticware 0.65ml Multi-Ultra PCR tubes
0.65-2ml reaction tubes
10-1 OOOpl filter tips
ART 10 reach filter tips
1.8ml Cryotubes
Tissue Moulds
7.5ml S-Monovette tubes
Bioquote Ltd 
STARLAB (UK) Ltd. 
STARLAB (UK) Ltd. 
Fisher Scientific 
Nalge (Europe) Ltd. 
Nalge (Europe) Ltd. 
Sarstedt Ltd.
Proprietary
Kits
Qiaquick Gel extraction kit 
Qiaquick PCR purification kit 
Wizard Plus SV miniprep kit 
Plasmid midi-prep kit 
DNA mini kit 
Dig-RNA labelling kit
Qiagen Ltd.
Qiagen Ltd.
Promega UK 
Qiagen Ltd.
Qiagen Ltd.
Roche Diagnostics Ltd.
Table 2-2. Reagents, plasticware and proprietary kits 
2.1.3 Buffers and solutions
Buffers and solutions are listed in alphabetical order for ease of location. Unless 
otherwise stated the water used in preparing these solutions was purified by 
reverse osmosis and deionised using the Millipore Elix-10 system. Ultrapure 
water water for general PCR was obtained from the Millipore Milli-Q system. In 
addition to the above treatm ent this water was UV treated, ultrafiltered to 
remove particles >5000 Daltons and finally filtered through a 0.22pm 
membrane. For ease of reference, solutions and buffers are listed alphabetically 
and uses are specified (where appropriate).
Buffer 1
Use: RNA in situ hybridisation
Component Final
concentration
Stock
concentration
Volume o f Stock 
(ml)
Tris (pH 7.5) 0.1M 1M 50
NaCl 0.1M 5M 10
MgCl2 2mM 1M 1
Triton X-100 0.05% 20% 1.25
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Buffer 2
Use: RNA in situ hybridisation.
0.5% blocking reagent (Roche Diagnositics Ltd.) in buffer 1.
Buffer 3
Use: RNA in situ hybridisation.
Volume: make up to 500ml with water
Component Final Stock Volume o f  Stock
concentration concentration (ml)
Tris (pH 9.5) 0.1M 1M 50
NaCl 0.1M 5M 10
MgC12 50mM 1M 25
DNA loading buffer
Use: loading DNA for gel electrophoresis
Volume: make up to 60ml with water_______
Component Amount
EDTA pH 8.0 3ml 0.5M stock
Ficoll 400 15g
Bromophenol blue 0.05g
Xylene cyanol 0.05g
Bromophenol blue marker runs at ~400bp; xylene cyanol at ~1500 bp
Hybridisation buffer -  CGH
Use: resuspending DNA probe prior to CGH
Volume: make up to 50 ml with water________________________
Component Final
concentration
Stock
concentration
Volume o f Stock 
(ml)
Formamide 25% 50% 25
Dextran Sulphate 10% 50% 10
SSC 2x 20x 5
Sodium Phosphate buffer* 40mM 0.5M 4
Denhardts Solution lx 5 Ox 1
*0.5M sodium phosphate buffer, pH 7: 288mM Na2HPC>4 + Na^PCU
Combine reagents thoroughly and mix. Filter sterilise, aliquot and store frozen at -20°C.
lkb+ ladder (quantitative)
Use: quantifying agarose gel electrophoresis products.
Volume: 1.2ml
Component Amount
(Id)
lkb+ ladder IS
DNA loading buffer 200
Water 925
When lOpl is used as reference ladder, the 1650 base marker band is 50ng.
Lysis Buffer
Use: DNA extraction
Volume: 500pi (or multiples thereof)
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Component Final
concentration
(mM)
Stock
concentration
(M)
Volume o f  Stock 
(Ml)
Trizma base (pH 7.5) 10 1 50
EDTA (pH7.5) 10 1 50
Water n/a n/a 400
Make up fresh for each extraction. Keep on ice.
Phosphate buffered saline (PBS) - lOx stock
Volume: 1000ml
Component Final Amount
concentration (g)
NaCl 1.37M 81.00
Na2HP04.12H20 0.1M 19.80
Na2HP04.H20 22.4mM 1.57
Add water to 800ml and pH to 7.4 with HC1. Make up to 1L with water and autoclave.
Polyoxyethylene ether W-l (W-l detergent)
Use: Degenerate oligonucleotide primed PCR.
Volume: 100ml
Dissolve lg of W-l in 80ml water, warming solution to 65°C to facilitate process. Make 
up to 100ml with water, filter-sterilise (22pm), aliquot and store at -20°C.
Proteinase K buffer
Use: RNA in situ hybridisation.
Volume: 500ml
Component Final Stock Volume o f Stock
concentration concentration (ml)
Tris (pH 7.4) 20mM 1M 10
CaCl2 2mM 0.1M 10
3M Sodium Acetate pH S.2
Use: Nucleic acid precipitation
Volume: 100ml
Dissolve 40.82g sodium acetate tri-hydrate in 50ml water. Adjust pH to 5.2 with glacial 
acetic acid. Increase volume to 100ml with water. Autoclave prior to use.
Salt sodium Citrate (SSC) -  20x stock
Use: In situ hybridisation (including comparative genomic hybridisation)
Volume: 1000ml
Component Amount
(g)
Sodium chloride 175.3
Tri-sodium citrate 88.2
Dissolve in 800ml water. Adjust pH (pH 7.0 with NaOH (5M); pH 5.2 with concentrated 
HC1) and make up to 1000ml with water.
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SST -  4x stock
Use: Comparative genomic hybridisation
Volume: 500ml
Component Volume
20x SSC-neutral 100ml
Water 400ml
Tween -20 250pl
N-Tris (hydroxymethyl)-3-aminopropanesulphonic acid (TAPS) buffer
Use: Degenerate oligonucleotide primed (DOP) PCR
Volume: 40ml
Component Final concentration Amount
TAPs 250mM 2.43g
KC1 500mM 1.49g
M gCh(lM ) 20mM 80pl
p-mercaptoethanol 28.8pM 280pl
Make up solution in 30ml water before adjusting pH to 9.3 with NaOH (5M). Adjust 
volume to 40ml with water. Filter-sterilise (22pm), aliquot and store at -20°C.
Tris-Borate-EDTA (TBE) buffer - lOx stock
Use: Running buffer for gel electrophoresis
Volume: make up to 2000ml with water
Component Final concentration Amount
(mM) (8)
Trizma base 89 216
Boric acid 89 110
Di-sodium EDTA 2.6 19
Dissolve in 1800ml water before adjusting pH to 8.3 with concentrated HC1.
Tris-EDTA (TE) buffer (10:lmM) -  lOx stock
Use: DNA extraction
Component Final concentration Amount
/mM /g
Trizma base 100 12.1
EDTA 10 3.72
Dissolve in 800ml water. Adjust pH to 8.0 with concentrated HC1. 
2.1.4 Tissue Culture
Name Supplier
General Media Glasgow’s Modified Eagle’s Sigma-Aldrich
Medium (GMEM)
Dubeccio’s Modified Eagle’s Sigma-Aldrich
Medium (DMEM)
RPMI - 1640 Sigma-Aldrich
Additive Fetal calf serum (1 Ox) PAA Laboratories Ltd.
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Name Supplier
Additive cont) Glutamine (lOOx) Invitrogen life technologies
Penicillin/ Streptomycin 
(10,000u/ml and 10,000pg/ml)
Invitrogen life technologies
Dimethyl sulphoxide (DMSO) Sigma-Aldrich
Trypsin/EDTA (0.5%/5.3mM) Invitrogen life technologies
Plasticware 50ml polypropylene tubes Falcon
1.8ml polypropylene cryotubes Nalge (Europe) Ltd.
Sterile Flat culture flask 
(25, 75 and 125 cm2)
Falcon
Sterile plastic pipettes 
(10 and 25ml)
LPA Italiana SPA
Table 2-3. Tissue culture materials 
2.1.4.1 A dditional media
The following media were prepared as required in the laboratory:
Luria Broth (LB)
Volume: 1000ml____________________________
Component Amount
 (8)
Tryptone 10
Yeast extract 5
NaCl____________ 10
Dissolve in 800ml and adjust to pH 7.5 with NaOH (5M). Make up to 1000ml and 
autoclave.
Tryptone Yeast culture medium - 2x (2TY)
Volume: 1000ml _______________________
Component Amount
 (8)
Tryptone 16
Yeast extract 10
NaCl____________ 5
Dissolve in 800ml. Make up to 1000ml and autoclave.
SOB
Volume: 1000ml
Component Final
concentration
Amount
(8)
Bactotryptone 2% 20
Yeast extract 0.5% 2
NaCl lOmM 0.584
KC1 2.5mM 0.186
MgCl2 lOmM See below
MgSC>4 lOmM See below
Prepare without MgCl2 and MgS04  and autoclave. To 100ml add 1ml of 1M MgCl2 and 
lml 1M MgS0 4  just before use (SOC).
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TFB
Volume: variable
Reagent Concentration
(mM)
K-MES 10
KCL 100
MnCl24H20 45
CaCl2.6H20 10
Hexamine C0CI3 3
K-MES is ImM morpholino ethanesulfonic acid (MES) adjusted to pH 6.3 with KOH 
and filter sterilised. TFB stored in 10ml aliquots at -20°C.
2.2 METHODS
2.2.1 DNA sources and extraction
DNA was extracted from both clinical specimens and tissue culture. Ethical 
approval for the project was given by Cambridge Local Research Ethics 
Committee (LREC 98/227). Data collected concerning the clinical specimens 
was kept in accordance w ith hospital guidelines on data protection and the 
research database was registered under the 1998 Data Protection Act.
2.2.1.1 Handling of clinical specimens
2.2.1.1.1 Fresh tissue biopsies
Fresh tissue specimens were collected from patients in the Colposcopy and 
Vulval clinics as well as the Gynaecological Oncology theatres at Addenbrookes 
Hospital Cambridge. Specimens for HPV typing were place in cryotubes and 
immediately snap frozen in liquid nitrogen before being stored at -70°C.
W here samples were required for CGH the biopsy was split using a sterile 
blade and half the biopsy was m ounted on edge in a tissue mould using OCT 
com pound before storage at -70°C. Subsequent manipulation of tissue samples 
was carried out in the category 2 area of the Division of Virology, University of 
Cambridge.
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2.2.1.1.2 Blood
Blood specimens were taken for immunological studies and control specimens. 
Sterile technique was used in the collection of samples. Samples were either 
processed or transferred to the collaborating laboratory at Xenova Research Ltd. 
w ithout delay.
2.2.1.1.3 Isolation of mononuclear cells from whole blood
Approximately 15ml of blood from the patient was transferred to a 50ml Falcon 
tube and mixed thoroughly with an equal volume of 0.9% sodium chloride by 
gentle inversion of the tube. A fresh Falcon tube was prepared containing 15ml 
of Lymphoprep. The blood/saline mixture was slowly added to the 
Lymphoprep so as to layer the blood/saline mix on top of the Lymphoprep. 
Care was taken to prevent mixing of the two layers. The layered solution was 
then centrifuged at 2000rpm (~800g) using a 'swing-out' rotor. The Falcon tube 
was then removed taking care not to disturb the 4 layers that will have formed. 
The mononuclear cells are to be found in the second layer and can be carefully 
draw n off with a pipette (layer order top-> bottom is plasma, mononuclear cells, 
lymphoprep, neutrophils and red cells). The mononuclear aspirate was then 
transferred to a clean tube and to which ~3 volumes of 0.9% sodium chloride 
solution was added. The tube was inverted to aid mixing of the liquids before 
centrifuging gently at lOOOrpm (~100g) for a further 10 minutes. The 
supernatant was discarded and the mononuclear cell pellet resuspended in 2ml 
of 0.9% sodium  chloride. The cell concentration was then estimated using a 
cytometer and an appropriate volume used for DNA extraction as detailed 
below.
2.2.1.2 Tissue culture
HPV-positive and HPV-negative cell lines were used to provide control DNA 
for PCR experiments.
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2.2.1.2,1 Cell lines
The following table details the cell lines used during this research. Frozen 
stocks were kindly provided by Dr. Jane Sterling, Division of Virology, 
University of Cambridge.
Cell Line Origin HPV status Reference
HaCaTs Immortalised aneuploid 
human keratinocytes
HPV negative (Boukamp et a l 1988)
SiHa Human epidermoid 
cervical carcinoma cells
1-2 copies of integrated 
HPV 16 per Cell
(Friedl et al., 1970)
CaSki Human epidermoid 
cervical carcinoma cells
-600 copies of HPV 16 
per cell (integrated as 
concatamers)
(Pattillo et al., 1977)
Table 2-4. Cells lines used for control DNA 
2.2.1.2.2 Cell culture technique
Cell culture preparation was carried out under sterile conditions in a Class II 
Laminar flow hood. Clean laboratory coats and gloves were available for this 
purpose and all equipm ent was w iped with 70% Ethanol prior to use. Cell line 
specific media are detailed in the following table.
Cell line Media Additives per 500ml media
HaCaTs GMEM 10% FCS; 2mM Glutamine; lOOu Penicillin; lOOpg 
streptomycin.
SiHa DMEM 10% FCS; 2mM Glutamine; lOOu Penicillin; lOOpg 
streptomycin.
CaSki RPMI-1640 10% FCS; 2mM Glutamine; lOOu Penicillin; lOOpg 
streptomycin.
Table 2-5. Cell line-specific media
2.2.1.2.3 Resuscitation of stored cell stocks
Cryotubes containing 1.5ml aliquots of cells (~2xl06cells per ml) frozen in the 
appropriate m edium  with 10% DMSO and stored in liquid nitrogen were 
thawed at 37°C before being transferred to 5-10ml of appropriate pre-warmed 
culture m edium  in a 50ml Falcon tube. The cells were separated by centrifuging 
at 1500rpm for 5 minutes. The supernatant was discarded and the cell pellet 
resuspended in the appropriate pre-warm ed culture medium. The volume of 
m edium  used was dependent on the size of tissue culture flask to be used (see
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table). The cell pellet was initially resuspended in one third of the appropriate 
volume of media, the rest being added directly to the tissue culture flask. The 
resuspended cells were then transferred gently to media in the flask. The flasks 
closed w ith the lids in the 'vent7 position and placed at 37°C in a 5% CO2 
incubator. Cell cultures were reviewed at 24 hours and the m edium  exchanged 
for fresh pre-warm ed medium. Cells were passed at -90% confluence.
Flask size 
(cm2)
Suggested volume of media 
(ml)
Maximum volume 
(ml)
25 7 8
75 15 20
125 30 40
Table 2-6. Suggested volumes of media for varying flask sizes
2.2.1.2.4 Passing o f confluent cells
The old culture m edium  was poured from the flask and the 'monolayer7 culture 
washed twice w ith 20ml PBS. 5ml T rypsin/ EDTA mix was added to 15ml PBS 
(total volume 20ml) and the solution added to the culture flask. The flasks were 
then incubated for -2m inutes at 37°C until the cells rounded-up and started to 
lift. Detachment of the cells was aided by tapping the flask. The cell solution 
was then added to an equal volume (20ml) of fresh culture medium in a 50ml 
tube to quench the trypsin and the cells pelleted by centrifuging at l,500rpm for 
2-4 minutes. The supernatant was poured away and the cell pellet gently 
resuspended in 10ml of fresh medium. The cells were then split (1/5-1/10) to a 
new culture flask into which the appropriate volume of culture medium had 
already been added (Table 2-6). Culture then proceeded as above.
2.2.1.2.5 Preparing frozen stocks
A freezing mix of 20% DMSO and media was prepared and kept cold. The cells 
were harvested as above and resuspended in 10 ml and the cell concentration 
estimated using a cytometer. An appropriate volume of the suspension was 
then pelleted using a centrifuge to yield approximately 2x10s cells. This cell 
pellet was then resuspended in 1-1.5ml DM SO/M edia mix and transferred to a 
cryotube. The cryotube of cells was then pu t into an insulated box and placed at
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-70°C overnight. The next day the frozen cell stock was transferred to the liquid 
nitrogen storage container.
2.2.1.3 DNA extraction
Samples for HPV typing were extracted in a separate area to the usual 
workspace to avoid possible contamination w ith HPV DNA.
2.2.1.3.1 DNA extraction from tissue biopsies
Hum an tissue biopsies were handled in the category 2 area of the Division of 
Virology, University of Cambridge. Biopsies were morcellated in sterile Petri 
dishes and the pieces placed into a 1.5ml tube containing 500pl of extraction 
buffer (comprising 465pl cold lysis buffer, 10pi proteinase K (10pg/ pi) and 25pi 
SDS (10%)). The tube was agitated for 18hours (overnight) at ~37°C. After 
inspection to ensure appropriate digestion the proteinase K was heat 
inactivated by heating to 95°C for 5-10 minutes. After a short period of 
centrifugation to remove drops from the lid of the tube, the solution was 
cleaned using the phenol/chloroform  method. Briefly, an equal volume of 
phenol was added to the tube, before pulse-vortexing to mix the liquids. The 
mixture was then centrifuged at 13,000rpm for 1 minute to allow separation of 
aqueous and phenolic phases. The phenol was removed from under the 
aqueous phase using a 'd raw n out' sterile glass pipette. An equal volume of 
chloroform was then added and the m ixture/centrifugation/rem oval process 
repeated. In order to ensure optimal purity of the DNA samples this whole 
process was repeated a second time. Finally the aqueous phase was transferred 
to a fresh 2ml tube. DNA was precipitated from solution by adding 1/10 
volume of 3M sodium  acetate and 2 V2 times the volume of 100% ethanol. After 
thorough mixing the tube was placed at -70°C for 30 minutes, or at -20°C 
overnight. The precipitated DNA was centrifuged at 13,000rpm for 30minutes 
before washing the pellet in 70% ethanol. After further centrifuging (13,000rpm, 
20 minutes) the excess ethanol was carefully decanted and the DNA pellet dried 
in a vacuum  desiccator before re-suspending in 150-200pl of ultrapure water.
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2.2.1.3.2 Extraction of DNA from cells
In contrast to the tissue specimens, large quantities of cells (from culture or 
blood) were available for DNA extraction. To maximise sample purity DNA 
was extracted from these samples using a proprietary kit (QIAamp DNA mini 
kit, QIAGEN). This method involves proteinase K digestion and DNA isolation 
using spin columns and a microcentrifuge. The lysate buffer provides optimal 
pH  conditions for binding to the spin column membrane. The membrane can 
then be washed w ith two different wash buffers to remove residual 
contaminants. After an additional centrifugation step to ensure all the wash 
buffer had been removed, the DNA was eluted from the column membrane 
using water.
2.2.1.3.3 Extraction o f DNA from microdissected frozen sections
Frozen sections were cut in the Departm ent of Histopathology, Addenbrooke's 
hospital, Cambridge. Sections were cut at a thickness of 7-10pm onto uncoated 
slides, taking care not to thaw  the sections onto the slides. The microtome blade 
was changed or cleaned thoroughly (xylene/HCL) between blocks to prevent 
cross-contamination. Slides were stored at -70°C until required. A reference 
section from either end of the run  was stained w ith haematoxylin and eosin 
(H /E) for histopathological review. Six to 10 sequential sections were then 
thawed into 70% ethanol to fix the slides, stained with H /E  and prepared for 
microdissection as detailed below:
Solution Time
70% Ethanol 
H20
30s 
30s 
30s 
30s 
30s 
30s 
30s 
30s 
30s 
30s 
5 mins
Haematoxylin
H20
70% EtOH 
90% EtOH 
Eosin
70% EtOH 
90% EtOH 
100% EtOH
Xylene
Table 2-7. Haematoxylin and Eosin staining protocol for frozen sections
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After staining and dehydration the slides were allowed to air dry. The target 
area of epithelium was identified for each case. The cells were then dissected 
under stereoscopic visualisation (10-15x magnification) using a sterile 25G 
needle m ounted on a 5ml sterile syringe. Only m oderate pressure was required 
and the dissected tissue tended to stick to the needle with static charge. The 
cells were then transferred into 60pl extraction buffer (comprising lm g /m l 
proteinase K, 1% Tween 20 and TE buffer pH8.0) in a thin walled 0.5ml tube. 
The extraction m ixture for one set of extractions was prepared as a batch 
mixture and aliquoted, retaining 1-2 aliquots for use as controls in subsequent 
PCR reactions. The tube was placed in a hotblock/therm al cycler at 38°C for 18 
hours. The tem perature was then raised to 95°C for 10 minutes to inactivate 
proteinase K and the resulting solution used neat in subsequent PCR reactions.
2.2.1.3.4 Histopathological review
All cases were reviewed by two independent consultant gynaecological 
pathologists (Dr N. Coleman, Hutchinson MRC Cancer Cell Unit and Dr R. 
Moseley, Addenbrooke's NHS Trust). Where discrepancies in classification 
were found both pathologists reviewed the sample and reached a consensus 
decision.
2.2.1.3.5 Assessing DNA concentration
Where sufficient volumes of DNA solution were available, an estimate of DNA 
concentration and purity was made using the sample absorbance at 260nm and 
280nm (A260 and A280). DNA at a known dilution (in 1ml total volume with 
water) was placed in a quartz cuvette and the A260 measured in a 
spectrophotometer after calibration with an appropriate water control. The 
concentration of DNA can be estimated by the following equation
Concentration (^xg/ml) = A260 x OD constant for DS-DNA x dilution factor
where A260 is the sample absorbance at 260nm (OD) and the OD constant for DS 
DNA is 50pg/m l. Purity of the sample was assessed by calculating the ratio of 
A26o:A28o which should be >1.6 and ideally >1.8.
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For samples where there was insufficient total volume to allow for repeat 
spectrophotometry to calculate the DNA concentration e.g. clinical PCR 
products, a known volume of sample was run  out on a 1 % agarose gel w ith two 
references ladders of known concentration. The 1650bp band of 1 Kb plus DNA 
ladder (Invitrogen Life Technologies) contains ~8% of the total mass applied to 
the gel. The ladder was therefore prepared in such a fashion that 10pi of ladder 
w ould have a 1650bp band equivalent to 50ng. An image of the gel was 
captured w ith 10pi and 20pl of ladder as reference standards (50 and lOOng). 
The image capture software (Flowgen) was used to define test and control 
bands, as well as gel background signal. The concentrations of the control 
bands were then specified to allow a standard curve to be constructed. DNA 
concentrations for the unknow n products could then be estimated by 
measuring the optical densitiy of the unknow n bands compared to those of the 
known controls.
2.2.2 Polymerase chain reaction
This section details the PCR methodology used during this thesis. Degenerate 
oligonucleotide prim ed PCR will be discussed in a later section.
2.2.2.1 PCR -  general considerations
The polymerase chain reaction is an exquisitely sensitive primer extension 
reaction for detecting and amplifying nucleic acids in vitro (Saiki et ah, 1988). 
Using thermostable polymerases with thermal cycling machines -105 fold 
amplification is achievable.
2.2.2.1.1 Thermal cyclers
Two thermal cyclers were used during this work and have been listed earlier. 
The first (Progene, Techne) operated by the 'block control' system, where the 
tem perature of the block was varied and a predetermined algorithm used to 
estimate the reaction mixture tem perature within the thin walled PCR reaction 
tubes. The second machine (PCR express, Hybaid) used a thermistor sensor to 
regulate tube temperature. This thermistor was placed into a PCR tube 
containing mineral oil, which was positioned in the thermal block. The
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thermistor attempts to provide an accurate measurement of the actual 
tem perature w ithin the reaction tubes. The samples are then held at the precise 
tem perature required for the specified time. This avoids the lag associated with 
block control machines where the sample tem perature lags behind the 
program m ed block temperature. The precise nature of the tim ing/ tem perature 
control allows a reduction in incubation times for each step. This machine also 
has a gradient block, which allows a tem perature gradient to be program m ed 
across the block, thereby enabling a range of annealing tem peratures to be 
investigated during a single PCR run.
2,2.2.1.2 Contamination prevention
The sensitivity of PCR is in itself a potential problem. Stringent methods were 
therefore adopted to prevent contamination. Reagents for PCR were stored at - 
20°C in a separate freezer area from DNA and all PCR buffers and solutions 
were aliquoted on receipt to reduce the risk of contamination being introduced 
to the stocks. The thermostable polymerases used were solely for the use of the 
investigator and were not part of the general laboratory stocks. The risk of 
contamination was further reduced by using dedicated, separate areas for the 
preparation of PCR solutions. Briefly, the reagents for a PCR reaction were 
made up into a 'master-mix' in a dedicated area within the Division of 
Virology. The 'master-mix' contained the common reagents required for all the 
PCRs to be set up. Aliquots of the mix can then be dispensed into each reaction 
tube. This reduces the num ber of pipetting steps and thus the potential for cross 
contamination between tube. Dedicated pipettes with filter-tips were used for 
this process. The equipm ent was kept in a sealed container and the bench space 
and container exterior were cleaned with an anti-DNA preparation (DNA-Zap, 
Ambion Ltd.) both prior to and following use. This product is a proprietary 
D N A/RNA degradation solution that is capable of degrading any nucleic acid 
down to free nucleotides. To avoid potential contamination by hum an DNA 
from the investigator a clean laboratory coat and gloves were worn. Target 
DNA was added to the reaction tubes in another area of the laboratory using a 
different set of filter tips and pipettes. No other investigators were using HPV
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DNA in this area. Finally, the products of the PCR reaction were m anipulated 
in a third bay.
2.2.2.1.3 Controls
All PCR reactions were run w ith appropriate negative and positive control 
reactions. For p-globin PCRs these included reactions w ith no template, the 
extraction buffer and placental DNA. For HPV detection this includes reactions 
with no template (water/extraction buffer), HPV negative DNA and HPV 
positive DNA at a known copy number. For DOP-PCR, the extraction mix and 
filter PCR grade water were used as negative controls. Amplification of a 
known am ount of the control DNA (~300ng) served as a positive control. 
Results from a PCR experiment were only used if all controls gave appropriate 
results.
2.2.2.1.4 Hot-start PCR
The degenerate-primers used in the HPV detection PCR systems are prone to 
non-specific amplification and the formation of primer-dimers. To reduce these 
deleterious effects a hot-start enzyme was used (HotStarTaq, Qiagen). This 
recombinant Taq DNA polymerase requires a prolonged period of heat 
activation (15 minutes at 95°C) before it exhibits any polymerase activity. As 
such the enzyme can be added to the 'master-mix' w ithout the worry of non­
specific product formation. All reaction components can be prepared at room 
tem perature w ithout the need to keep samples on ice. The prolonged initial 
heating step also ensures thorough denaturation of the target DNA.
2.2.1.2 Preparation of control DNA from HaCaT, CaSki and SiHa cell lines
HaCaT and CaSki or SiHa cell lines were used as a source of HPV-negative or - 
positive control DNA respectively (Table 2-4). The cell concentrations in cell 
suspensions were estimated using a haemocytometer. A volume of suspension 
equivalent to lx  106 cells was then used as a DNA source. DNA was extracted 
as using a proprietary kit (QIAamp DNA mini kit, QIAGEN) in the fashion 
described previously (section 2.2.1.3.2). The DNA was then eluted into a known 
volume (600pl). If the process is assumed to be completely efficient, the
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concentration of copies of HPV 16 can be estimated. Dilution of the DNA 
extract provides the opportunity to establish the sensitivity threshold for the 
various PCR systems used. HaCaT DNA is HPV-negative and provides an 
opportunity to investigate non-specific amplification in the PCR systems. The 
use of these controls will be further described in Chapter 3.
2.2.2.3 Primer sequences
The sequences and characteristics of the primers used during PCRs perform ed 
as part of this research are listed in the following table:
Use PCR Primer Bases Sequence 
5 ' - 3 ’
Tm
(°C)
Product
size
(bp)
HPV p-globin Forward 20 GAAGAGCCAAGGACAGGTAC 54 268
typing Reverse 20 CAACTTCATCCACGTTCACC 52
GP5+/6+ Forward 23 TTTGTTACTGTGGTAGATACTAC 50 -1 5 0
Reverse 25 G A A A AAT A A ACTGTA A ATC AT ATT C 46
M Y09/11 Forward 20 CGTCCMARRGGAWACTGATC 50-56 -4 5 0
Reverse 20 GCMCAGGGWCATAAYAATGG 50-54
Degenerate base code W = A or T; Y =C or T; R  = A or G
and M = A or C.
R iboprobe HPV 16 Forward 20 GCGGATCCGGGATGTAATGG 56
synthesis El 382
Reverse 26 GCGAATTCAAGCTTATACCCGCTGTG 60
HPV 16 Forward 21 GCGG ATCCT AC AAGGCC AG AG 58
E2 455
Reverse 26 GCGAATTCAAGCTTGCATGAACTTCC 58
HPV 16 Forward 20 GCGGATCCCGAAGTATCCTC 56
E4 278
Reverse 26 GCGAATTCAAGCTTCTATGGGTGTAG 58
HPV 16 Forward 23 GCGGATCCATGCACCAAAAGAGA 57
E6 497
Reverse 28 GCGAATTCAAGCTTTACAGCTGGGTTTC 60
HPV 16 Forward 24 GCGGATCCATGCATGGAGATACAC 59
E7 317
Reverse 27 CGAATTCAAGCTTTATGGTTTCTGAGA 55
HPV 16 Forward 20 GCGGATCCGTAAGCACGGAT 56
LI 367
Reverse 26 GCGAATTCAAGCTTCTGCATAAGCAC 58
HPV 16 Forward 22 GCGGATCCATGCGACACAAACG 59
L2 385
Reverse 26 GCGAATTCAAGCTTATGTTGGTGCAC 58
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Use PCR Primer Bases Sequence
5f-3>
Tm
m
Product
size
(bp)
In tegration HPV 16 Forward 19 AGGACGAGGACAAGGAAAA 49
PC R E2 1139
Reverse 20 GG AT GC AGT AT C A AG ATT TG 48
N B . T m  =  m eltin g  tem pera tu re  -  ca lcu la ted  by  ‘b a s ic ’ m ethod  4x (G + C )+ 2 x  (A + T ). A ctua l 
tem pera tu re  quo ted  by  supp lier w ill be sa lt-ad justed  and  higher.
Table 2-8. Primer sequences, Tm and amplicon sizes for primer pairs 
2.2.2.4 PCR reaction mixtures
Reagent Stock
concentration
Reaction
concentration
Volume
/pl
DNA template n/a n/a 2
Buffer X10 XI 5
NTP 2 mM 0.2 mM 5
(MgC12) ** 25 mM 2.0/2.5 mM (1/2)
Forward primer 10 pM 0.4 pM 2
Reverse primer 10 pM 0.4 pM 2
Taq polymerase 5 U/pl 0.05 U/pl 0.5
Water n/a n/a 33.5 (32.5/31.5)
TOTAL 50pl
Table 2-9. Standard 50pi PCR reaction mixture.
** PCR buffer contains MgCI2 at 15mM. Volume specified corresponds to additional volume of 
MgCI2 added for MY09/11 and Integration PCRs respectively, to obtain final concentration as 
specified. Water volume adjusted accordingly.
A standard PCR reaction mixture was used for P-globin, riboprobe synthesis 
and degenerate HPV-typing reactions. Additional magnesium chloride was 
used to improve amplification in the HPV 16E2/16E7 integration PCRs. The 
standard reaction volume used was 50pl, but the reaction was scaled up as 
required to produce more product e.g. for sequencing. All reaction mixtures 
were made up as a 'm aster mix', prior to aliquoting into each reaction tube . 
DNA template was then added to each tube individually. To reduce the chance 
of calculation errors, the templates for each PCR were entered into an Excel 
spreadsheet and macros used to allow the rapid and accurate calculation of the 
volumes of reagent required.
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2.2.2.5 PCR protocols
The following tables describe the PCR protocols used for p-globin, degenerate 
and HPV type-specific PCR. After an initial denaturing step at 95°C for 5 or 15 
minutes (dependent on whether a 'standard7 or 'hotstart7 Taq was used), the 
subsequent denaturing steps for each cycle were reduced to 94°C for 30 seconds 
each cycle to avoid unnecessary adverse effects on the efficacy of the Taq- 
polymerase, which has a half life of about 30mins at 95°C. Following the 
terminal elongation step, samples were held at 4°C prior to storage at -20°C or 
assessment by gel electrophoresis.
Primer set Step Temperature ( X?) Time (min) cycles
p-globin Initial denaturing 95 5 1
Amplification 94 0.5
56 1 35
72 1
Terminal elongation 72 7 1
MY09/11 Initial denaturing 95 15 1
Amplification 94 0.5
55 1 35
72 1
Terminal elongation 72 10 1
GP5+/6+ Initial denaturing 95 15 1
Amplification 94 0.5
50 2 40
72 1.5
Terminal elongation 72 4 1
Riboprobe Initial denaturing 95 5 1
synthesis
Amplification 94 0.5
56 1 35
72 1
Terminal elongation 72 7 1
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Printer set Step Temperature ( t ) Time (min) cycles
16E2 Initial denaturing 95 15 1
Integration
Amplificaton 94 0.5
59 1 38
72 2
Terminal elongation 72 7 1
16E7 Initial denaturing 95 5 1
Integration
Amplificaton 94 0.5
56 1 38
72 2
Terminal elongation 72 7 1
Table 2-10. PCR protocols for various primer s e t s  used . Following PCR all sam ples held at 
4°C.
2,2.2.5.1 Nested-PCR fo r H PV typing
When the MY09/11 and GP5+/6+ primer systems were used in a nested 
fashion the PCR mix and thermal cycling programs detailed above were 
employed with the following exceptions:
1. 0.5 pi of MY09/11 PCR product was used for the template in the nested 
GP5+/6+ PCR.
2. The GP5+/6+ amplification step was reduced to 30 cycles from 40 cycles.
2.2.2.6 HPV typing
The GP5+/6+ primer system (de Roda Husman et al, 1995) was used to amplify 
genital HPV types from clinical DNA. Ten microlitres of PCR product was run­
out by electrophoresis on a 1.5% agarose gel, stained with ~0.5jug/ml ethidium 
bromide and viewed using UV transillumination. Gel images were recorded 
using a gel imager (Flogen) and stored in TIFF format files for reproduction. All 
reactions were repeated at least once to ensure the results were reproducible. 
The positive PCR products were purified using a proprietary kit (Qiaquick PCR 
purification kit, Qiagen Ltd.). This system relies on salt and pH-dependent
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adsorption of DNA to a membrane w ithin a spin column. The m em brane is 
then washed to remove unwanted primers and contaminants before the DNA is 
eluted using low-salt solutions or water. Where only small am ounts of product 
resulted from the degenerate PCR amplification, the reaction volume was 
scaled-up and performed several times. The PCR products were pooled, 
adsorbed onto a single spin column and eluted into a low volume e.g. 30pl to 
provide a suitable concentration of PCR product for sequencing. Approximately 
20-30ng of GP5+/6+ PCR product was sent for sequencing at the DNA 
sequencing facility of the Department of Biochemistry, University of 
Cambridge. One of the primer pairs was used as the sequencing prim er and the 
sequence determined by automated fluorescent dye-terminator cycle 
sequencing (Sanger et ah, 1977). The resulting sequence was viewed using 
Chromas software (Technelysium Pty Ltd, Australia). Obvious errors in the 
autom ated base allocation were corrected manually. The corrected sequence 
was then exported in FAST A format and compared using a modified BLAST 
search (Altschul et ah, 1997) against the known hum an papillomavirus 
sequences held in the Los Alamos sequence library (h ttp ://h p v -  
web.lanl. gov /  std gen /  virus /  hpv /1. HPV type was allocated on the basis of > 
90% homology for a continuous sequence of over 100 bases.
During the latter part of this work, the MY09/11 primer system (Manos et ah, 
1989) was used to investigate those specimens found to be HPV-negative by 
GP5+/6+ PCR. If a clear product was visible on agarose gel electrophoresis then 
this was purified and sequenced in a similar fashion to the GP5+/6+ PCR 
product (see above), only using one of the MY09/11 primers as the sequencing 
primer. Equivocal or negative MY09/11 products were further subject to a 
nested PCR using the GP5+/6+ primers as the nested primers. Samples found 
to be positive on nested PCR were typed by purification and sequencing of the 
GP5+/6+ nested product in the m anner described previously.
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Figure 2-1. Cloning strategy for syn th esis  of HPV 16 riboprobes
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2.2.3 RNA in situ hybridisation for HPV 16 transcripts
The following sections describe the synthesis and use of HPV 16 RNA 
riboprobes.
2.2.3.1 Cloning strategy
The cloning strategy for the production of riboprobes is illustratrated in Figure
2-1. Cloning strategy for synthesis of HPV 16 riboprobes. Individual steps will 
be discussed in the following sections.
2.2.3.L I  Primer/probe design
The riboprobes were designed by Dr J. Sterling, Division of Virology, 
University of Cambridge. The primer sequences have already been listed in 
Table 2-8. Both forward and reverse primers incorporated restriction enzyme 
sites -  either BamHl or Eco R l/H in d  III - to allow ligation of the insert into an 
appropriate cloning vector. Probes were designed for each of the major ORFs 
except HPV E5. The precise details for the probes are specified in the following 
table.
HPV 16 
Target gene
Base range 
Probe ORF
Probe length 
(bases)
El 906-1266 859-2814 382
E2 2885-3318 2726-3853 455
E4 3364-3620 3333-3620 i n
E6 83-558 65-559 497
E7 562-857 544-858 317
LI 5702-6047 5528-7156 367
L2 4237-4600 4135-5658 385
Table 2-11. Design of HPV 16 riboprobes. Please note that probe length is 22 bases longer 
than HPV 16 target region as probes include restriction enzyme sites to facilitate cloning.
2.2.3.1.2 The PGEM -3Z cloning vector
The high-copy (300-700 copies/cell) pGEM-3Z vector (Promega UK) was used 
as a cloning vector. The vector has a multiple cloning region, which contains 
restriction enzyme sites for the three restriction enzymes encorporated into the 
RNA probes (BamHl, EcoRl and Hindlll). The vector has both the SP6 and T7
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RNA polymerase sites flanking the multiple cloning region (Figure 2-2) to allow 
for the highly specific synthesis of RNA in vitro.
Ssp 1 
2142
1 start
5
26
56
69
Figure 2-2. pGEM-3Z cloning vector showing ampicillin resistance, multiple cloning site
and Ssp1 restriction enzyme site
2.2.3.1.3 Preparation o f  plasmid DNA - 'midi prep’
A  inoculum of E. coli cells containing the pGEM-3Z plasmid (or plasmid with 
construct inserted) was picked from a glycerol stock kept at -70°C and placed 
into conical flask with 25ml of 2TY medium and 1 in 100 dilution of ampicillin 
(stock concentration 5mg/ml). A flask with at least four times the volume of the 
culture was used. The culture was incubated at 37°C overnight on a rotary 
shaker. Plasmid DNA was extracted using the QIAGEN-tip 100 plasmid midi- 
prep kit according to the manufacturer's protocol. This process involves the 
pelleting of cultured bacterial cells before subjecting them to alkaline lysis. The 
genomic DNA, cellular proteins, cell debris and SDS are then precipitated from 
the mixture. The supernatant containing plasmid DNA is purified by 
centrifuging at > 20,000 x g on two occasions before being passed through an 
anion exchange column. The plasmid DNA is preferentially bound under 
conditions of low-salt and appropriate pH. RNA, proteins, metabolites, and 
other low-molecular-weight impurities are removed by a medium-salt wash, 
and purified plasmid DNA is eluted in high-salt buffer. Finally, the DNA is
Ampicillin
resistance
EcoR1
BamHl
Hindlll
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concentrated and desalted by isopropanol precipitation and collected by 
centrifugation. The yield from a single column was typically resuspended in 
200pi of water to give a final concentration of ~ lp g /p l of plasmid DNA.
2.2.3.1.4 Restriction enzyme digestion
Both the PCR synthesised insert and cloning vector were prepared prior to 
ligation by 'cutting' with the appropriate restriction enzymes (usually BamHl 
and EcoRl). The total volume of enzyme was limited to < 10% of the reaction 
volume. The buffer was chosen from the manufacturer's datasheet, taking care 
that the buffer was appropriate for both enzymes being used. Restriction 
enzyme digestions were typically performed with several 
volum es/concentrations of target DNA in an attem pt to ensure the m axim um  
yield of fully 'cut' DNA was obtained. The volumes of reagents used in a 
typical reaction are illustrated in the following table.
Reagent Volume
/,d
DNA Variable (2/5/10)
Enzyme 1 1
Enzyme 2 1
Buffer 2
Water Variable (14/11/6)
Total 20pl
Table 2-12. Typical reaction mixture for Restriction enzyme digestion
The digested inserts were gel purified using the Qiagen gel extraction kit 
according to the manufacturer's protocol. The principle of this spin column 
based kit is identical to that of the PCR purification kit described previously 
(section 2.2.2.6). The products of the vector digestion reaction were assessed by 
electrophoresis on a 1 % agarose gel run out alongside uncut vector to confirm 
that all vector had been linearised. The cut vector was then subjected to 
treatm ent w ith calf intestinal alkaline phosphatase (CIP) in an attem pt to 
prevent the circular vector re-ligating. De-phosphorylation prevents such self­
112
Materials and Methods
ligation whilst permitting the vector to ligate to the phosphorylated term ini of 
another DNA fragment. Briefly, CIP was added to the RE mixture ( lu n it/  pm ol 
vector) and incubated in a water bath at 50°C for one hour. The CIP was then 
deactivated by adding 1/10 volume 500mM ethylene glycol tetraacetic acid 
and incubating at 65°C for forty-five minutes. The DNA was then cleaned using 
phenol:chloroform before ethanol precipitation and resuspension in an 
appropriate volume of water (for details of this step please see section 2.2.1)
2.2.3.1.5 Ligation reaction
Ligation of the insert and linearised vector was performed using DNA T4 
Ligase (1/10 by reaction volume) and lx  Ligase buffer (1/10 volume of lOx 
stock) in the reaction mixture. The reaction was performed for two hours at 
room tem perature or overnight at 15°C. Approximately lOOng of vector was 
used w ith a 10:1 vectorrinsert ratio by weight. The inserts were between seven 
to ten times smaller than the pGEM-3Z vector, and this ratio was chosen to 
provide an excess of linearised vector in the reaction to increase the chance of 
ligation. The reaction volume was typically 20pl, made up with water.
2.2.3.1.6 Preparation o f  competent bacteria
Plasmid constructs were initially transformed into E.coli TG-1 cells. Before 
transformation was performed, a stock of competent cells had to be made. The 
stock was obtained by inoculating 5mls of 2TY media with a tip culture from 
glycerol stocks of TG-1 cells and incubating at 37°C overnight on a rotary 
shaker. The next morning 200pl of this culture was transferred into 20ml of 
fresh 2TY m edium  and cultured until the culture medium reached an optical 
density of 0.3 at 600nm. The culture medium was then chilled on ice for five 
minutes to arrest growth, before harvesting the cells by centrifuging at 3000rpm 
for five minutes. The cell pellet was resuspended in 2.5ml of TFB before adding 
lOOpl of DMSO and incubating on ice for five minutes. Dithiothreitol (DTT; 
100pi) was then added and the mixture incubated on ice for a further ten 
minutes. Finally a further 100pi of DMSO was added and the mixture incubated
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on ice again for five minutes. The now competent cells were used for 
transformations in 200|il aliquots.
2.2.3.1.7 Transformation o f  bacteria with plasm id DNA
Ligated vector and insert were added to 200pl aliquots of freshly prepared 
competent cells. The volume of ligation reaction added was kept to < 10pi to 
avoid decreased transformation frequency due to an inhibitory characteristic of 
the reaction mixture. The mixture was kept on ice for forty minutes before 
administering a heat-shock by transferring the eppendorf tube to a w aterbath at 
42°C for two minutes. SOB (1ml) was then added to the heat-shocked cells and 
the culture incubated at 37°C for thirty minutes on a rotary shaker. Control 
transformations were also performed with vector alone (positive control), 
phosphatased-vector and water (negative controls).
2.2.3.1.8 Colony screening
The transformation reaction was assessed by plating lOOpl of the transform ed 
cells out onto an LB agar plate w ith ampicillin. The residual cell culture was 
then centrifuged for five minutes at 13,000rpm to pellet the remaining cells, part 
of the supernatant poured away and the remainder used to resuspend the cell 
pellet. This concentrated cell suspension was then used to make a second back­
up plate. The plates were marked and incubated overnight at 37°C.
Following overnight culture the plates were retrieved and the colonies counted. 
Only bacteria that have acquired antibiotic resistance as a result of 
transformation with the construct plasmid should grow on the selective plates. 
Control cultures comprising water or linearised, phosphatased vector and 
uncut vector provided negative and positive controls respectively. Colonies 
were circled and numbered, avoiding those smaller colonies on the peripheries 
where antibiotic concentration may be suboptimal. A selection of colonies was 
then used to set up cultures for mini-prep analysis. Selective LB agar plates 
(with ampicillin) were marked into zones using a permanent m arker on the 
underside of the plate. The colony of interest was then 'picked' by touching it 
with a cooled, flame-sterilised pipette tip. The tip was touched onto the
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appropriately marked area of the plate, then back onto the colony again before 
dropping the tip into 1.5-2ml of 2TY medium. The culture was incubated and 
agitated at 37°C for a further four to five hours before the plasm id/construct 
DNA was extracted using the mini-prep method detailed below. The backup 
plate was cultured overnight at 37°C, before sealing the plate w ith nescofilm 
and storing at 4°C.
2.2.3.1.8.1 Mini-prep method
The W izard SV miniprep kit (Promega, UK) was used according to the 
m anufacturers instructions. This is a spin column system that uses the same 
principles of alkaline lysis and sa lt/pH  dependent binding of DNA to a colum n 
based membrane to the larger scale Qiagen midi-prep kit described earlier. The 
plasmid DNA was eluted w ith lOOpl of water and stored at -20°C.
2.2.3.1.8.2 Confirming presence of successful construct
The presence of plasmid vector containing the required insert was initially 
confirmed by double digestion with the two REs used during the cloning 
procedure. Ten microlitres of the RE digest was then run out on a 1% agar gel 
stained with ethidium  bromide and visualised using UV transillumination. The 
presence of two bands corresponding to expected size of the vector (2743bp) 
and the insert (278-497bp) was strongly suggestive a successful cloning 
procedure. All constructs were then sequenced using primers directed at either 
the T7 or SP6 promotors adjacent to the cloning sites.
2.2.3,1.9 Long term storage o f  constructs
Following the successful cloning of the plasmid constructs into readily grown 
TG-1 cells, residual miniprep DNA was used to transform JM109 cells. These 
cells are both recombination (recA) and endonuclease (endA) deficient and 
were chosen to provide a stable host environment for the plasmid constructs. 
Glycerol stocks were prepared by first preparing a fresh subculture from an 
overnight tip culture (see above) in selective 2-TY medium. A 500pl aliquot of 
this second culture was added to 2ml of glycerol in a cryotube and frozen in an 
insulated box at -70°C before long-term storage in liquid nitrogen.
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2.2.3.2 RNA in situ hybridisation
2.23.2.1 In  vitro synthesis o f  riboprobes
Digoxigenin-UTP labelled riboprobes were synthesised from the plasmid 
constructs using a proprietary in vitro transcription kit (Roche Diagnostics Ltd.) 
according to the m anufacturer's instructions. Linearised transcription vector 
was prepared by RE digestion at either BamHl or EcoRl sites. The product was 
gel purified using the Qiagen gel extraction kit according to the manufacturers 
protocol. The T7 or SP6 prom oters were then used to initiate transcription with 
RNA polymerase leading to the production of anti-sense or sense probes (with 
reference to mRNA target) respectively. Digoxigenin labelled UTP was 
incorporated into the RNA transcript approximately every 20-25 nucleotides. 
Labelled probes were ethanol precipitated, the RNA pelleted by centrifugation 
and the pellet resuspended in dimethlyldicarbonate-treated water. RNase 
inhibitor was added to inhibit possible contaminating RNases.
2.23.2.2 Dot-blot hybridisation o f  digoxigenin-labelledprobes
The concentration of probe was assessed by dot-blot hybridisation of serial 
dilutions of the RNA probe. Briefly, a nitrocellulose membrane was marked 
with a grid. Each row of the grid was used to test a separate RNA probe. One 
microlitre of the neat probe was placed in the first column and a ten-fold serial 
dilution (with water) in each of the subsequent columns down to a dilution of 1 
in 100,000. A UV-crosslinker was used to bind the nucleic acid to the 
membrane. After washing to remove non-bound probe (1 minute in Buffer 1) 
and blocking non-specific signal (30 minutes in Buffer 2) the membrane was 
incubated w ith anti-digoxigenin antibody conjugated to alkaline phosphatase 
(30 minutes; 1 in 500 dilution in Buffer 2). The membrane was then subjected to 
stringency washing (Bufferl, 2x 5 minutes and Buffer 3, lx  5 minutes). 
Detection of bound antibody was performed by incubating the membrane in 
NBT/BCIP colour change solution (1 in 50 dilution in Buffer 3) in a dark 
container for up to 4 hours. The colour change reaction was ended by washing 
the filter in distilled water and the filter was then inspected. After drying, filters 
were stored in a sealed polythene bag.
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2.23.2.3 In  situ hybridisation protocol
The RNA ISH protocol requires steps to be performed on three consecutive
days. All steps were perform ed at room  tem perature in Coplin jars unless
otherwise stated. Technical assistance for RNA ISH was provided by Ms. A.
Nicholson, Division of Virology, University of Cambridge.
*
2.2.3.2.3.1 Prehybridisation
Paraffin-embedded tissue sections (7pm) were cut and mounted on APES 
coated slides (Mrs. B. Haynes, Departm ent of Histopathology, University of 
Cambridge). Slides for RNA ISH were first dewaxed by soaking in Xylene for 
two washes of two m inutes each before rehydrating using a graded series of 
alcohols (100%, 100%, 70%, 50% and 30%; 5 mins x2 for the 100% alcohol, then 
two minutes each subsequent step). Following gradual rehydration slides were 
washed in distilled water for tw o m inutes before a final five minute wash in 
phosphate-buffered saline (PBS). The sections were then fixed, to preserve 
tissue morphology and mRNA, using 4% paraformaldehyde in PBS for five 
minutes before washing in PBS ( 4 x 2  minutes). The slides were then incubated 
in pre-warmed proteinase K buffer for three m inutes at 37°C before treating 
with proteinase K solution (proteinase K buffer plus proteinase K (20pg/ ml)) 
for exactly ten minutes at 37°C. The sections were then washed in PBS ( 4 x 2  
minutes) and re-fixed in 4% paraform aldehyde in PBS for five minutes. After 
paraformaldehyde fixation, the slides were washed in PBS again ( 4 x 2  minutes) 
and acetylated to reduce non-specific background signal by treatment with 
acetic anhydride/triethanolam ine solution for ten minutes. The sections were 
then washed in PBS(4 x 2 minutes) and dehydrated using a graded alcohol 
series (30%,50%,70%,100% and 100%; 1 m inute each and 5 minutes for each of 
the 100% alcohol steps).
2.2.3.2.3.2 Hybridisation
The slides were then allowed to air dry prior to application of the probe to be 
tested. Ten micolitres of probe (1-1.5 in 10 dilution of probe in hybridisation 
buffer (Sigma)) was applied to each site before covering with a coverslip. The
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slides were placed into a prew arm ed, hum idified box and incubated overnight 
at 37°C.
2.2.3.2.3.3 Stringency washes and detection
The coverslips were rem oved by dipping slides into 2x SCC /  0.1% SDS at 55°C 
and the slides were washed in 2x SCC /  0.1% SDS at 55°C for ten minutes, 
ensuring that the tem perature in the coplin remained stable by insulating it in a 
polystyrene box and placing this on a magnetic stirrer. Unhybridised RNA was 
then removed by direct application of 2m g/m l RNases in 5x SSC and 
incubation at 37° C for fifteen minutes. The slides then underw ent further 
stringency washing in lx  SSC /  0.045% SDS at 65°C (2x 20 minutes). The slides 
were subsequently soaked in Buffer 2 for thirty minutes before incubation for 
thirty minutes with anti-digoxigenin antibody conjugated to alkaline 
phosphatase (1 in 500 dilution in Buffer 2). Following antibody detection, the 
slides were washed twice in Buffer 1 for fifteen minutes each time and soaked 
in Buffer 3 for thirty minutes. Antibody-probe binding was detected by 
application of NBT/BCIP colour change solution (125pl in 5ml Buffer 3) and 
incubation overnight in a dark  box. The following day, the colour change 
reaction was stopped by immersing the slides in lx  TE at pH8.0. The slides 
were then rinsed twice in PBS and water respectively before counterstaining 
with Eosin and m ounting w ith an aqueous m ountant (Faramount, Dako Ltd.).
2.2.3.2.3.4 Controls
Probing w ith the sense RNA probe provided an internal negative control for 
each hybridisation, whilst the use of a known keratin mRNA probe (keratin 10 
or 14, supplied by Dr J.C. Sterling, University of Cambridge) and sections from 
a proliferative w art served as a positive control for the technique.
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2.2.4 Comparative genomic hybridisation (CGH)
CGH was performed on DNA extracted from cells obtained by microdissection 
of appropriately prepared frozen sections (section 2.2.1).
2.2.4.1 Degenerate oligonucleotide-primed PCR (DOP-PCR)
Genomic 'test' and normal 'control' DNA was amplified and differentially 
labelled using DOP-PCR (for a detailed discussion of this technique, please see 
section 1.2.3.2.2.3.1)
2.2.4.1.1 Primary DOP-PCR
The primary amplification of genomic DNA was performed in a 50pl reaction 
using a PCR buffer kit comprising water, Buffer D and dNTP (Invitrogen), 
together with the 6MW prim er (5' CCG ACT CGA GNN NNN NAT GTG G 3'), 
high-concentration Taq polymerase (HT-Biotechnologies) and W l-detergent 
(Sigma-Aldrich Ltd.). The reaction m ixture and cycling conditions are described 
in the following tables:
Reagent Stock
concentration
Reaction
concentration
Volume
(Pi)
Microdisected n/a n/a 5
lysate
Buffer D X5 XI 10
dNTP 2mM 0.2 mM 5
W1 Detergent X20 XI 2.5
6MW primer 20 pM 2 pM 5
Taq polymerase 15 U/pl 0.15 U/pl 0.5
Water 22 n/a 22
TOTAL 50 pi
Table 2-13. Primary DOP-PCR reagents
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Step Temparature
/° C
Time 
/  min
Ramp cycles 
rate
Denaturing 95 9
Denaturing 94 1.5
Low specificity cycles Annealing 1 sec 0.23°C/s X5
Extension 3
High specificity Denaturing 94 0.5
cycles
Annealing 62 1 X30
Extension 72 1
Extension 72 7
Hold 4 indefinite
Table 2-14. Primary DOP-PCR cycling conditions
The suitability of amplified DNA was checked by gel electrophoresis using 5pl 
of reaction mixture and a 1 % agarose gel.
2.2.4.1.2 Secondary DOP-PCR
The amplified test and control DNA was then labelled by the incorporation of 
hapten conjugated dUTP using a second round of PCR with the 6MW primers. 
The second round of PCR was carried out under high specificity conditions 
(Table 2-16). The reaction mixture differs from the primary DOP-PCR in that 
the concentration of dTTP in the dNTP mixture was reduced to 1.6mM and 
replaced with labelled dUTP. Digoxigenin-ll-dUTP was used to label the test 
DNA and biotin-16-dUTP to label the control DNA (Boehringer Mannheim). 
The higher annealing tem perature of 62°C was used for all amplification cycles 
in the secondary DOP-PCR.
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Reagent Stock
concentration
Reaction
concentration
Volume /[A
Primary DOP n/a n/a 2.5
product
TAPs buffer X10 XI 5
dNTP 2mM A,G and C 0.2 mM 5
1.6mMT 0.16mM
dUTP-labelled ImM 0.02mM 2
W1 Detergent X20 XI 2.5
6MW primer 20 pM 2 pM 5
Taq polymerase 15 U/pl 0.15 U/pl 0.5
Water 27.5 n/a 27.5
TOTAL 50pl
Table 2-15. Reagents for secondary DOP-PCR (labelling)
Step Temparature
/°C
Time 
/  min
cycles
Denaturing 95 5
Denaturing 94 0.5
Annealing 62 1 29
Extension 72 1
Extension 72 7
Hold 4 Indefinite
Table 2-16. Secondary DOP-PCR cycling conditions 
2.2.4.2 Preparation of probe
Approximately 150ng of each labelled DNA was added to 15pg of Cot-1 
placental DNA (GibcoBRL) and the resulting DNA mixture precipitated with 
0.1 volumes 3M sodium acetate (pH5.2) and 2.5 volumes of absolute ethanol. 
The precipitate was resuspended in 16pl CGH hybridisation buffer (50% 
formamide, 10% dextran sulphate, 2xSSC, 40 mM sodium phosphate buffer 
(pH7) and lx  Denhardts solution (Sigma)). The probe was then denatured by
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incubation at 65°C for 10 m inutes before undertaking a pre-annealing step of 
37°C for 30 m inutes to facilitate competitive suppression of the highly repetitive 
sequences by the placental Cot-1 DNA.
2.2.4.3 Hybridisation
Normal male m etaphase slides (Abbott Diagnostic Division) were denatured at 
73 + /-  1 °C in prew arm ed 70% form am ide /  2xSSC for 4 minutes. Denatured 
slides were immediately cooled by placing into ice-cold 70% ethanol, before 
dehydrating using a graduated series of ethanols (70%, 90% and 100% ethanol 
for 5 minutes each). The dehydrated slides were then air-dried and 15pl of the 
prepared probe applied to the relevant metaphase site. The site was covered 
with a glass coverslip and sealed using a suitable rubber cement. The slide was 
then placed in a pre-warm ed incubation box at 37°C for at least 48 hours.
2.2.4.4 Stringency washing and Detection
The slides were first incubated in 2xSSC at 37°C to soften the adhesive and 
allow careful removal of the glass coverslip. Non-specific probe hybridisation 
was removed by washing in 50% form am ide /  lxSSC at 43°C for 5 minutes 
twice, followed by two further washes in O.lx SSC at 43°C for 5 minutes each. 
Slides were then incubated in 4xSST for 3 minutes. To reduce non-specific 
binding of detection reagents, lOOpl of 3% bovine serum albumin (BSA) /  4xSST 
was added to each site and the slides incubated for ~30 minutes. Excess 
blocking agent was then rem oved by three washes (3 minutes each) in 4xSST at 
37°C.
Digoxigenin-labelled test probe was detected using a 1 in 200 dilution of 
monoclonal m ouse anti-digoxigenin Fab fragments, conjugated to FITC (Roche 
Diagnostics ltd.). Biotin-labelled control probe was detected using a 1 in 400 
dilution of streptavidin conjugated to Cy3 (Amersham Biosciences ltd). 
Dilution was w ith 1 % BSA in 4xSST and perform ed in a light-tight pre-warmed 
incubation box at 37°C for 90 minutes.
Unbound streptavidin or antibody was rem oved by three washes of 3 minutes 
each at 37°C. Excess liquid was rem oved from the slide and the slides mounted
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using an anti-fade solution containing 0.4pM DAPI (Vectashield w ith DAPI, 
Vector laboratories).
2.2.4.5 CGH Imaging
Imaging and capture of CGH data was performed on an Axioplan II 
fluorescence microscope (Zeiss) equipped w ith the appropriate excitation and 
emission filters (Chroma Technology, Ltd) and a Sensys CCD camera (Roper 
Scientific) controlled by a Power M acintosh 7600 computer (Apple Computers 
Int.) running Sm artcapture VP software (Digital Scientific).
2.2.4.6 CGH Analysis
At least ten representative m etaphases were captured from each case and the 
results combined to produce and average fluorescence ratio along the length of 
each chromosome using QUIPS karyotyping and CGH interpretation software 
(Abbott Diagnostic Division -  Vysis). Increases and decreases in DNA sequence 
copy num ber were defined to test by reference ratios of > 1.15 and < 0.85 
respectively. Control experiments included template negative DOP-PCR 
reactions, hybridisation of DNA from normal vulval epithelium to normal 
control DNA, hybridisation from donor peripheral lymphocytes to normal 
control DNA and control DNA versus control DNA hybridisation. The 
reference ranges were constructed after a num ber of these normal to normal 
hybridisations showed that the m ean fluorescence ratio stayed between 0.85 
and 1.15 along all chromosomes.
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2.2.5 Vaccination and the measurement of immune response to HPV
Patients were recruited, vaccinated and histological, serological and 
haematological samples collected by the author at Addenbrooke's NHS trust. 
Cambridge. Vaccine and HPV-specific immune responses were measured in 
collaboration w ith two groups:
• Mr. C. Boswell, Xenova G roup pic, Cambridge, UK
• Dr. S. van der Burg, Tum our imm unology group, University of Leiden, 
the Netherlands
Details of the methods used to assess imm une responses to vaccination are 
included in the following section.
2.2.5.1 Vaccination by dermal scarification
Live recombinant vaccinia virus w as introduced into the patient by scarification 
of the skin of the upper arm. 50 pi of virus (~2.5 x 106 pfu) was applied in a 
fluid droplet over intact skin and the skin scratched superficially w ith a 
bevelled needle through the fluid which was then allowed to dry before 
covering w ith a waterproof dressing (Opsite, Smith & Nephew). The dressing 
was changed twice a week for approxim ately 4 weeks until the scab that formed 
as a result of the virus-induced inflamm ation separated and the vaccination site 
was healed. Samples for virological detection were taken from the surface of 
the dressing every week before its removal to test for the risk of possible 
contamination of the environment.
2.2.5.2 Anti-vaccinia ELISA
The anti-vaccinia ELISA used in this w ork was performed by Mr C. Boswell, 
Xenova group pic, Cambridge. Whole blood was collected in one 7.5ml S- 
Monovette tube (Sarstedt) at days 0, 28, 56 and 84. Serum was separated and 
stored at -20°C until required for analysis. Vaccinia-specific IgG was measured 
in patient sera by ELISA using W yeth strain vaccinia-infected Vero cell lysates 
as antigen and mock-infected Vero cell lysates as the control (Borysiewicz et al,
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1996). The titre at OD 0.5 w as determ ined using the line of best fit from the 
graph of the log sample dilution vs. sample W yeth OD minus sample Vero OD.
2.2.5.3 ELISPOT Technique
Whole blood was collected in S-Monovette 8.5ml CPDA tubes (Starstedt) and 
PBMC were isolated by density centrifugation on the same day. Cells were 
cryopreserved in vapour phase nitrogen until required.
2.2.5,3.1 Analysis o f  H P V  16-specific T-cell responses with overlapping E6- 
and E  7-peptides.
IFNy ELISPOT assays were perform ed by Dr. S.V. van der Burg of the Tumour 
Immunology Group, Unversity of Leiden, the Netherlands as has been 
described elsewhere (van der Burg et ah, 2001b). Briefly, PBMC were thawed 
and seeded at a density of 2x106 cells/w ell of a 24-well plate (Costar, 
Cambridge, MA) in 1ml of ISCOVE's m edium  (Gibco) enriched with 10% 
hum an AB serum, in the presence or absence of indicated E6 and E7 peptide 
pools. As a positive control, PBMC were cultured in the presence of a memory 
recall mix (MRM), consisting of a m ixture of tetanus toxoid (0.75LF/ml final 
concentration; National Institute of Public Health and Environment, Bilthoven, 
The Netherlands), Mycobacterium tuberculosis sonicate (2.5g/ml; generously 
donated by Dr P. Klatser, Royal Tropical Institute, Amsterdam, The 
Netherlands) and Candida albicans (0.005%, HAL Allergenen Lab. Haarlem, The 
Netherlands). The peptides used spanned the HPV 16 E6 and E7 protein and 
consisted of fifteen E6 and nine E7 overlapping 22-mer peptides. Peptides were 
used in pools of 4-5 peptides at a concentration of 5g/m l/peptide. The 
peptides, as indicated by their first and last amino acid, were used in the 
following pools: E6-I: 1-22, 11-32, 21-42, 31-52; E6-II: 41-62, 51-72, 61-82, 71-92; 
E6-III: 81-102, 91-112,101-122,111-132; E6-IV: 111-132,121-142,131-152,137-158; 
E7-I: 1-22, 11-32, 21-42, 31-52; E7-II: 41-62, 51-72, 61-82, 71-92, 77-98 (van der 
Burg et ah, 2001b). Following four days of incubation at 37°C, PBMC were 
harvested, washed and seeded in four replicate wells at a density of 105 
cells/well in lOOpl of ISCOVE's m edium  (Gibco) enriched with 10% FCS in a 
multiscreen 96-well plate (Millipore, Etten-Leur, The Netherlands) coated with
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an INFy catching antibody (Mabtech AB, Nacha, Sweden). The ELISPOT was 
otherwise perform ed according to the instructions of the m anufacturer 
(Mabtech). The num ber of spots were analysed with a fully autom ated 
computer-assisted video im aging analysis system (Carl Zeiss Vision). The 
background num ber of spots in the m edium  controls was 2.3+/-2 spots per 
50,000 PBMC. Specific spots w ere calculated by subtracting the mean num ber of 
spots + 2xSD of the m edium -only control from the mean num ber of spots in 
experimental wells. Antigen-specific T-cell frequencies were considered to be 
increased compared to non-responders w hen specific T-cell frequencies were 
>1/10,000 (van der Burg et al., 2001b). T-cell frequencies were considered to be 
boosted by the vaccine w hen they were at least 3 fold higher than before 
vaccination.
2,2,5.3.2 Analysis o f  CD8+ T-cell responses with H LA class I  restricted H P V  
epitopes.
CD8+ responses were investigated by Dr. S.V. van der Burg of the Tumour 
Immunology Group, Unversity of Leiden, the Netherland. ELISPOT plates 
(MAIPS410, Millipore) were prepared w ith the following antigens in triplicate 
wells: PH A lfig /m l; synthetic peptides (ISL) of HPV 16 E629-38, 59-67, 80-88 and E7n- 
20, 82-90, 86-93 (Kast et ah, 1994; Ressing et al.r 1995) influenza virus M I58-66/ and EBV 
BMLFI280-288 all at 25fig /m l or inactivated vaccinia virus and control uninfected 
Vero cell lysate 1:2500. Patient PBMC from each time point were thawed from 
cryopreserved stocks and resuspended in m edium  (RPMI (GibcoBRL), 10% AB 
serum (Sigma), 100 IU /m l penicillin, 100 fig/m l streptomycin, 2mM L- 
glutamine (all GibcoBRL)) at 5xl06/  ml. PBMC were then added to wells in 
triplicate, 2.5x10s to the PHA wells and 5x10s to each of the remaining wells 
containing antigen or m edium  alone. Following overnight incubation and 
washing, biotinylated monoclonal antibody to IFNy (7-B6-1-biotin, Mabtech) 
was added, followed by streptavidin-conjugated horseradish peroxidase 
(Mabtech). The assay was developed according to the manufacturer's 
instructions (Mabtech). A positive response to antigen was defined as greater 
than 20 spots (IFNy producing cells) per 106 PBMC in response to antigen
126
Materials and Methods
(following subtraction of background). A positive response following 
vaccination was recorded if the frequency of IFNy producing cells post­
vaccination was greater than 2 times the pre-vaccination response to an antigen.
2.2.6 Suppliers
The suppliers used for the reagents detailed above are listed in the following 
table.
Supplier Contact details Web address
Abbott Diagnostic division 
(includes Abbott -V ysis)
Abbott House 
Norden Road 
Maidenhead 
Berks SL6 4XF 
UK
www.abbotuk.com
www.vvsis.com
Agar Scientific Ltd. 66a Cambridge Road 
Stansted
Essex CM 24 8DA 
UK
www.aearscientific.com
Ambion (Europe) Ltd. Spitfire Close 
Ermine Business Park 
Huntingdon
Cambridgeshire PE29 6XY 
UK
www.ambion.com
Amersham Biosciences UK Amersham Place 
Little Chalfont 
Buckinghamshire HP7 9NA 
UK
www.apbiotech.com
Apple Computer Int. Hollyhill Industrial Estate 
Cork
Republic o f  Ireland
www.anDle.com/uk/
BDH Laboratory Supplies Poole
Dorset D H 15 ITD 
UK
www.bdh.com
Bioquote Ltd. The Raylor Centre 
James Street 
York YO10 3DW 
UK
www.bioauote.com
Chroma Technology Corp. 10 Imtech Lane 
PO box 489
www.chroma.com
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Supplier Contact details Web address
Rockingham V T 05101 
USA
Dako Ltd. Denmark House 
Angel Drive 
Ely
Cambs CB7 4ET 
UK
www.dako.co.uk
Digital Scientific Ltd. Sheraton House 
Castle Park 
Cambridge CB3 OAX 
UK
www.dieitalscientific.co.uk
Fisher Scientific Bishop M eadow Road 
Loughborough 
Leicestershire LEI 1 5RG 
UK
www.fisher.co.uk
HT Biotechnology Ltd. Ditton W alk 
Cambridge CB5 8QD 
UK
www.stratech.co.uk
Invitrogen life technologies 3 Fountain Drive 
Inchinnan Business Park 
Paisley 
UK
www.invitroeen.com
Merck Ltd. Merck House 
Poole
Dorset B H 15 1TD 
UK
www.merck-ltd.co.uk
Nalge (Europe) Ltd. Unit la , Thom e Business Park 
Hereford HR2 6JS 
UK
www.naleenelabware.com
PAA Laboratories ltd. 1 Guard Avenue 
Houndstone Business Park 
Yeovil
Somerset BA22 8YE 
UK
www.Daa.at
Promega UK Delta House 
Chilworth Science Park 
Southampton SO 16 7NS 
UK
www.Dromeea.com/uk/
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Supplier Contact details Web address
Qiagen Ltd. Boundary Court 
Gatwick Road 
Crawley
West Sussex RH10 2AX 
UK
www.aiaeen.com
Roche Diagnostics Ltd. Bell Lane 
Lewes
East Sussex BN71LG 
UK
www.biochem.roche.com
Roper Scientific c/o Universal Imaging Corporation 
Ltd.
PO Box 1192 
43 High Street 
Marlow
Buckinghamshire SL7 1GB 
UK
www.rooerscientific.com
Sarsted Ltd. 68 Boston Road 
Beaumont Leys 
Leicester LE4 1AW 
UK
www.sarstedt.com
Sigma-Aldrich Fancy Road 
Poole
Dorset BH12 4QH 
UK
www.siema-aldrich.com
STARLAB (UK) Ltd. Unit 4, Tanners Drive 
Blakelands
Milton Keynes MK14 5NA 
UK
http://www.starlab.de
Vector laboratories Ltd. 3 Accent Park 
Bake we 11 Road 
Orton Southgate 
Peterborough PE2 6XS 
UK
www.vectorlabs.com
Table 2-17. List of suppliers
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Chapter 3 Human papillomavirus infection and vulval 
intraepithelial neoplasia
3.1 Introduction
The association of oncogenic HPVs and their role in the development of 
neoplasia of the lower genital tract has been discussed in detail (section 1.2.1). 
The action of high-risk E6 and E7 proteins appears central to this process. 
Expression of these oncoproteins may become increasingly deregulated 
through the loss of transcriptional control that occurs during integration of viral 
DNA into the host genome (section 1.2.1.5). Viral integration has been 
extensively studied in cervical neoplasia, bu t data regarding the frequency and 
importance of such integration in both VIN and SCC of the vulva are lacking.
VIN remains a frustrating therapeutic challenge to the clinician. Current 
therapies are poorly tolerated and recurrence rates are high. In this respect, the 
association between HPV and VIN may provide a therapeutic opportunity. 
Viral gene products are attractive as targets for novel immunotherapies in HPV- 
associated VIN. To ensure that such therapies are directed at appropriate gene 
products, it is necessary to better understand the pattern of HPV gene 
expression within target lesions.
In this chapter, the use of sensitive PCR techniques to investigate the incidence 
of HPV infection and the physical state of the virus in women with vulval 
neoplasia will be described. In the m ethods section, the optimisation of the PCR 
systems employed to assess both the presence and physical state of HPVs will 
be detailed. The results section describes the use of these PCR systems to 
investigate a cohort of patients w ith vulval neoplasia, as well as the further 
investigation of gene expression in HPV 16-positive individuals using the 
technique of RNA in situ hybridisation.
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3.2 Methods
3.2.1 Optimising and validating PCRs for assessing the presence and 
physical state of human papillomaviruses
The HPV detection strategy used throughout this project is detailed in the 
methods chapter (section 2.2.2.6). Briefly both GP5+/6+ (de Roda Husm an et al, 
1995) and MY 09/11 (Manos et a l, 1989) primer systems were used 
independently and in a nested fashion. The E2 gene is commonly disrupted 
during integration (Schwarz et a l, 1985; Baker et al, 1987; Durst et al, 1987). 
Viral integration was therefore assessed using PCR to demonstrate the presence 
or absence of an intact E2 gene as a surrogate m arker for integration (Das et al, 
1992). All PCRs were optim ised for the specific reagents and apparatus used in 
this thesis. Modifications of the standard PCR protocols and their validation 
will be detailed in the following sections.
3.2.1.1 An annealing tem pera tu re  of 50°C perm its reduction in non-specific 
target DNA am plification w ith the GP5+/6+ p rim er system
The GP5+/6+ PCR system relies on the use of a low annealing temperature of 
40°C to allow sufficient annealing between consensus primers and template (de 
Roda Husm an et a l, 1995). Such low-stringency annealing conditions promote 
high-sensitivity detection of m ultiple HPV types, allowing for a degree of 
mismatch base pairing between the consensus primer and a variety of 
templates. However, the use of low annealing temperatures and high numbers 
of amplification cycles (40 cycles) tends to reduce PCR specificity and may 
result in the amplification of non-target DNA. As has been detailed elsewhere 
(section 2.2.2.6) HPV typing in this thesis was performed by the purification 
and sequencing of the PCR products obtained from the GP5+/6+ (and 
MY09/11) systems. It was therefore essential to reduce the levels of non-specific 
amplification to produce a 'pu re ' PCR product that was suited to direct 
sequencing. To investigate the effect of varying annealing temperatures on non­
specific amplification by the G P5+/ 6+ primers a series of PCR reactions were 
performed using a known am ount of HPV DNA from CaSki cells (equivalent to
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~200 copies of HPV16) mixed w ith HPV-negative DNA from human placental 
tissue (~300ng). The PCR was run  on a block-thermocycler with a gradient- 
block that allowed the reaction to be performed using multiple different 
annealing tem peratures within a single PCR experiment. The PCR mix was 
prepared as detailed in the m ethods section using a 'master-mix' approach to 
minimise variation between reaction tubes. Ten microlitres of reaction product 
were run out on a 1.5 % agarose gel stained with ethidium bromide and 
visualised using UV transillumination (Figure 3-1. Optimising annealing 
temperature for GP5+/6+ PCR with gradient PCR). A control reaction in which 
water replaced the target DNA was used as a negative control, whilst a reaction 
with the CaSki-extracted DNA alone was used a positive control.
expected
product 
(-150  bp)
n p> 1 1 2 3 A• 5 6 7 8 9 10 11 12
e c* K
9 s; b
♦
Lane 1 2 3 4 5 6 7 8 9 10 11 12
Tem p /  °C 40.1 40.5 41.3 42.7 44.4 46.4 48.3 50.3 52.6 54.0 54.7 55.2
Figure 3-1. Optimising annealing tem perature for GP5+/6+ PCR with gradient PCR
The negative and positive controls were appropriate. A product of ~150bp was 
visible in each of the lanes representing the range of annealing temperatures 
tested (40.1 °C to 55.2°C). The product corresponds to the amplicon expected 
from the GP5+/6+ primer system. At lower annealing temperatures multiple 
bands representing non-specific target DNA amplification were visualised. As
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expected, the am ount of non-specific amplification reduced w ith increasing 
annealing temperature. W hen the annealing tem perature approached 45°C, five 
degrees below the highest Tm for the primers this non-specific amplification 
had reduced considerably and by 48-50°C a solitary product was evident (lanes 
7 and 8). This result was reproducible.
3.2.1.2 The sensitivity o f H PV  detection (type 16) using GP5+/6+ rem ains 
acceptable under these new conditions
Although the increase in PCR specificity was desirable, such a significant 
increase in annealing tem perature m ight be expected to have a deleterious 
effect on PCR sensitivity. The sensitivity of the GP5+/6+ PCR performed at the 
new annealing tem perature of 50°C was therefore assessed. CaSki and SiHa 
cells were cultured and used to set up  a series of control template specimens as 
described previously (section 2.2.2.2). The assum ed concentration of HPV DNA 
is detailed in the table below.
SiHa cells 
Dilution______ Copies/ 2pi
N e a t 3 ,4 0 0
1 in  10 34 0
l i n  20 170
1 in  4 0 85
1 in  50 68
1 in  70 48
Table 3-1. Serial dilutions of DNA extracted from HPV-positive SiHa cell line.
Estimated number of copies per 2pl load specified.
Ten microlitres of PCR product was visualised by UV transillumination on a 
1.5% agarose gel stained w ith ethidium  bromide. Product of the expected 
amplicon size (~150bp) was visualised to a dilution of 1 in 70 suggesting that 
the sensitivity threshold for the modified PCR reaction was at worst 48 copies 
of HPV 16 DNA per 50pl reaction mixture (Figure 3-2).
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expected
<------------
product 
(-150 bp)
Figure 3-2. Sensitivity of GP5+/6+ primer sy stem  estab lished  using serial dilutions of 
SiHa cell DNA. Gel image has been inverted to facilitate visualisation of w eaker bands. Product 
just visible at 1 in 70 dilution suggesting a detection threshold > 48copies of HPV 16 per 50|il 
PCR reaction.
Control SiHa DNA was prepared from a known number of cells prepared in 
tissue culture. The estimation of the num ber of copies of HPV 16 was based on 
the assumption that SiHa cells contain one copy of HPV 16 DNA and that DNA 
extraction from the cells lines was 100% efficient. This is unlikely to be the case. 
The control DNA would therefore be expected to contain fewer copies of HPV 
16 than was estimated and the PCR is probably more sensitive than indicated 
by this experiment. It w ould appear that increasing the annealing temperature 
still permits the sensitive detection of HPV 16 DNA.
3.2.1.3 Sequence variation in target amplicon should permit the distinction 
of genital HPV types by genotyping of the GP5+/6+ PCR product
The purification, sequencing and virus typing of the GP5+/6+ PCR products is 
detailed in the method sections (section 2.2.2). Although this method of HPV 
typing has been used by others (Rosenthal et al., 2001) a multiple alignment of 
the GP5+/6+ products from a variety of HPV types was performed using the
200 *
100
a>
03O03
X
+
-Q
O
CNJ
C
o olO or-
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CLUSTAL W service at the European Bioinformatics Institute 
(h ttp ://  w w w .ebi.ac.uk/, Thom pson et ah, 1994). This alignment tool allows the 
simultaneous comparison of m ultiple nucleotide sequences. Despite the small 
size of the amplicon, significant variations between both size and sequence are 
seen for the differing HPV types.
CLUSTAL W ( 1 . 8 2 )  m u l t i p l e  s e q u e n c e  a l i g n m e n t
g p 6 b TTTGTTACTGTGGTAGATACCACACGCAGTACCAACATGA------ ------CATTATGTGCATCC 5 4
g p l l TTTGTTACTGTGGTAGATACCACACGCAGTACAAATATGA------ ------CACTATGTGCATCT 5 4
g p i 6 TTTGTTACTGTTGTTGATACTACACGCAGTACAAATATGT------ ------CATTATGTGCTGCC 54
g p i 8 TTTGTTACTGTGGTAGATACCACTCCCAGTACCAATTTAA------ ------CAATATGTGCTTCT 54
g p 4 5 TTTGTTACTGTAGTGGACACTACCCGCAGTACTAATTTAA------ ------CATTATGTGCCTCT 54
g p 3 i TTTGTTACTGTGGTAGATACCACACGTAGTACCAATATGT------ ------CTGTTTGTGCTGCA 54
g p 5 2 TTTGTCACAGTTGTGGATACCACTCGTAGCACTAACATGA------ ------CTTTATGTGCTGAG 54
g p 5 8 --------------------------------- GATACCACTCGTAGCACTAATATGA------ ------CATTATGCACTGAA 3 9
g p 3 3 TTTGTTACTGTGGTAGATACCACTCGCAGTACTAATATGA------ ------CTTTATGCACACAA 5 4
g p 8 TTTGTCACTGTGGTAGACAACACGCGAAACACCAATTTTAGTATTTCAGTTTACACTGAA 60
★ ★ ★  ★ ★ ★  ★ ★★★★ ★ ★ ★ ★ ★
g p 6 b  GTAACTACATCTT-------- CCA------ CA------- TACACCAATTCTGATTATAAAGAGTACATGCGT 1 0 5
g p l l  GTGTCTAAATCTG-------- CTA------ CA-------TACACTAATTCAGATTATAAGGAATACATGCGC 1 0 5
g p l 6  ATATCTACTTCAGAAACTA CA-------- TATAAAAATACTAACTTTAAGGAGTACCTACGA 1 0 8
g p l 8  ACACAGTCTCCTGTACCTGGGCAA TATGATGCTACCAAATTTAAGCAGTATAGCAGA 1 1 1
g p 4 5  ACACAAAATCCTGTGCCAAGTACA-------- TATGACCCTACTAAGTTTAAGCAGTATAGTAGA 1 1 1
g p 3 1  ATTGCAAACAGTGATACTA CA---------TTTAAAAGTAGTAATTTTAAAGAGTATTTAAGA 1 0 8
g p 5 2  GTTAAAAAGGAAA-------- GCA------ CA------- TATAAAAATGAAAATTTTAAGGAATACCTTCGT 1 0 5
g p 5 8  GTAACTAAGGAAG-------- GTA------ CA------- TATAAAAATGATAATTTTAAGGAATATGTACGT 9 0
g p 3 3  GTAACTAGTGACA-------- GTA------ CA------- TATAAAAATGAAAATTTTAAAGAATATATAAGA 1 0 5
g p 8  AATGGGGAACTTAAGAACATCACAGACTATAAATCAACCCAGTTCAGAGAATATCTGAGA 1 2 0
★ * ★ ★ ★ ★ ★ ★  ★
g p 6 b  CATGTGGAAGAGTATGATTTACAATTTATTTTTC 1 3 9
g p l l  CATGT GGAGGAGTT T GAT T TACAGT TTAT T T T T C 1 3 9
g p l 6  CATGGGGAGGAATATGATTTACAGTTTATTTTTC 1 4 2
g p l 8  CATGTTGAGGAATATGATTTGCAGTTTATTTTTC 1 4 5
g p 4  5 CAT GT GGAGGAATAT GAT T TACAGTT TATT T T T C 1 4 5
g p 3 1  CAT GG T GAGGAAT T T GAT T T ACAAT TTATATTTC 1 4 2
g p 5 2  CATGGCGAGGAATTTGATTTACAATTTATTTTTC 1 3 9
g p 5 8  CATGTTGAAGAATATGACTTACAGTTTGTTTTTC 1 2 4
g p 3 3  CATGTTGAAGAATATGATCTACAGTTTGTTTTTC 1 3 9
g p 8  CATGTAGAAGAATATGAAATTTCCCTCATATTAC 1 5 4
★*★★★★★★ ★ ★ ★★★★
Figure 3-3. CLUSTAL W multiple alignment for GP5+/6+ amplicons. Data shown for from 
HPV types 6b, 11, 16, 1 8 ,3 1 ,2 2 ,4 5 ,  52, 58 and the E V type8.
3.2.1.4 Non-specific am plification a t low -target concentration with MY09/11 
system is reduced by increasing the annealing tem perature
The MY09/11 prim er system was used to reassess samples negative by 
GP5+/6+ PCR and as part of the nested PCR protocol (section 2.2.2.5.1). A 
thermal cycler w ith a gradient block was used to assess the optimum annealing 
tem perature in order to minimize non-specific amplification at low target 
concentration. The m ethod used was similar to that used in optimising the
135
HPV and VIN
GP5+/6+ PCR system except that HPV negative DNA from HaCaT cells 
(~300ng) was used to provide a background signal in the presence of a 1 in 40 
dilution of SiHa cells (~85 copies per PCR). The Tm of the primer sets MY09 
and M yll are 56°C and 58°C respectively. A range of temperatures from 53°C 
upwards were assessed. A parallel PCR using HPV positive template DNA 
from SiHa cells (~85 copies of HPV16 per reaction) was performed to assess 
sensitivity at the various annealing tem peratures tested. Ten microlitres of PCR 
product were electrophoresed on a 1.5% agarose gel and visualised with UV 
light (Figure 3-4).
expected
product 
(-450  bp)
HaCaT cell DNA (300ng) 
containing 1 in 40 SIHa 
cell DNA
A B O D E  
1 in 40 SiHa cell DNA
Lane A B C D E
Annealing tem perature /  °C 53.1 54.7 57.0 58.9 61.3
Figure 3-4. Gradient PCR with MY09/11 primer se t  to establish  optimal annealing  
temperature. HaCaT/SiHa DNA mix used to a s s e s s  non-specific amplification at low tem plate 
concentrations. SiHa DNA used to a s s e s s  sensitivity simultaneously. 1 in 40 dilution of SiHa 
cells equa tes to approximately 85 copies of HPV 16 per reaction mixture.
The 'w ater tem plate' control was appropriately negative. Marked non-specific 
amplification with a resultant 'ladder' of PCR products was seen at low 
annealing temperatures. The am ount of such amplification decreased with
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increasing annealing temperature. The optim um  annealing temperature to 
achieve low non-specific amplification w ithout a marked reduction in 
sensitivity lies between 54.7 and 57°C. Given the melting temperatures of the 
primers an annealing tem perature of 55°C was used for further experiments.
3.2.1.5 Non-specific am plification produces a band close to the expected 
amplicon size from HPV-negative H aC aT  DNA
A non-specific ladder pattern was seen with initial PCR using the MY09/11 
primer system and known HPV-negative DNA from HaCaT cell lines (Figure
3-4). GP5+/6+ PCR produced no such false-positive band with HaCaT DNA 
suggesting that the DNA was truly HPV-negative. A further PCR was 
performed to compare such apparent non-specific amplification to a known 
'true-positive' signal from SiHa cell DNA. The HaCaT cell DNA template was 
diluted with water in a serial fashion to establish the effect on this amplification 
pattern. Ten microlitres of PCR product were electrophoresed on a double 
length 1.5% agarose gel and visualised w ith UV light (Figure 3-5).
Key to lanes 
Number______ Template
1 HaCaT
2 1 in 40 SiHa
3 1 in 5 HaCaT
4 1 in 40 SiHa
5 1 in 10 HaCaT
6 1 in 40 SiHa
7 1 in 50 HaCaT
8 1 in 40 SiHa
9 linlOOHaCaTs
^ 1  2 3 4 5 6 7  8 9 . 0*  *
T *  T —
Figure 3-5. Serial d ilutions of HPV-negative HaCaT DNA with adjacent signal from 1 in 40 
SiHa DNA dilution for com parison. Ladder is 1kB+ ladder.
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The amount of non-specific amplification decreased with decreasing 
concentration of HaCaT DNA and was minimal by 1 in 10 dilution (34ng 
target). Close inspection of the prom inent band seen between 400 and 500 bp in 
lane 2 shows a clear separation in size between this band and the adjacent band 
from the HPV-positive SiHa DNA template. Southern blotting and probing 
with a HPV 16 probe was perform ed by Ms A. Nicholson. In contrast to the 
SiHa lanes, no signal from the HaCaT lanes was observed suggesting that the 
product did not originate from an HPV 16 template. In addition, a subsequent 
nested PCR with GP5+/6+ prim ers failed to produce any product from the 
HaCaT DNA (data not shown) supporting this amplicon as a non-specific PCR 
product.
3.2.1.6 MY09/11 prim er system appears sensitive in detecting HPV 16 
infection
A repeat of the sensitivity PCR described in section 3.2.1.2 was performed to 
allow comparison of the efficacy of MY09/11 and GP5+/6+ primer systems.
a) b)
SiHa celts
Lane Dilution Copies/2u\
1 Neat 3,400
2 1 in 10 340
3 1 in 30 113
4 1 in 40 85
500 > expected
400 > product
(-450 bp)
*  A  1  2  8  S
££ Z  .E .E .£
Figure 3-6. a) Concentration of SiHa template per 2pl PCR load b) MY09/11 primer PCR 
showing reducing product with increasing dilution. Product clearly visible at 85 copies HPV 
16 per PCR.
The water control was appropriately negative. Serial dilutions of the SiHa cell 
line DNA showed a gradual decrease in the amount of PCR product (~450bp 
amplicon) from this primer system. Product was still readily visible at 85 copies
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HPV 16 per PCR and the sensitivity for the detection of HPV 16 therefore 
appears comparable to the GP5+/6+ primer system.
3.2.1.7 Nested PCR increases sensitivity for the detection of HPV
Where sufficient DNA remained nested PCR was employed to assess those 
clinical samples initially negative for HPV infection by GP5+/6+ PCR (section 
2.2.2.5.1). This technique relies on the positioning of the GP5+/6+ primer pair 
within the LI amplicon generated by the MY09/11 primer system (Figure 3-7).
Primer system s
-  MY09/MY11
-  GP5+/GP6+
I T T
5000 6000 7000
Figure 3-7. Relationship of MY09/MY11 (pink) and GP5+/GP6+ (green) primers to L1 ORF.
S equence data shown for HPV 16.
Illustrative gels from such a nested PCR are shown in the figure 3-8. All DNA 
samples were first assessed by PCR for the P-globin gene. A clear product of 
expected amplicon size (250bps) is visible for each sample confirming the 
suitability of the DNA samples for further analysis (Figure 3-8a). Four 
microlitres of DNA extract was used as a template in a PCR using the MY09/11 
primer system. A non-specific amplification pattern is seen for all of the clinical 
samples (Figure 3-8b; 238-293). Three negative controls were included for this 
experiment. They were 'no D N A /w ater' and two samples of the extraction 
buffer used to extract the clinical DNA samples (figure b; mix 1 and mix2). For 
the nested PCR reaction, 0.5pl of the primary MY09/11 PCR product was used 
as the PCR template in a GP5+/  6+ primer PCR that was limited to thirty cycles.
L 1
5 Cfirmm
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a) p—globin PCR for m icrodissected DNA
expected
product
(~268bp)
b) MY09/11 PCR for m icrodissected DNA
expected
product
(~450bp)
c) Nested GP5+/6+ PCR
expected
product
(~150bp)
Figure 3-8. Three stages of nested PCR for HPV typing, a) Microdissected DNA a sse sse d  
by p-globin PCR to en su re  ad eq u ate  quantity and quality of DNA preparation, b) Subsequent 
MY09/11 PCR show s non- specific type ladder for all clinical sam ples, c) Nested GP5+/6+ 
PCR using 0.5pl of MY09/11 product a s  a tem plate. C lear product of the expected size visible 
for 238,244 and 245. Sam ple 293 rem ains negative. All negative controls were taken through 
both rounds of the nested  reaction to en su re  no contam ination.
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Three of the four PCR clinical sam ples now  dem onstrated a 'clean7 product of 
the appropriate amplicon size following the nested PCR reaction (subjects 238, 
244, 245; Figure 3-8c). Subsequent purification and sequencing of the PCR 
products from this reaction revealed HPV infection with types 16, 6b and 16 
respectively.
The choice of negative controls is crucial to nested PCR. The technique has 
been estimated to be up  to 104 times m ore sensitive than single round PCR and 
is extremely prone to contamination. It was therefore necessary to include 
several negative controls. In addition to 'w a te r/n o  DNA7, template from all 
negative controls from the first MY09/11 PCR was entered into the nested 
reaction (Figure 3-8c; lanes 1-4).
3.2.1.8 PCR to assess the physical state of HPV
HPV 16 positive samples were assessed by type specific PCR for the E2 and E7 
genes (Das et al, 1992). The reactions were optimised for the apparatus and 
reagents used in this thesis. An alternative set of E7 primers, already available 
within the group, was used. The optim um  magnesium  concentration (2.5mM 
MgCh was found to be the same as specified in the original paper (gel not 
shown). Das and colleagues used an annealing tem perature of 55°C for both E7 
and E6 PCRs. A therm al cycler w ith  a gradient block was used to determine the 
optim um  annealing tem perature to ensure efficient amplification of HPV 
template w ithout unw anted non-specific amplification of HPV-negative DNA. 
DNA from HPV-negative HaCaT cells (300ng) and DNA form HPV-positive 
CaSki cells was used to provide negative and positive controls for this 
experiment (Figure 3-9).
Both PCRs show ed appropriate negative control reactions and produced 
products of appropriate sizes (E2=1139bp, E7=316 bp). The optimum ratio of 
non-specific amplification to correct amplification of the intended target DNA 
was achieved at 58°C E2 prim ers and 56°C for the E7 primers.
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E2 primers HaCaT DNA CaSki DNA
expected
product 
(-1139 bp)
I
+
-Q*
B D A B C D
E7 primers
HaCaT DNA CaSki DNA
expected
product 
(-316  bp)
a) n B C D A B C D
Lane Annealing
temperature
/  °C
A 55.1
B 55.9
C 57.8
D 60.9
Figure 3-9. Gradient PCR to establish the optimal 
annealing temperature for the E2 and E7 primer pairs 
used in the PCR to assess viral integration. HPV
negative HaCaT DNA used a s  tem plate to investigate non­
specific amplification. Dilution of CaSki cell DNA (<150 
cop ies of HPV 16) used  to a s s e s s  sensitivity of PCR. 
Optimal sensitivity with minimum non specific amplification 
ap p ears  to occur a t -58°C  for the E2 primers and -56°C  
for the E7 primers.
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Initial optimisation of the E2/E7 PCR was perform ed using a cheaper Taq 
polymerase from Amersham Biosciences UK. It can be seen from Figure 3-9 
(above) that despite the use of a high annealing tem perature of 58°C for the E2 
PCR, a considerable degree of non-specific amplification occurred w hen there 
was no HPV template (Figure 3-9; lanes 2-4). The use of /hot-start/ PCR to 
reduce non-specific amplification has been discussed in the methods section 
(section 2.2.2.1.4). W hen an appropriate hot-start Taq polymerase was used, 
non-specific amplification appeared reduced at all annealing temperatures 
tested and optimal at ~59°C (Figure 3-10, below).
Standard Taq Hot-start Taq
< » < ...............................
expected
<-------------
product 
(-1139 bp)
S i A B C D g l ^ A B C D g
CO " 5  *  COO *> O
Figure 3-10. Comparison of 'standard' and 'hot-start' Taq 
polymerases for E2 primer PCR.Target DNA comprises -150  
copies of HPV 16 extracted from CaSki cells mixed with 300ng 
of HPV-negative DNA from HaCaT cells. Reduced non-specific 
amplification visible with 'hot-start' Taq polymerase. Optimum 
sensitivity/specificity seen at 59°C.
Lane Annealing
temperature
/ C
A 57.5
B 58.2
C 58.7
D 59.0
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3.2.2 Riboprobe synthesis
Viral gene expression was assessed using mRNA ISH. The synthesis of the 
riboprobes and precise localisation is described in the methods (section 2.2.3). 
The relationship of the riboprobes to the HPV 16 ORFs is shown in Figure 3-11.
E7 E1 L2
E2 I L1
HE]
0 1000 2000 3000 4000 5000 6000 7000
Figure 3-11. HPV16 riboprobes. HPV16 genome is shown in linear fashion. Boxes denote 
open reading frames. Green lines show positions of riboprobes.
All pGEM-3Z constructs were sequenced using either SP6 or T7 promoters to 
confirm the appropriate sequence had been cloned into the vector. Digoxigenin- 
UTP labelled riboprobes were generated using a proprietary digoxigenin-RNA 
labelling kit (Roche Diagnostics Ltd.). Dot-blot hybridisations using serial 
dilutions of probe were used to establish the relative concentrations of each 
probe (Figure 3-14). Concentrations were compared to a positive control 
provided by the m anufacturer. Synthesis of anti-sense riboprobes using T7 
RNA polymerase appeared m ore effective than that of sense riboprobes using 
SP6 RNA polymerase. Once synthesized, riboprobes were stored at -20°C until 
required.
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Figure 3-12. Dot-blot hybridisation of newly 
synthesized riboprobes. Each row represents 
different probe. 'B' signifies construct linearised with 
BamH1 and transcribed with T7 RNA polym erase to 
yield an ti-sense RNA probe. 'E' signifies construct 
linearised with EcoR1 and transcribed with SP6 RNA 
polym erase to yield sen se  RNA probe. Anti-sense 
probes ap p ear to be more efficiently synthesised than 
the sen se  probes and are detectable at greater 
dilutions.
3.2.3 Source of tissue samples
Fresh and paraffin embedded tissue samples were obtained from patients 
referred to the gynaecological oncology centre and specialist vulval clinics at 
Addenbrooke's NHS trust, Cambridge between April 1999 and May 2002. Prior 
ethical approval for this work was obtained from the local research ethics 
committee (LREC 98/227).
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Figure 3-13 Pathology of vulval biopsies from sixty-seven individuals. (Six serial biopsies 
are included where the subsequent pathology differed from the index biopsy)
A total of one hundred and forty-eight specimens were available from sixty- 
seven individuals during the study period. Thirty-two individuals underwent
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serial biopsies during their clinical m anagem ent over the course of the study. 
The histopathological diagnosis was confirmed independently by two 
consultant gynaecological histopathologists. Where variation in opinion 
occurred, both consultants review ed the case and reached an agreed diagnosis. 
Approximately half the biopsies obtained were classed as showing VIN and the 
majority of these were high-grade lesions. The sixteen benign lesions included 
histologically normal biopsies; biopsies showing HPV change only; 
inflammatory dermatoses and benign papilloma.
3.2.4 Statistical methods used in analysis
The small size of the cohort studied m eant that non-parametric statistical 
methods were employed. Fishers exact test for the comparison of independent 
variables was used to compare proportions between two groups e.g. HPV 
status between groups. W hen the variable to be compared was continuous e.g. 
age, the Mann-Whitney U test w as used. Data was compiled using Access 
2000® and Excel 2000®. Statistical analysis was performed using SPSS 11.5®. 
Two-tailed tests were used and significance was assessed at the 95% level (p < 
0.05).
3.3 Results
3.3.1 Demographics and HPV status
The mean age of the patients studied was 55.2 years (range 32-86 years). The 
details for each of the pathological subgroups are shown in the following table:
Pathological
group
N Mean
age
(yrs)
Median
age
(yrs)
Standard
deviation
(yrs)
Min.
age
(yrs)
Max.
age
(yrs)
Benign/normal 17 49.4 48.0 13.3 33 74
Low-grade VIN 3 42.3 43.0 1.2 41 43
High-grade VIN 33 50.8 48.0 10.6 32 78
Vulval SCC 18 70.5 71.5 10.8 49 86
AIN 2 50.0 50.0 4.24 47 53
Table 3-2. Age distribution by pathological subgroup
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The m edian age for the patients w ith VIN was 48 years (range 32-78 years) 
compared to 72 years (range 49-86) for those w ith SCC of the vulva (p<0.001). 
The majority (72.6%) of patients studied were HPV-positive, including 94.3% of 
those patients w ith VIN. Subjects w ith VIN were significantly more likely to 
have HPV infection than those w ith carcinoma (94.3% vs. 58.8%; p=0.003). The 
predom inant infective agent in cases of VIN was HPV 16 (93.9%) w ith types 33 
and 56 accounting for the rem aining cases. PCR data regarding the physical 
state of the virus was available in 24/31 HPV 16 positive cases. HPV 16 was 
found to be integrated in half the cases of HPV 16-positive VIN. Serial biopsies 
over at least six m onths were available for longitudinal assessment of HPV 
status in fifteen patients. HPV status and the predom inant HPV type isolated by 
PCR remained stable in 11/15 (73.3%) of cases. Of the remaining four cases, two 
became HPV negative following the successful treatm ent of their disease; one 
showed resolution of HPV infection w ithout resolution of the disease and one 
patient showed a varying type betw een type 16 and type 33.
The majority of the thirty-six w om en w ith VIN were symptomatic (87.8%; data 
unavailable in 3 /36  cases). The m ost comm on symptoms were itch (60.0%) and 
soreness (36.7%). O ther reported sym ptom s included the finding of a lump 
(20.0%), discoloration (13.3%) or m ore rarely bleeding or discharge (6.7%). 
Accurate data on the duration of sym ptom s was available in 27/37 women with 
VIN. The m edian duration of sym ptom s was 24 m onths (range 3-180 months). 
Almost two-thirds (62.2%) of patients w ith VIN had already undergone 
previous treatm ent at the time of their referral. Although more women with 
VIN were smokers than those w ith benign vulval pathology, this difference was 
not statistically significant (45.7% vs. 33.3%; p=0.537). The current cervical 
smear was abnorm al in 12.5% of VIN patients, but almost half (48.6%) had a 
history of abnorm ality on previous cervical cytology.
3.3.2 In situ hybridisation -  tissue samples and casemix
RNA in situ hybridisation was perform ed on paraffin-embedded sections. Prior 
ethical approval for this w ork was obtained from the local research ethics
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committee (LREC 98/227). Sense probes were used on paired sections as a 
negative control for the hybridisation reaction. Experiments were repeated to 
ensure reproducibility. Sixty-three biopsies from thirty-one individuals were 
assessed during the study. The majority of samples taken were from high-grade 
VIN lesions, but specimens from vulval SCCs, high-grade AIN and both normal 
and inflammatory HPV-positive vulval skin were also available for assessment. 
Biopsies from several time points (range 2-5) were available from fourteen 
individuals. In nine of these patients the multiple biopsies demonstrated vulval 
intraepithelial lesions of an identical histopathological grade, whilst in five 
cases the grade of lesion varied between time points.
■  Normal
□  Inflammatory
□  HG-VIN/VAIN
■ SCC
■  AIN
64%
Figure 3-14. Relative frequency of pathological diagnoses from thirty-one individuals 
assessed by RNA in situ hybridisation
3.3.3 In situ hybridisation - results
Following RNA in situ hybridisation, sections were mounted under glass 
coverslips and assessed by conventional light microscopy by two observers (the 
author and Dr. J. Sterling). The results are detailed in Table 3-3 (overleaf).
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S am ple P rim ers fo r D iag n o sis P h y sica l s ta te HPV 16 riboprobe RNA su m m ary
No. HPV typ ing of v iru s E1 E2 E4 E6 E7 L1 L2
208 GP Normal Integrated + / + / + + / BS
224 GP Normal N/A + / + - / + / BS
266 TS Inflam Episomal / - - / - - / Neg
268 TS Inflam Episomal / / + / + / / BS
278 GP Inflam Integrated / / ? / + / / Neg/BS
277 TS Inflam Integrated / / + / ? / / Bs
256 N Inflam Episomal / / + / + / / BS
262 N AIN 3 Episomal / / + / - / / BS
210 GP VAIN 2 Integrated + + + + + + / Pos-lower
251 GP VIN 2 Episomal / / + ? + / / BS
282 GP VIN 2 Episomal / - - / + - / BS
241 GP VIN 2 Integrated - / + / + + / BS
265 GP VIN 3 Episomal ? - + + + + / Pos-lower
220 GP VIN 3 Integrated / + ? / + + / BS
239 GP VIN 3 Integrated / + + / + + BS
253 GP VIN 3 Integrated + / + / + + / BS
223 GP VIN 3 Episomal + ? + + + + Pos-upper
250 GP VIN 3 Episomal + + + + + + Pos-upper
252 N (56)/TS VIN 3 Integrated + / + / + + / BS
260 N (56) VIN 3 N/A + / + ? + - / BS
272 TS VIN 3 Integrated / / + / + + / BS
273 GP VIN 3 Episomal / / + / / / / BS
305 N VIN 3 Episomal / / ? / ? / / uncertain
283 GP VIN 3 Episomal / / + / + / / Pos-lower
205 GP VIN 3 Integrated + / + / + + / BS
230 GP VIN 3 N/A / + - / + + / bs
233 GP VIN 3 Integrated + + + / + + / BS,?Pos-lower
209 GP VIN 3 N/A + / + / - + / BS
199 GP VIN 3 Integrated / ? + / + + / BS
215 GP VIN 3 Integrated / + + / + + / bs
226 GP VIN 3 N/A / + + / + + / BS
243 N VIN 3 Integrated / / + / - / / bs
257 GP VIN 3 Episomal / / + / + / / BS
267 GP VIN 3 Episomal / / + / / / / BS
225 N VIN 3 Episom al / + + / + + / BS
204 GP VIN 3 Episom al + + + + + + + Pos-upper
217 GP VIN 3 Episom al + + + + + + ? Pos-upper
234 GP VIN 3 Episom al + + + + + + + Pos-upper
275 GP VIN 3 N/A + + + + + + / Pos-upper
306 M Y/GP VIN 3 Episomal / / + / / / / Pos-upper
219 GP/TS VIN 3 Negative / + + / / ? / BS
221 GP VIN 3 Integrated / / / / + ? + bs
242 GP VIN 3 Integrated / / + / ? / / bs
255 GP VIN 3 Integrated / / ? + - / / Neg/bs
202 GP VIN 3 Episomal + + + + + + + Pos-upper
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S am ple P rim ers for D iag n o sis P h y sica l s ta te HPV 16 riboprobe RNA su m m ary
No. HPV typing o f v iru s E1 E2 E4 E6 E7 L1 L2
216 GP (33) VIN 3 N/A + + + + / + + Pos-upper
235 GP VIN 3 Episomal I / / + + + / / Pos-upper
248 N VIN 3 Episomal + + + + + + / Pos-upper
264 GP VIN 3 Episomal / / + / + / / BS
211 GP VIN 3 Integrated - + + / + - / BS
222 GP VIN 3 Integrated / - - / + ? / bs
254 GP VIN 3 Integrated + / + / + + / BS
228 GP VIN 3 Episomal + + + + + Pos-upper
214 GP VIN 3 Integrated + / - / ? ? / uncertain
232 GP VIN 3 Integrated / ? + / ? ? / uncertain
245 GP VIN 3 Integrated / - - / ? / / Neg
304 TS VIN 3 Episomal / / + / + / / BS
249 MY s e e * Episomal / / + / + / / Pos-upper
284 GP/N (0) SCC Negative / / - / ? / / uncertain
274 N SCC Episomal ../ I / - / / - / Neg
238 N SCC Negative / / ? / ? / / uncertain
263 MY/N SCC Integrated / / + / + / / bs
259 TS SCC Integrated / / + / + / / BS
Table 3-3. Overview of RNA in situ hybridisation with digoxigenin labelled riboprobes.
Specim en num bers in italics indicate those  subjects from whom multiple biopsies were 
asse sse d . Prim ers used for HPV typing indicated -  ‘MY’-  MY09/11; ‘G P’ -  GP5+/6+; N’ -  
nested PCR and ’T S ’ -  type-specific primers. W here typing PCR indicated presence of different 
HPV type, this indicated in brackets. ‘Inflam’ indicates the histological diagnosis of inflammatory 
derm atoses. P resen ce  of signal observed with riboprobes tested  is indicated by '+’ and lack of a 
signal by 7* Indicates that the probe w as not used  to test that specim en. The predominant 
RNA pattern observed for all p robes used  is specified in right hand column. ‘P os’ - positive; 
■Meg’ -  negative and ‘BS’ -  blush and speck le pattern, ‘b s’ indicates a weaker signal than ‘BS’. 
This classification is based  on a s se ssm e n t by two observers. W here consensus could not be 
reached, the pattern is specified a s  ‘uncertain’.
‘specim en classed a s  SCC, but g en e  expression appeared  to be within adjacent VIN.
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Figure 3-15. Major patterns of viral transcription identified by RNA in situ 
hybridisation. All im ages are following ISH with HPV16 E7 riboprobes. a) Negative pattern; 
b) Blush-speckle pattern; c) Positive-lower pattern and d) Positive-up per pattern. Left hand 
images at 30x magnification. Right hand im ages at 120x magnification. Positive staining 
patterns taken from ca se s  of VIN 3. Negative im ages from ca se  of inflammatory dermatosis.
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Figure 3-16. Panel of riboprobes demonstrating discrete staining of upper layers of 
epithelium. All im ages at 30x magnification. H/E section show s characteristic appearance of 
undifferentiated VIN3 (case 202). S trongest RNA ISH signal typically obtained with riboprobes 
for HPV 16 E4 and E7.ln this case , a d iscrete pattern of staining affecting upper epithelium is 
clearly visible. L2 riboprobe signal exhibits ’b lush’ pattern of positive staining.
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3.3.3.1 Distinct patterns of viral transcripts identified using RNA in situ 
hybridisation
For samples deem ed positive by both assessors, three broad categories of 
staining were identified. Some sam ples show ed discrete nuclear or cytoplasmic 
staining clearly identified as affecting either the upper (more common) or lower 
(less common) layers of the vulval epithelium. A larger group of samples 
exhibited a more diffuse pattern  of staining, w ith a "blush7 a n d /o r  "speckling7 
appearance, affecting a proportion of the epithelium. Whilst the interpretation 
of this third group was som ew hat m ore subjective than the distinct pattern 
observed for the other two groups, the pattern did appear to be distinct from 
both the negative control hybridisations w ith the sense probes and the negative 
results observed for some clinical specimens. The results for biopsies that could 
not be classified by consensus were graded "uncertain7.
In situ pattern Number o f  
samples
Number o f  
individuals
Negative 4 4
Uncertain 5 4
Blush/Speckle 37 22
Positive - lower 3 3
Positive - upper 13 5
Table 3-4. Frequency of RNA in situ hybridisation patterns. Multiple biopsies from seven 
individuals were graded differently, one individual showing three different patterns for three 
separate biopsies.
3.3.3.2 Variations in RNA in situ pattern over time
Biopsies from m ultiple time points were available from fourteen patients, nine 
demonstrating the same grade of intraepithelial neoplasia and five patients in 
whom  the histological grade varied by one level. For patients with a consistent 
histological diagnosis the RNA in situ pattern  also remained consistent. The 
pattern of staining however differed betw een cases. Of the remaining five
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patients in w hom  the histological diagnosis varied between biopsies, three 
patients also showed a variation in the predom inant pattern of mRNA observed 
by in situ hybridisation. For tw o of these patients, an increased histological 
grade was associated w ith the finding of a discrete as opposed to diffuse mRNA 
pattern of in situ staining (sample num bers 251/265 and 224/210).
3.3.3.3 The effect o f immunotherapy on viral transcription as assessed by 
RNA in situ hybridisation
Twelve patients who provided specimens for this work were subjects 
participating in a vaccination trial that will be described in detail later in this 
thesis (Chapter 5). These patients were vaccinated with a viral vector vaccine 
encoding the high-risk oncoproteins E6 and E7 from HPV type 16 and 18. 
Subjects were followed over a six-month period with respect to the 
development of HPV-specific cytotoxic im m unity and potential clinical effect. 
Ten of the patients did not show a change in the pattern of RNA in situ 
hybridisation dem onstrated following vaccination. For the two remaining 
patients, whilst the predom inant pattern  observed did not change, differences 
were observed for the high-risk oncoproteins. In one patient, who acheived 
complete clearance of her high-grade VAIN, mRNA for HPV 16 E6 was 
detectable at screening but undetectable 3 m onths following vaccination when 
her disease had resolved (patient YF, samples 210 and 224). In the second of 
these patients, HPV 16 E7 mRNA w as evident on the pre-vaccination biopsy, 
but not on the biopsy taken at six m onths following vaccination (patient FS, 
samples 221 and 255). This patient had partial regression of her disease.
3.4 Discussion
The patients studied in this chapter appear typical of those with VIN and vulval 
SCC. The m edian age of 48.0 yrs for patients w ith high-grade VIN is similar to 
both institutional and population data reported previously (Buscema et ah, 
1988; Sturgeon et ah, 1992; Jones et ah, 1994; Haefner et ah, 1995; I.S.G.V.D., 1996; 
Iversen et ah, 1998; Joura et al., 2000). Over two-thirds of patients with VIN were
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under the age of fifty, lending support to the high-incidence of the disease 
previously reported in younger w om en (Jones et al, 1994; Herod et a l, 1996; 
Joura et a l, 2000). As m ight be expected, patients with invasive disease were 
significantly older than those w ith VIN.
The vast majority of w om en w ith VIN in the present study were symptomatic, a 
finding in agreem ent w ith m any previous studies (see section 1.1.5). The most 
common sym ptoms were those of pruritus and soreness. The high median 
duration of sym ptoms (24 m onths), as well as the fact that almost two-thirds of 
subjects had undergone previous treatm ent for their VIN, confirm the chronic, 
often recurrent nature of this condition. A history of current or previous 
abnormal cervical cytology in alm ost half our cohort of patients with VIN is in 
keeping w ith the findings of an  earlier British study (Herod et a l , 1996). 
However, the incidence of sm oking in the cohort w ith VIN (45.7%) was perhaps 
not as high as has been previously described (Jones et al, 1994; Modesitt et al, 
1998).
The results presented in this chapter confirm earlier suggestions of the strong 
association between high-grade VIN and HPV infection (Haefner et al, 1995; 
Hording et al, 1995; van Beurden et a l, 1995; Madeleine et al, 1997; van Beurden 
et al, 1998a). The strategy of testing w ith MY09/11 and GP5+/6+ primer 
systems both independently and in a nested fashion should detect HPV with 
high sensitivity and the high incidence of HPV infection in patients w ith VIN 
(-95%) would support this. It should be noted that the data presented in this 
chapter only applies to basalo id /w arty  VIN. Differentiated VIN was not 
studied in the current work. The data w ould tend to support the views of 
H ording and colleagues, w ho feel that VIN 3 is indicative of underlying HPV 
infection (Hording et al, 1993). In keeping w ith previous studies (reviewed in 
section 1.1.4.1) HPV infection was significantly more common in those patients 
with VIN as opposed to SCC of the vulva (94.3% vs. 58.8%; p=0.003). The low 
number of patients w ith SCC of the vulva makes it hard to draw comparisons 
between HPV-positive and HPV-negative individuals. It was not possible to 
classify the SCCs further into basalo id /w arty  and keratinising subtypes.
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The GP5+/6+ prim er system w as initially chosen instead of the MY09/11 
system to take advantage of the fact that those prim er systems that amplify 
smaller products are typically m ore sensitive in detecting the desired target 
DNA. PCR to identify genital HPV infection was not available within the 
research group and it was therefore appropriate to ensure optimisation of one 
PCR system in the first instance. W ith increasing expertise in the technique of 
PCR, the MY09/11 prim er system  was optimised and used to test samples that 
were negative for HPV by G P5+/6+ PCR. The GP5+/6+ and MY09/11 primer 
systems vary in their ability to detect different genital HPV types (Qu et al., 
1997) and using both to screen for HPV infection could therefore increase the 
ability to detect HPV w ithin a clinical sample. Qu and colleagues found the 
GP5+/6+ and MY09/11 systems to be equally effective with regard to the 
detection of HPV 16, the m ost com m on viral type isolated from patients in this 
study. However, some samples were found to be positive for HPV 16 by 
MY09/11 rather than GP5+/6+ PCR and it w ould therefore appear that the use 
of both prim er systems m ight increase the sensitivity of HPV detection.
As expected, nested PCR for HPV detection was more sensitive than single­
round PCR. It could therefore be argued that the nested PCR typing system 
should have been em ployed from  the start of this project. However, the 
additional sensitivity occurred at the expense of a high risk of contamination. 
The negative controls (water and extraction mix) m ust be taken through both 
rounds of PCR for the result to be valid. Whilst a high sensitivity for the 
detection of HPV infection is helpful in ensuring cases labelled as 'HPV- 
negative' are truly negative, the biological relevance of cases designated as 
'HPV-positive' on the basis of a highly sensitive PCR, able to detect HPV at 
limited copy num ber, may be questionable. From a clinical viewpoint, the 
demonstration of viral transcription or integration may have more of an impact 
on the pathogenesis of neoplasia than HPV infection alone. However, the 
limited data available suggests that infection in normal vulval skin is 
infrequent. Using type-specific PCR, H ording et al. failed to demonstrate HPV 
in 101 normal vulval biopsies (Hording et a l, 1993). This finding is in stark
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contrast to the uterine cervix, w here transient infection w ith HPV in the absence 
of dysplasia is a common occurrence (Ho et al, 1998). The different architecture 
of the transformation zone may account for the ease with which HPV can access 
the cervix but as yet unidentified difference in the host immune response may 
also play a part in the variation in HPV infection w ith anatomical site. Vulval 
HPV infection may be m ore significant than  its cervical counterpart and it is 
therefore appropriate to use a highly sensitive PCR technique when assessing 
vulval specimens.
The high incidence of HPV 16 infection in VIN is in keeping with the findings of 
others (discussed in detail in section 1.1.4.1). Direct sequencing has been used to 
demonstrate frequent HPV 16 infection in VIN (van Beurden et al, 1995; 
Rosenthal et a l, 2001). A potential lim itation of direct sequencing for HPV 
typing is the inability of the m ethod to detect multiple infections. The use of a 
second round of type-specific PCR (van den Brule et al, 1990) or hybridisation 
of the PCR product to type-specific probes (Kleter et al, 1999) could have 
overcome this problem. However, previous studies that have used 
methodology able to detect m ultiple HPV infection have shown that such 
infections are unusual in VIN (Haefner et a l, 1995; Hording et al, 1995; 
Madeleine et a l, 1997). This fact, coupled w ith the available resources and 
timescale of the current project, led to the choice of direct sequencing to type 
clinical specimens. Three samples from  two individuals produced a positive 
signal following HPV 16 RNA in situ hybridisation despite the isolation of a 
different HPV type by PC R/sequencing (samples 216, 252 and 250 -  HPV type 
33, 56 and 56 respectively). In one of these samples (sample 252), the prescence 
of HPV 16 was confirmed using type-specific PCR, indicating that the RNA ISH 
result reflected infection w ith m ultiple HPV types rather than non-specific 
hybridisation of the HPV 16 riboprobe. It would therefore appear that, 
although uncommon, infection w ith m ultiple HPV types can occur in VIN. The 
MY09/11 prim er pair system m ay be more effective in amplifying multiple 
HPV types from  a single specimen than its GP5+/6+ counterpart (Qu et al,
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1997) and may therefore be the m ost appropriate primer system should 
information on m ultiple infections be required.
The serial nature of biopsies in fifteen individuals provides some information as 
to the stability of HR-HPV infection in individuals with high-grade VIN. In the 
majority (11/15) of these patients the predom inant HPV type isolated following 
PCR remained the same. In one individual the type varied between HPV 16 and 
HPV 33, both recognised HPV types associated w ith high-grade VIN. It seems 
likely that this latter case may reflect a mixed infection, with variance in the 
HPV type amplified by PCR at differing time points. Three HPV-positive 
individuals became HPV-negative during follow-up. None of these can be 
regarded as spontaneous clearance of the virus as all had been treated either by 
vaccination w ith a viral vector vaccine directed against HPV types 16 and 18 
(see Chapter 5) or with Imiquimod (a topical cytokine mediator described in 
section 1.1.7.3.3). In two of these patients resolution of the disease was 
accompanied by the disappearance of HPV from clinical specimens. The small 
numbers of patients w ith serial biopsies make it difficult to draw  any firm 
conclusions from this dataset. As m ight be expected, it appears that most 
women with persistent disease rem ain HPV-positive and that the predom inant 
type of virus does not change. This finding w ould support the role of HPV 
infection in the developm ent of high-grade VIN.
Whilst no data exists for its role in VIN, viral integration has been proposed as a 
key step in the developm ent of HPV-related carcinoma of the uterine cervix 
(section 1.2.1.5). Estimates of the percentage of high-grade CIN lesions 
containing integrated viral DNA vary considerably, but analysis of invasive 
disease has show n the vast majority of invasive lesions to contain integrated 
high-risk viral DNA (Park et al., 1997; Kalantari et al., 2001). Viral integration 
was assessed using PCR for the E2 gene as a surrogate marker, as this gene is 
commonly disrupted during integration into the host genome (Choo et al., 1987; 
Das et al., 1992). Approximately half the HPV-positive VIN samples available 
for analysis showed loss of this gene and were therefore designated as 
integrated. This finding w ould suggest that integration commonly occurs
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before the development of malignancy and may serve to drive malignant 
progression in vulval neoplasia. Recent work on the W12 cervical cancer cell 
line would support the role of integration early on in oncogenesis. Integration 
in this cell line precedes the developm ent of high-level chromosomal instability 
(Pett et al., 2004). The authors found that increasing levels of the E7 oncoprotein 
correlated w ith increasing num erical and structural chromosomal aberrations. 
They postulate that loss of E2-mediated transcriptional repression lies behind 
increasing E7 protein levels and suggest that integration is a critical step in 
cervical carcinogenesis. Using an E2-based PCR to assess integration may have 
some problems. Loss of the E2 am plicon w ith a positive PCR for E7 is assumed 
to indicate disruption of the E2 ORF occurring during integration. The 
technique relies upon prim er sequences located at either end of the E2 ORF, 
giving an amplicon of over lk b  in size. The amplicons from the HPV E7 ORF 
are typically m uch smaller (-300 kb). As such, loss of an E2 signal might simply 
reflect less effective amplification of the larger DNA target. This system may 
also underestimate the true extent of integration, as it does not allow the 
detection of mixed populations of cells w here the virus exists in both episomal 
and integrant forms. Such cases will produce amplicons in both E2 and E7 PCRs 
and would therefore be classified as episomal by this technique. Some workers 
have proposed that the E2:E7 ratios provided by quantitative PCR may allow 
for discrimination of such mixed cell populations (Peitsaro et ah, 2002). The ratio 
thresholds of E2:E7 proposed in the study report by Peitsaro (1.0 ± 0.05 for 
episomal HPV) were however arbitrary and had not been statistically 
validated3.
Other techniques are available to assess the physical state of HPV in clinical 
specimens. Restriction enzyme digestion (M atsukura et al, 1989) can allow the 
distinction of episome from integrant by the pattern of bands observed 
following digestion with no-cut and single-cut restriction enzymes. This 
technique requires large am ounts of DNA and w ould not have been suitable for 
this study. The recent developm ent of sequence-based techniques may provide
3 Professor S. Syrjanen, personal communication, HPV 2002, Paris.
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more biologically relevant inform ation regarding viral integration. The APOT 
technique (Amplification of Papillom avirus Transcripts) is an RT-PCR assay 
that allows the size-based distinction of mRNA transcripts derived form 
integrated viral DNA from those derived from episomes (Klaes et al, 1999). 
Reverse transcription of all mRNA is initiated using an oligo(dT)i7 primer 
coupled to a linker sequence. A nested PCR using E7-specific primers and 
primers for the linker sequence then amplifies all viral E7 transcripts. The most 
common E6/E7 transcript from  viral episomes is spliced from the E l splice 
donor signal to the E4 splice acceptor site before termination at the 
polyadenylation site (Schwarz et al., 1985; Sherman et a l, 1992). In contrast, 
transcripts from integrated DNA are longer and usually have viral sequences at 
their 5' ends w ith flanking cellular sequences at their 3' ends. APOT has the 
advantage that the technique identifies transcriptionally active DNA, which is 
likely to be of greater biological significance. Technical difficulties, mainly due 
to the limited stability of mRNA in clinical samples, limit the application of this 
technique. Fresh tissue samples were available for the majority of cases in the 
current work and this technique m ight have been employed.
The riboprobes synthesized in this study were able to detect RNA transcription 
within a subset of the vulval lesions studied. The E4 and E7 probes gave the 
strongest signals in positive cases (Figure 3-16). Initial experiments suggested 
that these probes appeared predictive of the likelihood of further positive 
signals with other riboprobes. In view of the limited availability of tissue from 
the small biopsies available, the initial in situ experiments were therefore 
performed w ith this pair of probes. The clarity and intensity of signal achieved 
with the E6 riboprobe was disappointing throughout the study. Whilst this may 
reflect low levels of E6 transcription, other authors have found transcripts 
initiated w ithin E6 to be common w ithin high-grade lower genital tract lesions 
of the vulva and cervix (Crum e t a l , 1989; Park et a l , 1991b; Nakagawa et a l , 
2000b). It may therefore be that the design or sequence of the probe was flawed. 
However, all pGEM-3Z constructs were sequenced prior to their usage, and 
each riboprobe was designed to fall w ithin the relevant ORF using data from
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the Los Alamos national laboratory HPV sequence library (h ttp :/ /h p v -  
web.lanl.gov/ stdgen / v iru s /h p v /L
Three distinct patterns were seen for those HPV 16 cases found to be positive 
for RNA expression by in situ hybridisation w ith the riboprobes described 
earlier (Figure 3-15). The m ost prevalent pattern was that of 'blush ' and 
'speckle'. This pattern was sometimes observed throughout the entire thickness 
of the epithelium, but was lim ited to the upper one to two thirds in other cases. 
The widespread distribution of such staining raises the possibility that the 
pattern seen represented background signal rather than target mRNA 
expression. However, the corresponding negative signal seen w ith the sense 
probe for these cases w ould tend to suggest the result is valid. Indeed, Park et 
al. (1991b) used tritium-labelled sub-genomic probes to demonstrate transcripts 
throughout the full thickness of the epithelium  in basaloid VIN 3. The authors 
found the topographical pattern  of transcription for E6-E7 to be similar to that 
of L1-L2. In the current work, a similar relationship between the early and late 
transcripts was seen for those subjects w ith a 'blush-speckle' pattern. This wide 
distribution of transcripts is biologically plausible. If HPV is causally related to 
vulval neoplasia, one w ould expect transcription and translation to extend 
upw ards from the area of viral entry in the basal epithelium. Furthermore, 
following evidence of the clonal nature of high-grade VIN (Tate et al., 1997; Lin 
et al, 1998; Pinto et ah, 2000), viral activity w ould be expected in all cells 
following clonal expansion. Such a diffuse distribution of transcripts does not 
seem to be unique to intraepithelial neoplasia of the vulva. A study of high- 
grade CIN also dem onstrated early transcripts throughout the full thickness of 
the epithelium (Diirst et al., 1992). It is im portant to note that the 'blush- 
speckle' pattern was also identified in biopsies from both histologically normal 
and inflammatory lesions. This finding is in contrast to that of Hording et al. 
(1993) who found were unable to demonstrate HPV infection using PCR in over 
one hundred norm al vulval biopsies. The significance of this infection is 
uncertain. W hilst transient HPV infection is extremely common in the cervix 
(Ho et al., 1998) little is known about the natural history of infection in the
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vulval area. HPV may in fact be active as a driving force for m alignant change 
at an early stage, before the onset of histological change. Furthermore, the data 
presented here w ould tend to support those w ho feel that far from being 
mutually exclusive pathw ays, inflamm atory dermatoses and HPV infection can 
act simultaneously as cofactors in the developm ent of intraepithelial disease 
and malignancy (Kiene et al., 1991; Ansink et ah, 1994; Haefner et al., 1995). The 
data may however be biased. Biopsies of normal and inflammatory tissue were 
not collected in a truly prospective fashion and may not be representative of 
such lesions as a whole. Clinical practice dictates that painful biopsies are not 
routinely performed w hen there is little concern regarding the possibility of 
malignancy. Many subjects w ith  no previous history of VIN or carcinoma will 
first undergo a period of observation or a therapeutic trial w ith topical agents 
such as steroids prior to their referral to the hospital clinic for assessment. As 
such, cases reviewed in the clinic will commonly be those with longstanding or 
resistant disease and those w ith a recent history of topical immunosuppressive 
use. Both these features m ay potentially increase the likelihood of HPV 
infection. Other biopsies were obtained from symptomatic patients or those 
attending colposcopy clinics w ith a history of cervical or vulval intraepithelial 
disease. These lesions m ay not therefore be truly reflective of normal vulval 
tissue or indeed inflammatory dermatoses.
Two patterns of discrete positive staining using the antisense riboprobes were 
seen in VIN, namely 'upper' and 'low er' patterns. In such cases, the staining 
pattern was readily identified and often focal in nature. Positive staining 
affecting the lower epithelium  was dem onstrated using the riboprobes for one 
of the high-risk transcripts, E6 or E7 (see Figure 3-15c). Other transcripts 
identified in these cases localised to the upper epithelium. The 'positive-lower' 
pattern w ould appear to fit m ost comfortably with the classical concept of 
subversion of cell growth in the basal cells of the epithelium as a result of HR- 
HPV infection. In productive infections, expression of E4 and the late genes 
occurs in the upper layers in a differentiation-dependent fashion (section 
1.2.1.3). Recent work suggests that in cervical HSILs, the order of life cycle
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events is preserved but the infection may be abortive w ith E4 and LI often 
limited to small areas at the epithelial surface (Middleton et al, 2003). Whilst 
late gene transcripts were never found in the lower layers of the epithelium, the 
limited num ber of cases exhibiting the 'positive-lower7 pattern and restricted 
numbers of sections available for each case make it difficult to draw  such 
conclusions w ith respect to the viral life cycle in VIN.
In one case of high grade VAIN exhibiting the positive-low er7 pattern (case 
210), a wide variety of transcripts were detected. These included the transcript 
for HPV 16 E2. This is of particular interest in view of the fact that the sample 
was thought to contain HPV 16 in its integrated form. As integration commonly 
occurs w ithin the E2 region (Baker et a l, 1987; Schneider-Maunoury et al, 1987), 
one would expect the E2 transcript to be missing in such a case. It is possible 
that the lesion was incorrectly designated as containing integrated DNA due to 
the PCR methodology used (see above). It is also possible that integration might 
have occurred at the 37 end of the E2 ORF w ith preservation of an E2 transcript 
detectable by mRNA ISH. As the mRNA signal from E4 was also demonstrated 
in this patient, this cannot be the case here and the pattern of mRNA ISH would 
suggest the presence of viral episomes. HPV may exist in varying states within 
cervical neoplasms (M atsukura et a l, 1989) and any coexistant episomal DNA 
could have resulted in the production of HPV E2 transcripts.
The 'positive-upper7 pattern  was dem onstrated in thirteen samples from five 
different individuals. In these individuals all transcripts identified, including 
those from the high-risk E6 and E7 ORFs, were seen in the upper layers of the 
epithelium. Recent w ork on CIN suggests that E7 protein is expressed higher 
up the epithelium  of high-grade lesions (Middleton et al, 2003). However, this 
expression occurs as an extension of the more usual parabasal distribution of 
these oncoproteins. In those individuals designated as showing a 'positive 
upper7 pattern viral transcripts for E6/E7 were not seen in the basal two-thirds 
of the epithelium  and the pattern w ould not appear to represent the 'delay7 in 
the virus life-cycle presented by M iddleton and colleagues.
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The focal nature of staining observed could possibly reflect variations in probe 
sensitivity in a particular section, bu t the reproducible nature of the pattern 
would tend to mitigate against this explanation. The fact that focal upper 
staining was seen across the whole panel of riboprobes for some cases raises the 
possibility that the RNA ISH m ethod has threshold sensitivity and that the 
signal only became positive in the upper layers where the virus was present in 
high copy num bers following the completion of a productive life cycle. 
Certainly others have found transcription of both early and late viral transcripts 
to increase w ith increasing differentiation, w ith late viral transcripts even being 
identified in well differentiated regions of vulval SCCs (Park et al.f 1991b). The 
relative persistence of differentiation and cornification seen in VIN lesions 
could facilitate completion of the HPV life cycle at this site.
A striking observation is that all cases showing a "positive upper" staining 
pattern were found to contain episomal DNA by PCR analysis. Episomal viral 
DNA is found at high copy num bers in the upper part of the epithelium during 
productive infections. It m ight therefore be the case that transcripts only 
reached readily detectable levels following transcription from large amounts of 
extrachromosomal viral DNA in the upper epithelium. Crum et al. (1989) used 
riboprobes from the ORFs upstream  and downstream  to the El ORF (where 
integration commonly occurs) to assess the origin of transcripts demonstrated 
in a series of biopsies from  patients w ith CIN or VIN. The observation that the 
downstream  probe (E2-E5-L2 region) gave at least an equivalent signal to the 
upstream  probe (E6-E7 region) supports the notion that most of the signal 
observed in this study originated from transcription of viral episomes. Whilst it 
would appear that episomal DNA is essential for the production of late viral 
proteins in vegetative or productive infections (Frattini et al, 1996), the 
contribution of episomes to m alignant transformation is less clear. In vitro 
studies rather tend to reinforce the importance of integrated HR-HPV DNA in 
oncogenesis. The SK-v cell line was established from a lesion of VIN known to 
contain episomal HPV 16. In animal studies, the cell line behaves in a 
phenotypically similar way to the original pre-malignant lesion, but subsequent
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detailed characterisation of the SK-v line has shown it to contain solely 
integrated DNA (Schneider-M aunoury et al., 1987). Following this discovery the 
authors used a specific probe to show that integrants were indeed present in the 
clinical lesion from which the cell line was established. Furthermore, Le and 
colleagues (1988) were able to show that transformation of keratinocytes by a 
hybrid viral-human DNA fragm ent extracted from a HPV-positive tum our was 
dependent on the juxtaposition of integrated viral and cellular DNA. 
Nevertheless, episomal DNA may contribute to m alignant progression. Recent 
work using organotypic raft cultures has shown that transcripts derived from 
episomal HPV 16 are sufficient to induce centrosome abnormalities and 
chromosomal instability (Duensing et al., 2001b). The resulting structural 
damage may in turn  favour viral integration and the induction of integrant 
derived transcripts w ith m arked transform ing capacity.
To improve the sensitivity of mRNA detection and confirm the focal 
transcription patterns described above, the ISH method used could be 
modified. Firstly, it w ould be attractive to have a reliable positive control with 
which to further optimise the RNA ISH protocol. The clinical biopsies used in 
these studies were limited in size and it was difficult to justify using a positive 
case as a control for future experiments. With the advent of organotypic raft 
cultures and well characterised cell lines such as the W12 line (Stanley et ah, 
1989), it may be possible to develop a reliable and renewable source of controls 
for future experiments. Keratin probes and appropriate control specimens were 
used to guard against m ethod failure for RNA ISH. It would perhaps have been 
appropriate to include a probe for a common epithelial transcript such as p- 
actin to control for mRNA quality w ithin individual clinical sections. Following 
the use of such a control during the investigation of HPV 16 E7 transcripts in 
cervical SCC, van den Brule and colleagues (1991) concluded that failure to 
detect mRNA in the specimens was m ost likely secondary to mRNA 
degradation rather than absence of signal. Such a control might have helped in 
the interpretation of both the 'negative' and 'blush-speckle' patterns seen in the 
current series.
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Using snap-frozen sections m ight have im proved the quality of mRNA 
available for the in situ, bu t unfortunately such specimens are less useful for 
histological diagnosis and splitting the small vulval biopsies to allow freezing 
of one portion and form alin fixation of the other was not always practical. 
Labelling probes with radioisotopes and using long exposures might further 
enhance sensitivity. However, although these techniques have been used 
successfully (Crum et ah, 1989; D urst et al, 1992), they are time consuming, 
more dangerous and prone to increased background signal. More recently 
catalyzed reporter molecule deposition has been used to provide signal 
amplification w ithout increasing background signal in ISH. The most common 
technique employed is that of tyram ide signal amplification (TSA). Bound 
probe is detected using the appropriate hapten bound to horseradish 
peroxidase (HRP). The immobilised HRP is then used to convert labelled 
tyramide (the reporter molecule) into a short lived and reactive intermediate 
that binds to cellular proteins immediately adjacent to the bound primary 
antibody. A secondary antibody is then used to detect the bound, labelled 
tyramide. Pre-treatment of the specimens to quench endogenous peroxidase e.g. 
with hydrogen peroxidase, may reduce background. The technique increases 
the sensitivity of ISH and has even been used to detect low copy number 
nucleic acid sequences (Evans et a l, 2003).
Only three of the six SCCs studied showed a positive staining pattern following 
RNA ISH. In one of the cases the focal 'positive-upper' staining reported 
appeared to be w ithin a focus of high-grade VIN within the invasive lesion. 
Two of the carcinomas show ed the diffuse 'blush-speckle' pattern described 
above. Positive signals were only identified w ith both E4 and E7 riboprobes. It 
is therefore difficult to establish clear difference between preinvasive and 
invasive disease. Unfortunately, the limitations of tissue availability and time 
have prevented a more thorough assessment of the carcinoma specimens with 
the full panel of riboprobes. However, the broad spectrum of transcripts seen in 
the high-grade VIN lesions and in particular, the strong signals identified with 
E7, does not indicate a clear change in expression pattern between pre-
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malignant and malignant lesions. Park et al. (1991b) dem onstrated focal 
transcription of a full range of transcripts, including those from late genes, in 
well differentiated areas of 'w arty ' SCCs. The authors conclude that it is the 
degree of differentiation rather than stage of disease that determines the pattern 
of transcription.
A strength of the data presented in this chapter is the serial biopsies available 
from fourteen patients w ith VIN. These biopsies reveal that the pattern of viral 
transcription appears to rem ain consistent over time in lesions that 
demonstrated consistent histological grade. Five patients showed variations in 
the histological grade of lesion. It is interesting to note for two of these patients 
that an increased grade of V IN /V A IN  was associated with a discrete rather 
than focal pattern of staining. Following the discussion above, it may be that the 
higher-grade of lesion was associated w ith increased viral load, which may 
favour such a staining pattern.
The effect of im m unotherapy on viral transcription was assessed following 
vaccination w ith a viral-vector vaccine, expressing HPV 16 E6 and E7. The 
choice of the oncoproteins as targets for imm unotherapy makes biological 
sense. In cervical disease, transcripts from both ORFs are commonly found in 
both HSILs and SCCs. The strong in situ signals achieved with the E7 
riboprobes and the fact that E7 was identified in both pre-malignant and 
malignant lesions w ould support the use of the same targets in immunotherapy 
directed against vulval disease. Unfortunately, no clear effect on viral 
transcription was seen following successful vaccination. Of the twelve patients 
studied, transcription patterns observed using RNA ISH remained unchanged 
in ten patients over the six-month follow-up. It is however encouraging that the 
patient who had disease clearance following vaccination, also showed loss of 
mRNA signal for transcripts that had been demonstrated pre-vaccination 
(patient YF; samples 210/224). The loss of E7 mRNA signal in a second patient 
in whom partial disease regression occurred also lends support to the potential 
of imm unotherapy as a treatm ent for this condition.
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The data presented in this chapter have reinforced the previous suggestions of a 
strong association between HPV 16 infection and VIN. The virus appears to be 
transcriptionally active and the broad range of transcripts identified in pre- 
malignant lesions raises several possible targets for potential immunotherapies. 
The extent of transcription in VIN prevents the selection of a specific transcript 
pattern as a possible m arker for the development of malignancy. W hether post- 
transcriptional modifications will affect the expression of viral proteins and 
thereby influence the biological effects of HPV remains to be seen. 
Transcriptionally active virus was identified in both normal and inflammatory 
biopsies and it seems likely that whilst HPV gene expression may be a driving 
factor early in the vulval oncogenesis, other cellular and genetic factors may be 
more influential at the key step of progression to invasion. Integration of HPV 
into the host genome was also surprisingly common in pre-malignant lesion, 
being dem onstrated in half the HPV-positive VIN lesions tested. This finding 
would tend to suggest integration has a role early on in oncogenesis, and that 
secondary events such as genetic dam age may be more influential in the 
progression to vulval malignancy.
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Chapter 4 Genomic copy number imbalance in vulval 
neoplasia
4.1 Introduction
A review of the literature supports the notion of VIN as a pre-malignant 
condition. However, our understanding of the mechanisms behind disease 
progression is limited. The available effective therapeutic options are surgical 
and carry w ith them both physical and psychological morbidity. A greater 
understanding of the pathw ay from the prem alignant to m alignant lesion 
would assist in a more focussed approach to the treatm ent of patients, perhaps 
even limiting intervention to those in w hom  the risk of progression were high 
or even inevitable.
Whilst recurrent genetic alterations have been described for both CIN and 
cervical SCC, only limited data exist for vulval neoplasia. As has been described 
elsewhere (section 1.2.3.2.2.1), the majority of information available comes from 
small loss of heterozygosity studies using a limited panel of microsatellite 
markers. CGH provides an opportunity to study both gains and losses across 
the tum our genome. To date, only three small studies have used this technique 
to study vulval neoplasia (Jee et al., 2001; Allen et al., 2002; Micci et al., 2003). All 
these studies focussed on SCC of the vulva. By studying pre-invasive lesions 
(VIN), common copy num ber imbalances (CNI) may become apparent, 
supporting the notion of VIN as a m alignant precursor lesion. The relative 
frequency of CNIs in low and high-grade VIN and vulval SCC may also be 
informative. Abnormalities that increase in frequency from one grade to 
another may reflect clonal expansion of cells with such CNIs. These 
abnormalities may therefore confer a selection advantage to cells that acquire 
them and could indicate potential m arkers of disease progression.
In this chapter, microdissection, DOP-PCR and CGH are used to investigate the 
number and frequency of CNI in 25 individuals w ith VIN (4 low-grade lesions 
and 24 high-grade lesions) as well seven individuals with SCC. The number
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and site of CNI in each grade of disease will be presented in conjunction with 
data regarding the presence and physical state of oncogenic HPVs.
4.2 Methods
4.2.1 Microdissection and DNA extraction
As described previously (section 2.2.1), frozen 10pm tissue sections were first 
stained with haematoxylin and eosin before microdissection. Typically between 
three and five sections were microdissected, dependent upon the thickness of 
the abnormal epithelium. It is estimated that approximately 1000-1500 cells 
were retrieved for each case. All cases provided sufficient amounts of DNA for 
CGH as assessed by PCR for the P-globin gene (Figure 4-2). The epidermal 
nature of the vulval lesions studied m ade dissection relatively straightforward. 
Kallionemi et al have estimated that 50% contamination with non-tumour cells 
is the limit for detection of monosomies or trisomies (Kallioniemi et al, 1994). It 
is very unlikely that contamination in our series exceeded 10%.
a) Figure 4-1. Microdissection of frozen section
a) Haematoxylin and eosin stained reference 
section showing VIN 3
b) Corresponding frozen section after desiccation
c) Microdissection of the epithelial layer leaving 
basem ent m em brane intact
b) c)
&
4.2.2 DOP-PCR amplification
DNA from microdissected lysates of vulval lesions was amplified and 
differentially labelled by DOP-PCR as described in section 2.2.4.I. Water and 
lysis buffer (prepared and treated in the same fashion as the DNA lysates) were 
used as negative controls for all prim ary DOP-PCR reactions. Visible product in
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Figure 4-2. PCR products from each stage of CGH paint preparation
a) Quality of DNA obtained from microdissection a sse sse d  by p-globin PCR. W ater and 
extraction buffer act as  negative controls. Placental DNA acts as  positive control.
(10|il of PCR product /1  % ag a ro se  gel)
b) Initial amplification of m icrodissected DNA using DOP1 PCR. Amplified DNA visible as 
broad sm ear. W ater and extraction buffer act a s  negative controls. WBC DNA acts as 
positive control a s  well a s  providing tem plate for DOP2 PCR.
(5pl of PCRproduct /1 %  agarose  gel)
c) Further amplification and labelling of DOP1 product using DOP2 PCR. Labelled control 
normal WBC DNA prepared for each  te s t sam ple.
(5pl of PCR product /1 %  agarose  gel)
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either negative control lane on gel electrophoresis led to that PCR reaction 
being discarded and the experim ent repeated. Approximately 300ng of DNA 
from control normal PBMCs was used as a positive control for the primary 
DOP-PCR and to provide norm al DNA for labelling in the subsequent 
secondary DOP-PCR (Figure 4-2).
4.2.3 Control hybridisations and threshold values for CGH
Aneuploidy is common in both cervical and vulval SIL (Cellier et al., 1970; 
Lerma et ah, 1999). Data from  cervical SIL suggest that the majority of cases 
have a peritetraploid population of cells (Cellier et al, 1970). Therefore to detect 
a single copy num ber change present in 100% of sampled cells, the fluorescent 
intensity ratio thresholds should theoretically be set to 0.75 for loss and 1.25 for 
gain. It is unlikely that ploidy change will affect every cell within a target lesion 
and contamination to some degree by normal cells is inevitable. Both these 
factors will reduce the chance of a sam pled lesion achieving such a high change 
in fluorescence intensity ratio. To detect a single copy loss or gain present in 
50% of sampled cells these thresholds should be adjusted to 0.875 and 1.125 
respectively. These theoretical limits were tested using a series of control 
hybridisation experiments (n=6) using tissue from both histologically normal 
vulval biopsies and paired control normal PBMC. Whereas false-positive 
abnormalities can be identified in 'norm al7 tissue when thresholds are set at 0.9 
for loss and 1.1 for gain, no such abnormalities were seen when levels were set 
to 0.85 and 1.15 respectively. This finding is identical to that found by other 
investigators w ithin the group studying cervical SIL (Alazawi, 2003). 
Thresholds of 0.85 for copy num ber loss and 1.15 for gain were therefore used 
for the subsequent analysis of lesional tissue.
4.2.4 Chromosomal regions excluded in analysis
The repeat-rich sequences found in peri-centromeric and heteterochromatic 
DNA can generate false positive CGH abnormalities for these regions. An 
attempt was m ade to suppress probe binding to these regions using hum an
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placental Cot-1 DNA. These regions are highly polymorphic in copy num ber 
between individuals and suppression may therefore vary (Kallioniemi et al, 
1994). Ratio changes occurring w ithin or immediately adjacent to these regions 
should therefore be interpreted w ith  caution and were excluded in the analysis 
of this dataset.
The green and red fluorescent signals will gradually decrease towards the 
telomeres. As the fluorescent intensity begins to approach the level of 
background fluorescence, the ratio changes observed become unreliable 
(Kallioniemi et al., 1994). This is indicated by increasing confidence intervals 
seen on the display karyogram  (Figure 1-15). Isolated gains and losses 
involving the telomeres were therefore excluded from analysis.
Problems in the detection of deletions by CGH at specific chromosomal loci 
have also been reported, notably chromosomes lp32-pter, 19 and 22 
(Kallioniemi et al, 1994). The ratio profiles at these points show significant 
intra-experimental variations and may occasionally be well below the average 
ratio, leading to the false suggestion of a deletion. In keeping w ith common 
practice, the short chromosomes 19 and 22 were therefore excluded from 
analysis. The reported variation in fluorescence seen towards the telomere of 
chromosome lp  has been attributed to this region being a gene rich area. 
Control DNA is usually of better quality than the test DNA and this region may 
therefore be better represented following DOP-PCR amplification. Once again, 
this may lead to the reporting of a false Toss' for this area. However, in this 
series, only gains, not losses, were seen for this region. Such gains were not 
found in control biopsies from  isolated norm al vulval skin and high-level (ratio 
>1.5) gains were found in some individuals w ith high-grade disease. These 
facts would suggest that the copy-num ber gains demonstrated for lp  are valid 
and the data has therefore been included in the analysis.
4.2.5 Statistical methods used in analysis
Although this study includes more cases of CGH analysis in vulval neoplasia 
than any study published to date, the rarity of condition means that the actual
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numbers involved are small. The data does not therefore meet the criteria for 
the application of parametric statistical tests and non-parametric m ethods m ust 
be employed. Fisher's exact test for the comparison of independent variables 
was used to compare proportions betw een two groups e.g. frequency of gains 
and losses found to affect different chromosomal arms between two 
pathological groups. The Mann-W hitney U test was used to compare the 
frequency distribution of CNIs betw een two pathological groups. The Kruskal- 
Wallis test was used to investigate overall similarities in CNIs between all the 
pathological groups studied. The Jonckheere-Terpstra test perm itted further 
investigation of the order of this relationship. Data was compiled using Excel 
2000® and statistical analysis w as perform ed using SPSS 11.5®. Two-tailed tests 
were used and significance w as assessed at the 95% level (p < 0.05).
4.3 Results
4.3.1 Tissue samples and patient demographics
Fresh tissue samples were obtained from patients referred to the gynaecological 
oncology centre and specialist vulval clinics at Addenbrooke's NHS Trust, 
Cambridge between April 1999 and May 2002. Prior ethical approval for this 
work was obtained from the local research ethics committee (LREC 98/227). 
The histopathological diagnosis was confirmed independently by two 
consultant gynaecological histopathologists. Where variation in opinion 
occurred (n=2), both consultants reviewed the case and reached an agreed 
diagnosis. Control tissue included peripheral blood mononuclear cells from 
normal individuals, biopsies from  wom en w ith non-neoplastic vulval 
dermatoses and paired biopsies of adjacent normal vulval skin from women 
with vulval carcinoma who were undergoing wide local excision under general 
anaesthetic.
The m edian age of cases in this study was 54 years (range 37-82) and that of 
controls 52 years (range 33-81; p=0.960). The data for individual cohorts is 
shown in the Table 4-1.
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Cohort N Median age
/yrs
Average age
/yrs
Age range
/yrs
Control -  normal 4 51 47.5 33-55
Control -  assoc with neoplasia 5 72 63.8 46-81
Low-grade VIN 4 46 51.5 42-72
High-grade VIN 24 49 53.0 37-78
Vulval SCC 7 77 74.4 54-86
Table 4-1. Age distribution of participants in CGH study
The median age of patients with VIN was 49yrs and over half of the patients 
(15/28) were under 50yrs on recruitm ent to the study. Most patients (20/24) 
with VIN were symptomatic. The most common symptom was itch (Figure 4-3) 
Seventeen women had had previous treatm ent for their disease.
9% 3%
■ Itch
■  Soreness 
□  lump
□  Colour
□  bleeding
Figure 4-3 Sym ptom s a sso c ia ted  with vulval intraepithelial neoplasia
The seven carcinomas included in the study were all SCCs and comprised three 
stage II cancers and four stage III tumours (all by virtue of lymph node 
metastasis). Vulval SCCs may be subdivided on the basis of the degree of 
differentiation of tum our cells. Grade I tumours contain no undifferentiated
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cells, whilst grade II and grade III lesions contain <50% and >50% 
undifferentiated cells respectively.
Six of the seven tum ours were m oderately differentiated (grade II), whilst one 
of the stage II lesions was well differentiated (grade I). The staging and grade 
for each specimen is detailed in Table 4-2 and Table 4-3.
FIGO stage Description
I Tumour < 2cm confined to vulva
II Tumour >2cm confined to vulva
III Local spread to involve vagina or urethra or anus; ipsilateral 
lymph node metastases
IV Local invasion into bladder or rectum; contralateral lymph node 
metastases; pelvic lymph nodes or distant metastases
Table 4-2. FIGO staging for SCC of the vulva
Study no. Age /yrs Stage Grade
284 11 II 2
238 82 II 2
244 70 III 2
249 54 III 2
259B 86 II 1
274 71 III 2
281 81 III 2
Table 4-3. Staging and grading of seven vulval cancers analysed by CGH
When compared to those patients w ith VIN (of any grade), patients with SCC of 
the vulva were more likely to be over 50 years of age (7/7 vs. 12/28; p=0.009).
4.3.2 HPV status
The m ethodology used for HPV testing is described in detail in section 2.2.2.6. 
All positive PCRs were repeated at least twice. HPV type was assigned by 
comparison of the sequence of the PCR product with the available HPV 
sequences available in the HPV database of the Los Alamos National
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Laboratory, University of California. Samples were assessed using the MY09/11 
and GP5+/ 6+ prim er systems, both in isolation and as a nested PCR, before 
being labelled as HPV negative. The majority of patients (85.7%) were infected 
by HPV. Data for individual cases is presented w ith the corresponding data for 
CNI in Table 4-4, Table 4-5 and Table 4-6.
The overall infection rate was significantly higher for patients with VIN than for 
those with carcinoma (26/28 vs. 4 /7 ; p=0.044). The oncogenic type, HPV 16, 
accounted for 88.5% of infections in cases of VIN, with HPV 33 and 56 
accounting for the rem ainder of infections. In HPV 16 positive VIN, the virus 
was deemed to be integrated on the basis of PCR in 65.2% of cases. Oncogenic 
HPV types 16 or 56 were isolated from  75% of the HPV positive carcinoma. PCR 
suggested HPV 16 to be integrated in 50% of HPV 16 positive vulval SCCs. 
Isolated infection w ith the LR-HPV type HPV 6b was found in one case of 
vulval SCC.
4.3.3 CGH analysis of vulval neoplasia
CGH analysis was perform ed for a total of 44 vulval biopsies (Table 4-1). The 
technique of CGH is described in detail elsewhere (section 2.2.4). A mean of 
twelve metaphases (range 9-15) was captured for each case. These were then 
analysed to provide a m ean fluorescence intensity ratio along the length of each 
chromosome. CNIs detected for LSIL, HSIL and invasive SCCs are shown in the 
display karyograms (Figures 4-4 to 4-6) and in the summary tables (Tables 4-4 
to 4-6).
It should be noted that control DNA (labelled red) was from PBMCs from a 
male donor w ith a normal karyotype by conventional banding analysis. Test 
DNA (labelled green) was from  female subjects only. This provided an internal 
control for the quality of CGH hybridisation and accounts for the green signal 
from the X chromosome and the red signal from the Y chromosome. The CGH 
experiments were repeated in a proportion of the cases (8/35; 23%) confirming 
that the findings were reproducible.
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Fig 4-4. Summary Karyogram - high-grade VIN (n=24)
Copy number gains shown in green to right of chromosome with areas of high-level gain (ratio >1.5) shown in blue. Losses in red to left.
VO Figure 4-5. Summary karyogram - Squamous cell carcinoma of the vulva (n=7)Copy number gains shown in green to right of chromosome. Losses in red to left.
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Figure 4-6. Summmary karyogram - 'Normal' associated with neoplasia (n=5, marked with *) and low-grade VIN/VAIN (n=4)
Copy number gains shown in green to right of chromosome. Losses in red to the left.
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Table 4-4. Summary table showing copy number imbalances for high-grade VIN lesions (n=24)
Chromosome arms showing copy number gains have been shaded green and those with high-level gains (ratio >1.5) are shaded blue. Chromosome arms 
showing copy number losses are shaded red. Those with both gains and losses have been shaded yellow. Chromosomes excluded from analysis shaded 
grey. * indicates sam ple in which paired biopsy w as HPV positive, but microdissected specimen HPV negative. The presence and type of HPV infection are 
specified in the appropriate columns. The physical state of the virus is specified in the fourth column (integ- integrated, epi - episomal and n/a- not 
available/applicable).
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Table 4-5. Summary table showing copy number imbalances for squamous cell carcinoma of the vulva (n=7)
Chromosome arms showing copy number gains have been shaded green. Chromosome arms showing copy number losses are shaded red. Those with both 
gains and losses have been shaded yellow. Chromosomes excluded from analysis shaded grey. * indicates sample in which paired biopsy was HPV positive, 
but microdissected specimen HPV negative. The presence and type of HPV infection are specified in the appropriate columns. The physical state of the virus 
is specified in the fourth column (integ- integrated, epi - episomal and n/a- not available/applicable).
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Table 4-6. Summary table showing copy number imbalances for 'normal' biopsies associated with neoplasia (n=5) and low-grade VINA/AIN (n=4)
Chromosome arms showing copy number gains have been shaded green. Chromosome arms showing copy number losses are shaded red. Those with both 
gains and losses have been shaded yellow. Chromosomes excluded from analysis shaded grey. Where normal epithelium was obtained from tissue 
adjacent to a vulval lesion, then the pathology of that lesion is indicated. The presence and type of HPV infection are specified in the appropriate columns. 
The physical state of the virus is specified in the fifth column (integ- integrated, epi - episomal and n/a- not available/applicable).
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CNI and vulval neoplasia
4.3.3.1 CGH demonstrates a consistent pattern of CNI in high-grade VIN
Twenty-four biopsies from  twenty-one cases of high-grade VIN were included 
in the analysis. In three cases, biopsies at different time points (3-6 months 
apart) showed different grades of VIN and were included as distinct cases for 
analysis. The display karyogram  (Figure 4-4) and summary table (Table 4-4) 
reveal the high frequency and distribution of CNI in high-grade VIN. The 
m edian num ber of chrom osome arm s involved was 15.5 per case (range 2-30). 
Whilst the low num bers of HPV-negative VINs prevent statistical analysis, the 
mean num ber of arm s involved in CNIs was substantially higher for HPV 
positive lesions (16.4 arm s/case; range 2-30) than was seen in the sole HPV 
negative case (6 arms). W hen HPV positive cases were considered, those with 
integrated HPV DNA (n=12) appeared  to have marginally more CNIs per case 
than those in which the HPV DNA rem ained episomal (n=8). This difference 
did not reach statistical significance (m edian CNIs per case 16.0 (4-30) vs. 12.5 
(2-29); p=0.615).
The most common gains seen were: l p  (96%); 9q (88%); 20q (75%); 20p (63%); 
lq  (59%); 16p (58%); 17q (54%); 21q (46%); l l q  (42%); 17p (42%); 3q (38%); 6p 
(38%) and 16q (38%). High-level amplification (ratio >1.5) was seen in nine 
cases of high-grade VIN affecting l p  (six cases), 20q (five cases), 21q (three 
cases), 3q, 5p, 9q, 16p, 17q and 20p (one case each)
The most common losses dem onstrated in high-grade VIN were: 4q (71%); l l q  
(67%); 2q (58%); l i p  (54%); 2p (50%); 4p (50%); 5q (50%); 3p (38%) and 6q (33%).
4.3.3.2 CGH demonstrates a consistent pattern of CNI in SCC of the vulva
Seven cases of invasive SCC of the vulva were available for analysis. The 
m edian num ber of arm s show ing CNI on CGH was 18.0 (range 3-22). In the 
four samples dem onstrated to be HPV-positive by PCR, the median num ber of 
arms show ing CNI was 11.5 (range 3-22). The three HPV-negative samples 
showed a m edian of 18 arm s/case  (range 3-19). The most common copy 
num ber gains dem onstrated were: 17p (71%); lp  (57%); 8q (57%); 9q (57%); 17q 
(57%); 3q (43%); l l q  (43%); 16p (43%); 16q (43%); 20p (43%) and 20q (43%). The
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most common losses demonstrated were 3p (57%); 4q (57%); 8p (57%); 2q (43%); 
4p (43%) and 7q (43%).
4.3.3.3 Low-grade VIN/VAIN shows low frequency of CNIs as 
dem onstrated by CGH
Four low-grade lesions were available for analysis (3 vulval and one 
vulvovaginal lesion). The median number of chromosomal arms affected per 
case was 3.0 (range 1-4). Gains were seen to affect chromosome lp , 16p and 17. 
Copy num ber increases affecting chromosome 17 accounted for five out of the 
nine gains seen. Gain of lp  was also common, occurring in three of the four 
cases. Only two of the four cases showed losses, both affecting 9p.
4.3.3.4 The incidence of CNI varies with pathological grade of lesion
no. of affected  
arms
25
20
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5
0
□  >50%  
■  >40%
□  >30%
N orm al N orm al - Low
(n=4) ad ja c e n t g rad e
(n=5) (n=4)
High C an ce r
g rad e  (n=7)
(n=24)
Figure 4-7. Number of chromosomal arms showing high-frequency (> 30%) incidence of 
CNI by grade of abnormality. CNIs further sub-divided into those found in > 30,40 or 50% of 
cases.
The extent of CNI demonstrated by CGH varied according to the degree of 
abnormality of the vulval skin. Whilst CNI was not shown in DNA extracted 
from normal vulval skin biopsies, multiple chromosomal arms were affected in
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cases of high-grade VIN and SCC of the vulva. CNIs were deemed to occur at 
high-frequency when at least 30% cases were affected. Figure 4-7 shows the 
number of chromosome arms affected by high-frequency CNIs in a graphical 
format. It can be seen that both the total number of chromosomal arms affected 
and the frequency with which CNI affected those arms varied between normal 
vulval skin, normal skin (adjacent to high-grade/SCC), low-grade, high-grade 
and invasive neoplasia. The overall pattern of CNI for each sub-group of vulval 
neoplasia is shown in Figure 4-8. Analysis of the pathological subgroups using 
the Kruskal-Wallis test for several independent samples demonstrated a 
significant difference (p=0.011) in the number of CNI per case between 
pathological groups (Table 4-7). There was no significant trend towards 
increasing num ber of CNIs w ith increasing grade of abnormality when assessed 
by the Jonckheere-Terpstra test (p=0.146).
30.00-
20.00 -
m
10
10.00 -
z
0.00 j  ¥ ----------------- ,------------------ ,-------
Low-grade VIN High-grade VIN Vulval cancer
Vulval pathology
Figure 4-8. Total number of arms affected by CNI for subgroups of vulval neoplasia.
Medians are  shown in red.
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Low-grade VIN High-grade VIN Vulval cancer
N 4.00 24.00 7.00
LQ 1.25 10.00 5.00
Median 3.00 15.50 18.00
UQ 4.00 22.00 19.00
Mean 2.75 15.75 12.86
St. deviation 1.50 7.99 8.11
Kruskal-Wallis test p=0.011
Jonckheere-Terpstra test p=0.146
Table 4-7. Variation in CNIs/case between pathological subgroups. Significance difference 
found between groups when assessed using the Kruskal Wallis test (bold).
4.3.3.5 Significant differences in CN I a t specific chrom osom al loci w ere seen 
between grades of vulval neoplasia
The comparative distribution of CNIs for low- and high-grade VIN and vulval 
SCC is shown in Figure 4-9 (overleaf). Only CNIs that were found in > 30% of 
cases are included on this com parative graph. Low-grade VIN shows far fewer 
high frequency CNIs w hen com pared to either high-grade VIN or vulval SCC. 
In contrast, the distribution of high-frequency CNIs is similar for high-grade 
VIN and vulval SCC. Fisher's exact test w as used to compare the frequency of 
CNI on each chromosomal arm  betw een pathological subgroups. Significant 
differences were found betw een the various pathological subgroups. The 
results of the two-tailed tests are sum m arised in Table 4-8.
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Figure 4-9. Comparative high frequency copy number imbalances for low grade VIN, 
high grade VIN and SCC of the vulva
Charts show  the percen tage of c a se s  exhibiting CNI (gains shown as  positive in □ ,  losses 
shown as  negative inH ). Selected chromosom al arm s shown are those where frequency of 
CNI ex ceed s 30% in at least one sam ple group. Arms showing significant differences 
between low- and high-grade VIN are indicated by ■ . Arms showing significant 
differences betw een high-grade VIN and SCC are indicated by *  .
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Pathological groups Significant difference in CNI
compared
Gains Losses
Low- vs. High-grade VIN 9q (0.002) 4q (0.016)
20p (0.035) l lq  (0.024)
20q (0.010)
High-grade VIN vs. SCC lp (0.028) 8p (0.014)
8q (0.029) l ip  (0.025)
l ip  (0.045) 21q (0.045)
Table 4-8. Significant differences in CNI demonstrated at specific chromosomal loci.
Exact p-values show n in brackets.
W hen low and high-grade VIN w ere compared, there was a significant 
difference in copy num ber loss for chrom osomes 4q and l l q  and a significant 
difference in copy num ber gain for 9q and chromosome 20. W hen high-grade 
VIN lesions were com pared w ith vulval cancer specimens, significant 
differences were seen for chrom osomes 8p, l i p  and 21 q (CN losses) and lp , 8q 
and l l q  (CN gains). W ithin the subgroup of high-grade VIN lesions found to be 
HPV 16 positive, the physical state of the virus did not appear to affect the 
incidence of CNI at any given chromosomal arm.
4.3.3.6 CGH shows CNIs in histologically normal tissue taken from areas of 
skin adjacent to high-grade VIN or carcinoma
Whilst histologically norm al biopsies from individuals w ithout vulval neoplasia 
did not show CNIs, the same was not true for 'norm al' biopsies from 
individuals w ith concurrent/recent high-grade VIN or invasive SCC of the 
vulva (Figure 4-6). Of the five such cases analysed, CNIs were demonstrated in 
three. These were all gains affecting chromosome lp  or chromosome 17 (17p 
and 17q equally affected).
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4.4 Discussion
Data on the genetic changes associated w ith vulval neoplasia are limited. To 
date only three studies have used CGH to establish recurrent patterns of genetic 
abnormalities in a small num ber (n=36 total) of SCCs of the vulva (Jee et al, 
2001; Allen et ah, 2002; Micci et al., 2003). No studies of CGH in VIN have yet 
been published. This study includes 28 cases of VIN and 7 cases of vulval SCC 
and may therefore provide a valuable insight into the genetic abnormalities 
associated w ith vulval neoplasia.
The cohort of wom en studied appears to be representative of patients suffering 
w ith VIN and vulval carcinoma. Over half of the wom en with VIN were under 
50yrs of age, which lends some support to the argum ents of other authors 
(Herod et al., 1996; Jones et al., 1997; Joura et al., 2000; Thuis et al., 2000) who feel 
that the incidence of VIN m ay be increasing in younger women. Given this age 
distribution and the basalo id /w arty  histological nature of the lesions studied, it 
was not surprising to find that over 90% of cases of VIN were positive for HPV. 
The predom inance of HPV16 infection is in keeping with previous data. HPV 
infection was not how ever confined to younger patients. Three of the twenty- 
six cases of VIN positive for HPV infection were over 70 years, which is in 
agreem ent w ith the findings of Haefner and colleagues (1995) who found HPV- 
positive VIN occurred into the eigth decade. The majority of patients w ith VIN 
were symptomatic, although VIN occurred in asymptomatic women in 16.7% of 
cases. This finding em phasises the potential importance of inspection of the 
vulva, particularly w ithin a high-risk group such as those women attending the 
colposcopy clinic for abnorm al cervical cytology.
Seven cases of vulval carcinoma were available for analysis. Patients with 
carcinoma were m ore likely to be over 50 years of age than patients with high- 
grade VIN (11/24 vs. 7 /7 ; p=0.025). The identification of an isolated LR-HPV 
infection (type 6b) is unusual bu t has been documented previously (Kasher et 
al., 1988). It should be noted that the association of such infections does not 
indicate a causal role for this virus type in the development of carcinoma.
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It was extremely difficult to obtain normal vulval epithelium for control 
hybridisations. Previous LOH studies of cervical intraepithelial neoplasia have 
used cervical strom a as control norm al tissue, but the different anatomy of the 
vulva does not easily provide for such a control. The sensory innervation of the 
vulva necessitates the adm inistration of local anaesthetic prior to taking a 
biopsy. This fact, coupled w ith the psychosexual morbidity associated with 
vulval surgery, m eans that biopsies are not taken as readily as may be the case 
in cervical disease. For these reasons 'norm al' biopsies were usually obtained 
either as opportune specim ens w here the clinical suspicion of pathology was 
incorrect and the subsequent histology proved normal; or from benign 
inflammatory derm atoses w here confirmatory histology was being sought; or 
as a paired specimen w here the subject was undergoing an excisional treatm ent 
under anaesthetic for an adjacent pathology e.g. SCC of the vulva. Although 
histologically unrem arkable such epithelium  m ay not be otherwise normal. 
There is evidence from the study of X chromosome inactivation (Tate et al., 
1997; Rosenthal et al., 2002) and microsatellite m arkers (Rosenthal et al., 2002) 
that VIN is usually monoclonal and that vulval SCC may share the same 
monoclonal origins as adjacent VIN (Rosenthal et al., 2002). Furthermore, such 
clonal expansion m ay occur before the developm ent of cytological atypia (Tate 
et al., 1997; Lin et al., 1998). It is therefore perhaps unsurprising that three of the 
four 'norm al' biopsies taken from  patients w ith concurrent high-grade lesions 
or invasive disease show ed CNI. The abnormalities detected were all gains and 
affected chrom osome 1 a n d /o r  chromosome 17. The finding of aneusomy 
affecting chrom osome 17 is in keeping w ith data from an earlier study, which 
used chromosome-specific FISH to identify chromosome 17 aneusomy in vulval 
neoplasia (Carlson et al., 2000). N ot only was such aneusomy common in vulval 
carcinoma, but it could also be identified in biopsies from histologically normal 
or inflamed tissue adjacent to such carcinomas. These findings support the 
concept of aneuploidy as a driving force at an early stage of vulval 
carcinogenesis.
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In order to overcome the relative paucity of true normal control biopsies it 
w ould have been possible to use archival material from the pathology tissue 
bank. However, a strength of this study is the quality of DNA available from 
fresh frozen biopsies. Variations in fixation time and processing techniques 
involved in producing paraffin em bedded sections may result in DNA damage 
which has been show n to adversely affect the yield achieved w ith DOP-PCR 
amplification (Speicher et al., 1993). The optim um  length of DNA probe of 600- 
2000bp is more readily achieved w ith the large am ounts of high quality DNA 
that can be extracted from  frozen tissue sections. To ensure consistent high 
quality CGH experiments a decision w as therefore m ade to limit this study to 
frozen tissue specimens. It is both probable and plausible that lack of CNIs 
dem onstrated in the true norm al biopsies studies is likely to be reflective of 
normal vulval skin. Furthermore, w ork on other sites in the lower genital tract 
w ould support this. Using the same m ethodology, Alazawi (2003) failed to 
demonstrate CNIs in nine control norm al cervical biopsies.
CNIs were a common finding in both high-grade VIN and vulval carcinoma. 
Three previous studies using CGH in vulval carcinoma have examined 10, 18 
and 8 cases of vulval SCC respectively (Jee et a l, 2001; Allen et al, 2002; Micci et 
al, 2003). All found fewer CNIs per case than w ere dem onstrated in this study -  
mean CN Is/case 2.6 (0-11), 3.2 (0-5) and 5.3 (2-17) respectively vs. 12.9 (3-22). 
Whilst the higher fluorescence intensity ratio thresholds used by Allen et al. (>
1.2 for gain and < 0.80 for loss) and  Micci et al. (> 1.25 for gain and < 0.75 for 
loss) may explain the lower frequency of CNIs seen in these studies, the 
previous work by Jee et al. used similar fluorescence intensity ratio thresholds 
to those chosen in this thesis (>1.17 for gains and <0.85 for losses). 
Contamination by normal cells could reduce the sensitivity of CGH to detect 
CNIs of either low frequency or am plitude. It is difficult to assess the precise 
m ethods of microdissection used in these earlier studies. It would appear that 
Jee and colleagues scraped epithelium  from  unstained lOpm sections using a 
scalpel blade (Jee et al., 2001). In the w ork presented in this thesis, frozen 
sections were first stained w ith  haem atoxylin and eosin before microdissection
192
CNI and vulval neoplasia
w ith a 23G needle. Great care was taken to avoid contamination w ith any 
normal cells from around the lesion of interest and this could have improved 
the sensitivity to detect CNIs. Such precision has been associated w ith higher 
than usual CNIs per case in a study of cervical SILs (Aubele et al., 1998). It 
should be noted that control norm al hybridisations (n=6) did not show any 
evidence of CNIs and that several of the common gains were found as high 
level gains in some cases, supporting the CNIs seen as true results. 
Furthermore, the four cases of low-grade VIN studied showed far fewer CNIs 
per case (median 3.0, m ean 2.75 (range 1-4)) suggesting that there is not a 
simple threshold effect and that CNIs vary w ith the degree of vulval neoplasia. 
A further possible explanation for the high frequency of CNI found in VIN is 
the possibility of selection bias affecting the VIN case mix for this study. All 
patients were recruited at a tertiary referral centre through specialist vulval and 
gynaecological oncology clinics. A lthough patients can also be referred direct 
from local prim ary care providers, m any have been treated for some time at 
other units and are sent to the centre for help w ith resistant disease. As such, 
the cases studied m ight well reflect established VIN, which may well be 
genetically unstable and have had  time to develop m ultiple abnormalities.
The frequency of CNIs per case was significantly different between the 
pathological subgroups (Kruskal-Wallis test; p=0.011). There was no significant 
trend of increasing CNIs w ith  increasing grade of neoplasia (Jonckheere- 
Terpstra test; p=0.146). The tw o pathologists reviewing the biopsies showed 
excellent agreem ent in their grading of intra-epithelial lesions, but this is not 
always the case. Preti and colleagues used a panel of sixty-six vulval biopsies to 
show significant interobserver variation in the use of the current three-tiered 
grading system  betw een six consultant pathologists (Preti et ah, 2000). The 
authors found that w hen VIN 2 and 3 were combined into a single 'high-grade' 
class interobserver agreem ent in diagnosis was more likely. Other authors have 
suggested that in practice a two-tiered grading system is already in operation 
and should therefore be considered for routine clinical use (van Beurden et ah,
1999). Such a classification w ould be in keeping with the Bethesda system
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already in place for CIN (Solomon et al., 2002). The data presented here suggest 
that it may also be biologically appropriate to consider such a two-tiered 
grading system  for VIN. H igh-grade VIN lesions show significantly more CNIs 
per case than the low-grade lesions (median CN Is/case 15.5 (2-30) vs. m edian 
3.0 (1-4); p=0.003). In contrast there was no significant difference between the 
VIN 2 and VIN 3 subgroups of the high-grade cohort (median C N Is/case 19.0 
(9-30) vs. 15.0 (2-29); p=0.521). Therefore, where CNIs are concerned, a two- 
tiered grading system for VIN w ould seem to be acceptable.
CNIs in low-grade lesions w ere lim ited to gains affecting chromosome lp , 16p 
chromosome 17 and loss affecting 9p. All of these abnormalities were seen in 
high-grade lesions. The relative low num bers of low-grade cases makes it 
difficult to draw  firm  conclusions regarding the relevance of these 
abnormalities w ith regard to disease progression. The high frequency of gains 
seen on chromosome lp  and 17p in both high and low-grade lesions, as well as 
in normal skin adjacent to VIN 3 or carcinoma, suggests that these 
abnormalities may occur early on in the neoplastic process. Gain in lp  was seen 
in almost all cases of high-grade VIN. As has been stated previously, VIN 
appears to be clonal. It is therefore likely that gain in lp  is acquired from the 
low-grade precursor lesion and m ay be im portant in the prediction of 
progression risk in low-grade disease.
High-grade VIN shows high num bers of both gains and losses affecting a wide 
variety of chromosomal arms. All but one case was positive for HR-HPV 
infection. W hen HPV16 positive cases are considered, there was no significant 
difference in the frequency of CNI between those in which the virus was 
episomal and those w here it was integrated (n=8; median CNI/case 12.5 (2-29) 
vs. n=12; m edian C N I/case  16.0 (4-30); p=0.615). As has previously been 
described (section 1.2.1.5), loss of E2 expression as a result of integration may 
result in loss of transcriptional control of the high-risk oncoproteins E6 and E7 
(Schwarz et a l, 1985; Cripe et a l, 1987), a reduction in apoptosis (Webster et al,
2000) and im m une m odulation (Alazawi et al, 2002). One might therefore 
expect integration to be associated w ith greater genetic instability and increased
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num bers of CNIs. Whilst PCR for the E2 gene was found to correlate accurately 
w ith the physical state of the virus as assessed by Southern blotting (Das et al, 
1992), the technique will fail to identify cases in which the virus is present in 
both integrated and episomal forms. The inclusion of cases as episomal in 
which the virus is predom inantly integrated might therefore mask any real 
difference betw een the two groups. The use of alternative m ethods to assess 
viral integration, such as the amplification of papillomavirus transcripts 
(APOT) technique, m ight help to identify such mixed populations (Klaes et al,
1999). Integration usually results in disruption or deletion of the viral early- 
region polyadenylation signal. Transcripts derived from integrated E6/E7 
oncoproteins will therefore show  viral sequences at their 5 '-ends and cellular 
sequences at their 3 '-ends. In contrast, the most common E6-E7 viral transcript 
from episomal DNA is spliced at the E l-donor site signal to the E4-splice 
acceptor site and is term inated at the viral polyadenylation site (Schwarz et al., 
1985; Sherman et al., 1992). APOT uses RT-PCR to distinguish between 
integrated and episomal viral transcripts on the basis of these structural 
differences at the 3'-ends. Amplification by nested PCR allows the distinction 
between integrant-derived and episome-derived transcripts on the basis of a 
size difference. Accepting the lim itation of target stability inherent to any RNA- 
based technique, APOT could provide further functional information, in that 
only samples containing transcriptionally active HPV will test positive.
The common CN gains seen in this series of patients with high-grade VIN have 
are described in detail elsewhere (section 4.3.3.I. and Figure 4-4). Whilst no 
published CGH data exist for patients with VIN, several of these gains (namely 
lp , lq , 3q, 6p, 9q, l lq ,  16q, 17p, 17q and 20q) were found in one of more of the 
earlier series of CGH perform ed on vulval cancers (Jee et al, 2001; Allen et al, 
2002; Micci et a l, 2003). High-level gains (ratio >1.5) were seen for at least one 
case in the majority of the regions commonly seen in this study, suggesting that 
they were m ost likely to be true gains. Observed gains affecting 20p have not 
previously been dem onstrated in vulval neoplasia but have been shown in 
CGH studies of CIN and cervical SCC (Heselmeyer et al, 1996; Heselmeyer et
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al, 1997b; Dellas et al., 1999; Kirchhoff et al., 1999; Matthews et al., 2000; 
Kirchhoff et a l, 2001; Rao et al., 2004).
Gain affecting lp  has already been discussed in the context of low-grade 
disease and histologically norm al tissue adjacent to VIN 3/SCC. This aberration 
(consensus region lp32 -pter) was seen in almost every high-grade lesion and 
over half the carcinomas (p=0.028). In addition, a quarter of high-grade VINs 
showed high-level gain affecting this region. In contrast, neither Allen et al. nor 
Jee et al. found any gains on lp  in twenty-eight vulval carcinomas. However, in 
a recent small series of eight SCCs investigated w ith CGH, similar aberrations 
were found in three cases (Micci et al., 2003). This lower reported incidence of 
gain of lp  affecting SCCs is in keeping w ith the current series. The selection 
advantage conferred by gain in l p  m ay be im portant for the transition from 
low- to high-grade VIN. It is m ore difficult to explain the reduced frequency of 
gain in lp  in SCCs com pared to high-grade VIN, although it is possible that 
genetically unstable lesions could lose this CNI as they progress to carcinoma.
Aneusomy of chromosome 17 in high-grade VIN and SCC, as well as normal 
and inflammatory tissue adjacent to such lesions, has been dem onstrated using 
chromosome specific FISH (Carlson et al., 2000; section 1.2.3.1). It is interesting 
that whilst m ost samples were found to show gains in CN, loss of chromosome 
17 was found in 5% of sam ples (n=110) and was significantly associated with 
HPV-positive VIN 3. Almost all the VIN 3 patients in the current study were 
shown to be HPV-positive using PCR. Despite this, CN gains affecting 
chromosome 17 (p a n d /o r  q) w ere far more common than losses. The proposed 
association cannot therefore be confirmed. Several studies have focussed on 
LOH around the p53 locus (chromosome 17pl3.1) and such loss has been linked 
to the developm ent of HPV-negative vulval SCCs (Flowers et al., 1999; 
Rosenthal et al., 2001). As has been described previously, a major function of the 
viral oncoproteins from HR-HPV is to target cellular p53 (section 1.2.1.4), so 
there w ould be little selection pressure to develop a mutation affecting this TSG 
in the presence of HR-HPV infection. Gain affecting chromosome 17 has been 
found in CGH studies of cervical cancer specimens (Heselmeyer et al, 1996;
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Dellas et al., 1999), in vitro studies of HPV-transfected cells (Solinas-Toldo et al, 
1997) and cervical cancer cell lines (Solinas-Toldo et al, 1997; Harris et al, 2003) 
and SCCs at other anatomical sites (Voravud et al, 1993). Amplifications 
affecting both arms of chromosome 17 are also common to some other 
neoplasms including osteosarcoma (Lau et al, 2004) and breast cancer (Wu et al,
2000). Many potential oncogenes are located on chromosome 17, including 
ERBB2 (17qll.2-12) which was found to be amplified in seven of fifty cervical 
carcinomas studied (Mitra et al, 1994).
Gain of 3q has been reported in both published CGH studies of vulval SCC (Jee 
et al, 2001; Allen et al, 2002) as well as a recent cytogenetic study of vulval and 
vaginal tumours (Micci et al, 2003). In our study the gain of 3q often involved 
the whole arm, both for cases of VIN and vulval SCC. The smallest area of gain 
appeared to be 3q21-23, which is in keeping with Allen and colleagues' finding 
in HPV-positive SCCs of the vulva (Allen et al, 2002). In five of the nine VIN 
cases showing gain of 3q and two of the three cases of vulval SCC, this gain was 
accompanied by loss on 3p. The loss on 3p tended towards loss of the whole 
arm.
3f 9
i t
i
■
Figure 4-10. Possible isochromosome formation involving chromosome three. Copy 
num ber loss affecting short arm indicated by red fluorescent signal. Copy number gain affecting 
long arm indicated by predom inance of green fluorescence. Chromosome pair from case  281.
Together, these changes suggest the possibility of isochromosome formation 
with loss of 3p and retention of 3q (Figure 4-10 above). The previous studies of
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SCC of the vulva found these tw o abnormalities to be common (Jee et al., 2001; 
Allen et al., 2002; Micci et al., 2003). Other authors have described similar 
changes in CIN and SCC of the cervix (Heselmeyer et al., 1996; Dellas et al., 
1999; Kirchhoff et al., 1999; M atthews et al., 2000; Kirchhoff et al., 2001; Rao et al., 
2004). The relative frequencies of gain in 3q between CIN and early invasive 
SCC of the cervix led Heselmeyer and colleagues to propose that the gain of 3q 
was an early event that defined the transition from pre-invasive to invasive 
disease (Heselmeyer et al., 1996). However, the finding of the same gain in 2 /9  
cases of CIN 2 suggests that its presence does not indicate inevitable 
progression to carcinoma (Kirchhoff et al., 2001). Nevertheless, the recurrent 
nature of gain in 3q and its presence at higher frequency in invasive carcinoma 
than in pre-invasive disease (both in vulval and cervical disease) w ould support 
an im portant role for this region in carcinogenesis of the lower genital tract. It is 
w orth noting Allen and colleagues found the gain of 3q to be exclusive to HPV 
positive tum ours (Allen et al., 2002). Furtherm ore, the cervical tum ours assessed 
by Heselmeyer et al. were HPV-positive (Heselmeyer et al., 1996) and 3q gain 
was common to three of four HPV-positive cell lines assessed in vitro (Solinas- 
Toldo et al., 1997). This gain is also seen in HPV-positive anal cancer and its 
precursor lesions (Heselmeyer et al., 1997a; Haga et al., 2001) leading to the 
suggestion that gain of 3q could be an aberration specifically associated with 
HPV-related anogenital oncogenesis. In the current study, all the high-grade 
VINs exhibiting this gain w ere HPV-positive and two of the three SCCs also 
harboured the virus. The third  tum our was HPV-negative when assessed using 
the microdissected DNA, but HPV positive (HPV16/episomal) when a paired 
biopsy from the same patient w as re-tested. As such, this data w ould further 
support the role of 3q gain in HPV-related neoplasia of the lower genital tract.
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Figure 4-11. High-level gain of 5p. Short arm s of chrom osom e 5 clearly show predominantly 
green fluorescence compatible with copy num ber gain in the tumour. Threshold for gain se t at 
1.15. F luorescence ratio ex ceed s 1.5 indicating high-level copy num ber gain. Sam ple 
chrom osom e pair taken from ca se  271.
Gain in 5p was seen in one case of high-grade VIN (high-level gain, ratio >1.5) 
and one case of invasive carcinoma. This gain has previously been 
demonstrated in invasive vulval carcinoma (Allen et al., 2002; Micci et al, 2003), 
but not in pre-invasive disease. In cervical neoplasia, gain in 5p is commonly 
found in advanced cervical carcinoma, often present as a high-level gain or 
amplification (Heselmeyer et al, 1997b; Kirchhoff et al, 1999; Rao et al, 2004). In 
vitro work confirms this aberration is common in both HPV-transfected 
immortal keratinocytes (Solinas-Toldo et al, 1997) and cervical cancer cell lines 
(Solinas-Toldo et al., 1997; Dowen et al., 2003; Harris et al., 2003). Studying the 
HR-HPV containing W12 cell line has demonstrated isochromosome 5p 
formation at m edium to late passage (Dowen et al., 2003), as the cell line 
acquires an invasive phenotype (Pett et al, 2004). In the face of this evidence, 
the finding of 5p gain in high-grade VIN must however be interpreted with 
caution. The source biopsy for this lesion (study no. 271) was taken during a 
wide local excision for a known poorly differentiated carcinoma, occurring on a 
background of high-grade VIN. Histological assessment of the fresh frozen 
biopsy failed to demonstrate any invasion, even when reassessed by an 
unblinded pathologist in the light of the CGH result. Frozen sections are 
inferior in quality to paraffin-embedded sections with regard to tissue
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morphology and histological assessment. This is particularly true for those that 
have been desiccated prior to microdissection. As invasive foci are a relatively 
common finding in VIN 3 (section 1.1.3) it is possible that the adjacent frozen 
sections used for CGH contained foci of invasion, which were missed at the 
time of microdissection and inadvertently included. However, it remains 
possible that this aberration occurred in an area of true preinvasive disease. In 
this case one could conclude that acquisition of gain in 5p m ight occur earlier 
on in vulval carcinogenesis than  is the case in SCC of the cervix. The lesion from 
case 271 does appear highly genetically unstable w ith thirteen arm s affected by 
CNI, two by high-level gains and may be an extreme case.
Several novel high frequency gains were noted in this series of high-grade 
VINs, specifically gains on 20p, 21q and l lq .  Gains affecting 20p, including 
high-level gains, have been dem onstrated in SCC of the cervix (Heselmeyer et 
al., 1997b; Rao et al., 2004) and  in CIN 2 (Kirchhoff et al., 2001). In addition, Allen 
and colleagues found gain in 20p in one of eighteen SCCs of the vulva (Allen et 
al., 2002). The gains seen in VIN and vulval carcinoma in this series were far 
more common and w ere frequently associated w ith gain of 20q. This seems 
most likely to reflect aneusom y of this chromosome. This region has been found 
to be similarly affected in squam ous cell carcinomas at other sites, including 
oral, oesophageal and gastric cancers (Struski et al., 2002) and in other tum ours 
of the genital tract (Sonoda et al., 1997). In vitro studies within our group using 
the W12 HR-HPV cell line have show n that gain of 20p is a common event and 
is associated w ith im m ortalisation of the cells4.
Gain in 21 q has not been previously described for either vulval or cervical 
neoplasia. Indeed, for SCCs affecting the head and neck this region more 
usually exhibits loss (Struski et al., 2002) and may be associated with poor 
prognosis (Yamamoto et a l, 2003). Two of the seven vulval carcinomas assessed 
in this thesis show ed a similar loss for this region and Allen et al. documented 
loss in one of their eight HPV-negative vulval carcinomas (Allen et al., 2002).
4 Dr. Mark Pett, MRC Cancer Cell Unit, Hutchinson MRC, Cambridge, personal communication, 2004
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However, high-level gains were evident in three of the eleven cases of high- 
grade VINs, supporting the validity of CN gain in this region. The relative 
infrequency of this aberration in SCC of the vulva (1/7 cases) suggests that the 
CNI may occur as a consequence of genetic instability associated with high- 
grade VIN. Genetic loss from this region may be more important than gain in 
the development of invasive carcinoma.
CGH studies of genital neoplasia have previously shown losses affecting 
chromosome 11 (p and q) in vulval carcinoma (Jee et al, 2001; Allen et al, 2002; 
Micci et al, 2003) and in both pre-invasive and invasive squamous neoplasms of 
the cervix (Herod et al, 1996; Heselmeyer et al, 1996; Kirchhoff et al, 1999; 
Matthews et al, 2000; Harris et al, 2003; Rao et al, 2004). CGH data is supported 
by LOH studies in vulval carcinoma (Flowers et al, 1999; Pinto et al, 1999; 
Rosenthal et al, 2001; Rosenthal et al, 2002) and cervical cancer (for review see 
Lazo, 1999). These studies suggest the potential of TSGs both on the short and 
long arms of chromosome 11. This concept is further supported by animal work 
with SiHa and HeLa cell lines, where transfer of normal chromosome 11 to 
these cells prevents their usual tumorigenic action in nude mice (Saxon et al, 
1986; Koi et al, 1989). Loss affecting l i p  and l l q  was common in high grade 
VIN. Although ratio profiles for l i p  approached fluorescence intensity ratio 
thresholds for the SCCs in this thesis, loss was only seen affecting l lq  in the 
carcinomas.
Figure 4-12. Pattern of copy number loss and gain affecting chromosome 11. Red
fluorescence clearly visible affecting short and long arms. Small subcentromeric area of gain 
seen  a s  distinct a rea  of green fluorescence. Sam ple chrom osom e pair from case  252.
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A striking feature of both high-grade VIN was the frequent finding of a small 
area of gain on chrom osome l l q  (llql2.1-13.5), between the two areas of loss 
on l i p  and l lq .  This pattern  was often obvious at the time of inspection of the 
m etaphase dow n the fluorescence microscope (Figure 4-12). This area also 
showed gain in two of the seven vulval carcinomas studied (a third case 
showed gain of the whole chromosome). Gain on l l q  has previously been 
dem onstrated in molecular cytogenetic studies of HPV-transfected (Solinas- 
Toldo et al., 1997) and cervical cancer cell lines (Solinas-Toldo et al, 1997; Harris 
et al, 2003). Allen et al. found gain in a similar region of l l q  by CGH in two 
HPV-negative vulval SCCs (Allen et a l, 2002), but this has not otherwise been 
reported in other CGH studies of lower genital tract neoplasia. The l lq l3  locus 
contains several potential oncogenes including CCND1, which encodes cyclin 
D1 and EMS1, which encodes a filamentous actin binding protein. Copy 
num ber gains have been m apped to this locus for breast and oesophageal 
carcinoma, where such gains have been associated w ith poor prognosis (Hui et 
al, 1997; Yen et a l, 2001). W hilst there are no data to support these genes as 
oncogenes in vulval neoplasia, it should be noted that classical cytogenetic 
studies have show n breakpoints occurring in this region (Worsham et al, 1991; 
Micci et a l, 2003) and in vitro studies of cervical cancer cell lines have shown 
high level amplifications affecting l l q l 3  (Harris et a l, 2003).
In addition to the losses on chrom osome 11, CGH revealed other non-random  
pattern of CN losses affecting both high-grade VIN and SCC of the vulva. The 
association of loss of 3p w ith  gain in 3q and possible isochromosome formation 
has been alluded to earlier. This was a common area of loss affecting 38% of 
high-grade VINs and 57% of carcinomas. Loss of 3p was common to all 
previous CGH studies of vulval SCC (Jee et al, 2001; Allen et al, 2002; Micci et 
al, 2003) and  is also in agreem ent with microsatellite-based LOH studies of 
both VIN and vulval carcinoma (Flowers et a l, 1999; Pinto et al, 1999; Rosenthal 
et al, 2001). Allen et al found loss on 3p to be more frequent in HPV positive 
SCCs (Allen et a l, 2002), whilst two of the LOH studies found the reverse to be
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true (Flowers et al., 1999; Rosenthal et al., 2001). In the current study, loss of 3p 
was common in HPV-positive high-grade VIN and found in both HPV-positive 
and negative carcinomas.
Loss on chromosome 4 (p and q) was a common finding in both high-grade 
VINs and SCCs. Previous CGH studies show a conflicting pattern for this loss. 
Although loss on 4p was the m ost comm on aberration found in the small study 
by Jee et al., the other two studies have found this change in far fewer 
carcinomas (Allen et al., 2002; Micci et al., 2003). Evidence from in vitro studies 
suggests that chromosome 4 contains genes im portant in prom oting cellular 
senescence that are lost in squam ous cell carcinoma (Ning et al., 1991; Loughran 
et al., 1997; Forsyth et al., 2002). One possible mechanism for this senescence 
may be repression of telomerase (Backsch et al., 2001).
Copy num ber loss on chrom osome 2 was comm on in the current series. Loss 
affecting 2q has been docum ented by several authors in both CIN and invasive 
cervical SCC (Heselmeyer et al., 1996; Heselmeyer et al., 1997b; Kirchhoff et al., 
2001; Rao et al., 2004). Loss in the current series was a mixture of discrete loss 
affecting 2p a n d /o r  2q and loss of the entire chromosome suggestive of 
aneuploidy. The frequency of copy num ber loss was much higher than has 
previously been reported (Allen et al., 2002; Micci et al., 2003). Classical 
cytogenetic studies of vulval SCC have implicated chromosome 2q as a 
common region for structural chromosomal rearrangements (Worsham et al., 
1991; Teixeira et al., 1999; Micci et al., 2003). An in vitro study has suggested that 
the introduction of chrom osome 2 to SiHa cervical cancer cells induces 
senescence (Uejima et al., 1995). Loss of chromosome 2 may therefore be another 
mechanism of prom oting immortality. More recent work by the same group has 
implicated a region on 2q and, in contrast to chromosome 4, the induction of 
senescence appears to be independent of telomerase (Uejima et al., 1998).
Many of the abnorm alities identified in the seven cases of invasive carcinoma 
were also found in high-grade VIN. There was a significant difference in gain of 
8q betw een SCC of the vulva and high-grade VIN (p=0.029). This was a
203
CNI and vulval neoplasia
common gain in all of the previous series of CGH in vulval cancer (Jee et al., 
2001; Allen et al., 2002; Micci et al., 2003). In contrast to Allen and colleagues 
who found this gain to be more common in HPV-negative cancers, gain of 8q 
was spread evenly between HPV-positive and negative tumours. This region 
shows amplification in a variety of tum ours including both SCCs and other cell 
types (Struski et al., 2002) and has been shown to contain the proto-oncogene 
MYC (8q24) which is commonly amplified in SCC of the cervix (Ocadiz et al, 
1987). Allen et al. suggested the smallest area of gain was centromeric to this 
proto-oncogene (Allen et al., 2002). In the current study, gains often affected 
most of the arm and were associated with loss of 8p suggesting the possible 
formation of an isochromosome (Figure 4-13). Micci et al. found a high 
frequency of such an isochromosome in their assessment of 35 SCCs of the 
vulva using classical cytogenetic techniques (Micci et al., 2003).m i Hi
51
Figure 4-13. Chromosome 8 showing possible isochromosome formation. Copy number 
loss affecting short arm of chrom osom e 8 visible a s  red fluorescent signal whilst gain affecting 
long arm indicated by green fluorescence. Sam ple chrom osom e pair from case  259B.
The low numbers of SCCs assessed make it difficult to compare subdivisions 
within the group. The frequency of CNI (arms/case) suggests the possibility of 
two subgroups (Figure 4-8), w ith four cases showing high numbers of CNIs (8- 
22 arm s/case) and three cases relatively few CNIs (3-5 arms/case) This 
difference may simply reflect the low sample number, but it is worth noting 
that three of four patients in the high CNI group had metastatic disease (Stage 
III) compared to one of three patients in the low CNI group. It is not possible to
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assess CNI according to stage of the vulval SCCs previously reported, as the 
authors do not provide this information.
VIN lesions dem onstrate frequent CNIs, many of which are shared by invasive 
carcinomas. This finding provides further support for high-grade VIN as a truly 
m alignant precursor lesion. The regions showing CNIs in VIN and SCC of the 
vulva are similar to those of their cervical counterparts. Ideally, selective 
abnormalities dem onstrated in the current w ork could be confirmed using 
interphase cytogenetics (reviewed by Wolfe et a l, 1997). The frequency and 
incidence of high-level gains is m uch greater in high-grade VIN than 
CIN/cervical SCC (Heselmeyer et a l, 1996; Kirchhoff et al, 1999), suggesting 
that vulval neoplasia may in fact be m ore genetically unstable than cervical 
neoplasia. This finding w ould fit w ith  the clinical observation that the time of 
progression from high-grade disease to invasive carcinoma may be much 
shorter in untreated VIN than cervical disease (Jones et al, 1994). The high 
frequency of isochromosomes and other rearrangem ents found by Micci and 
colleagues in vulval cancer w ould  also support a high level of genetic instability 
in vulval neoplasia (Micci et a l, 2003). The frequency of CNIs observed in this 
study was higher than in other studies of both vulval and cervical disease. 
However, the results were reproducible, control hybridisations were normal 
and high-level gains were found for m any of the observed regions supporting 
the validity of my findings. Low-grade lesions appear to show far fewer CNIs 
than high-grade VIN. The findings in high-grade lesions give little reassurance 
to clinicians faced w ith the problem  of m anaging women with such lesions. 
Many of these lesions appear to be highly unstable showing multiple CNIs with 
high-level gains and amplifications. In some cases changes that have been 
associated w ith invasive lesions a n d /o r  poor prognosis at other sites (e.g. loss 
of 3p /ga in  of 3q, gain in 5p, gain in l lq )  are evident in histologically pre- 
invasive lesions. Coupled w ith the clinical reality of occult invasion in high- 
grade disease (Chafe et a l, 1988; H ording et al, 1995; Modesitt et al, 1998; 
Husseinzadeh et a l, 1999; Thuis et a l, 2000), non-surgical management of high- 
grade VIN should therefore be approached w ith caution. However, whilst this
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w ork has helped to increase our understanding of the genetic changes 
associated w ith vulval carcinogenesis, it remains to be seen if the aberrations 
identified have functional consequences. The availability of data from the 
hum an genome project and high-throughput array techniques should allow 
further investigation based on the novel findings presented here.
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Chapter 5 Therapeutic vaccination as a treatment for 
high-grade vulval and vaginal intraepithelial neoplasia
5.1 Introduction
The high prevalence of HPV infection in high-grade VIN has led investigators 
to postulate that im m unotherapy targeting virally infected cells m ight be of use 
in treating this debilitating condition. The im m une response to HPV has been 
considered in detail elsewhere (section 1.2.2). For established disease, the 
induction of a cell-mediated cytotoxic response appears necessary to produce 
disease regression by clearance of virally infected cells. Such a response is 
dependent on both the presentation of viral antigens to immune effector cells 
and the developm ent of a local cytokine milieu that favours a cytotoxic 
response. The cytokine m odulator Im iquim od is effective in the treatm ent of 
benign viral w arts and has already been used to treat small num bers of patients 
w ith high-grade VIN (section 1.1.7.3.3). Inducing clinically effective HPV- 
specific CMI remains a highly desirable goal. In this chapter, the safety, 
immunogenicity and efficacy of a recom binant vaccinia candidate vaccine will 
be described.
5.1.1 TA-HPV - a recombinant vaccinia vaccine
This phase II clinical trial described in this chapter used the TA-HPV 
recombinant vaccinia vaccine from  Xenova Group pic, Cambridge5. TA-HPV is 
derived from the W yeth strain  of vaccinia, which was widely used in the 
smallpox vaccination campaign. The virus has an established safety profile, is 
relatively easy to m anipulate and is effective at generating a cell-mediated 
immune response. The construction and characterisation of TA-HPV has been 
described elsewhere (Boursnell et a l, 1996). The vaccine contains the fused E6 
and E7 ORFs from  HPV 16 and 18, each under the control of a vaccinia 
prom oter (Figure 5-1). These two HPV types were chosen as they rank amongst 
the most com m on in HPV-associated lower genital tract neoplasia. The E6 and
5 formerly Cantab Pharmaceuticals pic.
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E7 oncoproteins appear to be central to HPV related oncogenesis (section 
1.2.1.4) and the ORFs are known to be transcribed in both high-grade cervical 
(Shirasawa et al., 1991) and vulval intraepithelial lesions (Park et al., 1991b; van 
Beurden et al., 1995). The E7 gene of both HPV types was first modified by 
mutation of the retinoblastoma gene product binding sequence so that there can 
be no binding of the resultant viral protein with retinoblastoma protein. The 
fused E6 and modified E7 genes have previously been demonstrated to show 
no transforming activity. The lytic, rather than persistent, nature of the vaccina 
infection further adds to the safety of the construct. A persistent local infection 
might promote tum our development at the vaccination site. A region in the 
HPV 18 E6 coding sequence was further modified to remove a potential signal 
for vaccinia virus early transcription (Borysiewicz et al., 1996; Boursnell et al., 
1996; Kaufmann et al, 2002). The virus was prepared at a concentration of 1 x 
108 plaque-forming un its/m l and stored securely at -80°C
HPV 16 E6 and E7 HPV 18 E6 and E7
m utagenesis to create  single open reading frame
 1 I
m utagenesis to abolish E7-Rb binding activity
mutagenesis to remove
a) TTTTTNT motif
b) Inter-gene homology
H6 p7.5
~ T =  .....
HPV 16 E6/E7 HPV 18 E6/E7
Figure 5-1. Construction of the recombinant vaccinia vaccine TA-HPV. High-risk ORFs 
from HPV 16 and 18 fused and modified before insertion into Wyeth vaccinia strain under the 
control of vaccinia promoters.
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5.2 Methods
5.2.1 Trial Protocol
TA-HPV was adm inistered as part of a phase II open labelled trial in subjects 
with high-grade vulval or vaginal intraepithelial neoplasia (VIN or VAIN). 
Patients were recruited in the gynaecological oncology and vulval clinics at 
Addenbrooke's NHS Trust, Cambridge. Prior ethics approval was obtained 
(LREC 99 /  321). An overview of the trial protocol is given in Figure 5-2.
5.2.1.1 Screening and exclusion criteria
Women between the ages of eighteen and sixty years w ith high-grade VIN, 
VAIN or AIN were assessed for inclusion in the trial. They were diagnosed by 
histological interpretation of a biopsy and screened for haematological, 
biochemical, and immunological abnorm alities by blood testing. W omen were 
not considered for inclusion if the use of live vaccinia virus could be expected to 
be detrimental either to their health or to the health of their close contacts. Thus, 
women with any degree of im m unosuppression (including those receiving 
therapeutic im m unosuppressive agents), a history of severe allergic reaction, 
active atopic eczema, or other w idespread inflammatory or exfoliative skin 
disease were not considered for the trial. In addition, women were excluded 
from consideration for vaccination if they were in close contact w ith children 
under the age of 5 or w ith  individuals w ith known or suspected immune 
suppression or active eczema. Pregnant wom en or those at risk of pregnancy 
were also excluded from the trial. After screening investigations, patients were 
excluded if they had any haematological evidence of imm unosuppression or 
abnormal renal or liver function.
5.2.1.2 Vaccination technique
TA-HPV (in an estim ated dose of 2.5 x 105 plaque-forming units) was 
introduced into the patient by scarification through a 50pl drop of the virus 
suspension applied to the skin of the upper arm  overlying the deltoid muscle. 
The area w as allowed to dry before covering with a waterproof dressing (Opsite
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Plus, Smith & Nephew). The dressing was changed twice a week until the scab, 
which formed as a result of the virus-induced inflammation, had separated and 
the vaccination site was healed. Samples for virological detection were taken 
from the surface of the dressing every week before its removal to test for the 
risk of possible contamination of the environment, and on separation, the final 
scab was tested for the presence of live virus. As a genetically modified vaccine, 
the use of TA-HPV was subject to prior approval by the Gene Therapy 
Adivisory Committee (GTAC) of the Department of Health, the National Health 
and Safety Executive (HSE) and the Medicines Control Agency (MCA).
a) Vaccination, day 0 b) Day 4
c) Day 7 d) Day 11
Figure 5-3. The local response/take to a successful vaccination with TA-HPV. a) Initial 
vaccination by scarification through a  50pl drop of TA-HPV applied to the skin over the deltoid 
region of the arm. b) Typical blister formation, associated  with viral replication, usually occurs 
within 2-4 days. Subject may develop mild tem perature and axillary lymphadenopathy. 
c) Blistering/erythema commonly maximal at around day 7 d) As viral replication decreases, 
scab  forms a t blister site. W hen left uncovered, scab  typically separates between day 10 and 21 
leaving a small sca r a t the vaccination site. Due to virus containment with an occlusive dressing, 
the time to scab  separation w as longer (median 26.5 days, range 15-32 days).
211
Therapeutic vaccination in AGIN
5.2.2 Follow-up
After vaccination, all subjects were followed for a six-month period. Trial visits 
were initially monthly until three months, followed by a final review at six 
months. No other treatm ent for the genital intraepithelial neoplasia was given 
during the trial or in the m onth preceding the vaccination. Data was collected to 
allow the assessment of vaccine safety as well as clinical, virological and 
immunological responses over the course of the study period.
The occurrence of adverse events was docum ented at each visit during the trial 
period. In addition to the clinical assessment, the haematological and 
biochemical investigations perform ed on the screening visit were repeated at 
the three-month visit to investigate possible systemic effects following 
vaccination. Swabs from the outside of the occlusive dressing were tested for 
the presence of live virus to confirm  virus containm ent during the study.
The extent of the disease was assessed by direct m easurem ent and 
photographic record of up to tw o m arker lesions in each case. The longest 
diameter of each m arker lesion w as recorded serially through the study. Three 
biopsies of the visible areas w ere taken at time points: before the vaccination 
and at 12 and 24 weeks after vaccination. Care was taken to ensure that the 
biopsies were taken so as not to directly influence the diameter of the lesion 
being studied. The biopsies were analyzed by two independent pathologists 
and the intraepithelial neoplasia graded according to the three-tier ISSVD 
classification. The presence of HPV detectable by polymerase chain 
amplification in tissue was sought at each biopsy point. Any symptomatic 
change was recorded w ith particular reference to irritation and pain. 
Assessment was by subjective grading of symptoms into one of four categories: 
nil; mild; moderate; or severe. After vaccination, subjects were actively 
questioned to ascertain the nature of any systemic symptoms potentially 
attributable to vaccination, and all additional medications were recorded. 
PBMCs and serum  samples were taken prior to and following vaccination on a 
m onthly basis for the first three months. These samples were used for 
immunological testing using ELISPOT to assess the development of
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HPVspecific CTL responses and ELISA to assess the antibody response to the 
vaccinia vector (section 2.2.5).
5.2.2.1 Collaborators
Patients were recruited, vaccinated and followed up  by the author under the 
clinical supervision of Dr. J. Sterling, Consultant Dermatologist, Addenbrooke's 
NHS Trust. HPV typing was perform ed by the author. Pathological assessment 
of the tissue biopsies was perform ed by Dr. R. Moseley and Dr N. Coleman, 
Departm ent of Histopathology, Addenbrooke's NHS Trust. The TA-HPV 
vaccine construct was supplied by Xenova Group Pic., Cambridge. HLA typing 
was performed on serum  sam ples by the Xenova Group Pic and the data 
analaysed by the Im munology group headed by Professor P. Stern of the 
Paterson Institute of Cancer Research at the Christie Hospital, Manchester. 
Vaccine and HPV specific im m une responses were measured in collaboration 
with two groups: Mr. C. Boswell, Xenova Group pic, Cambridge, UK and Dr. S. 
van der Burg, Tum our Im m unology Group, University of Leiden, The 
Netherlands. The author and Dr J. Sterling were responsible for collating and 
interpreting data from this study.
5.3 Results
5.3.1 Patients, HPV and HLA typing
Twelve wom en were recruited for vaccination (Table 5-1). The age range was 
42-54 years w ith a m edian of 47.5 years. The diagnosis of AGIN had been made 
between 3 m onths and 14 years (mean, 3.4 years) before the start of the vaccine 
trial. The disease was multifocal in eight women. All women had high-grade 
anogenital intraepithelial neoplasia. Eleven women had VIN (grade III) and one 
wom an (no. 5) had VAIN (grade II). Previous treatments received by half the 
patients included excisional surgery, laser ablation, and topical imiquimod 
cream. All patients were positive for HR-HPV, with eleven of the twelve 
wom en infected by HPV-16. HPV-33 was identified in one woman (no. 10). Ten 
of the patients were HLA-A2 haplotype.
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Study
number
Age Diagnosis Duration o f  
disease
HPV type HLA-A type
1 48 VIN 3 11 years 16 2,68
2 49 VIN 3 8 years 16 2,3
3 47 VIN 3 1 year 16 2,24
4 49 VIN 3 2.5 years 16 2,3
5 44 VAIN 2 3 months 16 2,3
6 47 VIN 3 6 months 16 1,2
7 42 VIN 3 1 year 16 2,32
8 49 VIN 3 2 years 16 1,24
9 45 VIN 3 3 months 16 2,26
10 42 VIN 3 4 months 33 2,24
11 52 VIN 3 14 years 16 2
12 53 VIN 3 3 months 16 3
Table 5-1. Patients enrolled in TA-HPV vaccination study
5.3.2 Vaccine safety
Vaccine safety was assessed in term s of both the risk to the individual patient 
and the potential risk to the environm ent of virus escape.
5.3.2.1 Adverse events
There was no detectable adverse effect on kidney, liver, or bone m arrow 
function as assessed by blood sam ples and in no patient was there a significant 
increase in disease area or progression. All patients remained generally well 
during and after the vaccination. A local reaction at the site of vaccination at 
approximately 7-10 days w as common but temporarily limited arm  movement 
in only tw o patients. A small area of scarring was left at the vaccination site.
5.3.2.2 Virus containment
The swabs taken from  the outside of the dressing each week before its removal 
showed no evidence in any case of escape of the active virus from beneath the 
dressing to the exterior. A total of fifty-seven swabs from twelve patients were 
assayed, and no virus particles were detected in any of the samples. Occlusive 
dressings w ere w orn over the vaccination site until the scab formed, dried and 
then separated from the skin. Gauze samples from under each dressing were
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tested for the presence of live TA-HPV. Live virus was detected in the under 
surface of the dressing in all patients after vaccination for a mean of 21 days. In 
five of the twelve patients, live virus was detected in the final sample 
containing the scab. In seven patients, no live virus was detected in the final 
sample.
5.3.3 Clinical response
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Figure 5-4. Percentage reduction in marker lesion size. Sum of widest diam eter(s) at six 
months shown a s  a percentage reduction com pared with the diam eter pre-vaccination. 
Interrupted red line show s 50% reduction in size. Subject no. 10 w as the only patient not 
positive for HPV 16.
Ten of the twelve treated wom en (83%) experienced some reduction in the size 
of the affected area over the six months after vaccination with a mean reduction 
in marker lesion diameter of 40% (Figure 5-4). In one woman (no. 5), there was 
complete clearance of the abnormal area with histological normality at three 
months after vaccination. In nine women, the grade of the marker lesion(s) 
remained unchanged, but there was a reduction of the extent of the abnormal 
epithelium. The size of the affected area was assessed by the longest diameter of 
identifiable lesion(s). In these nine individuals, the reduction in length ranged 
from 22 to 65% with five of the treated women showing at least 50% reduction
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in total m axim um  lesional diameter. Two wom en (nos. 1 and 10) showed no 
reduction in the size of the affected area of vulval disease. In the 11 wom en in 
w hom  VIN was still present a t the end of the study, the same HPV type was 
still detectable in the abnorm al epithelium. In one patient (no. 5) whose high- 
grade VAIN cleared after vaccination, HPV 16 was no longer detectable in the 
previously abnorm al area of the vagina. In one of the two patients w ho failed to 
respond to vaccination, HPV 33 was the HPV type isolated. The sym ptoms of 
VIN experienced by the patients in the study included irritation, soreness, and 
pain. There was no overall change in sym ptom  score between pre- and post­
vaccination, w ith three w om en noticing a slight worsening of symptoms, three 
women having a slight im provem ent, and  six wom en experiencing no change.
5.3.4 Immune responses
Blood samples were taken prior to and four, eight and twelve weeks following 
vaccination w ith TA-HPV. In addition to the HPV-specific responses that the 
construct should elicit, antibody and T-cell responses to the vaccinia vector 
were measured. The assessm ent of the im m une responses to the vaccine 
construct was perform ed in collaboration as described previously. The methods 
employed to detect such responses have been described in detail elsewhere 
(section 2.2.5).
5.3.4.1 Vaccine-induced im m unity  against the vaccinia vector.
To monitor the impact of the vaccine on the immune system, the responses to 
vaccinia were m easured. Both antibody and T-cell responses against vaccinia 
were strongly increased after vaccination in almost all patients (Figure 5-5). 
Before vaccination, anti-vaccinia IgG was detected in nine of twelve patients 
(nos. 2, 3, 4, 5, 6, 8, 9, 10, and 12). Post-vaccination, IgG responses in eleven of 
twelve patients (not no. 8) increased approximately ten-fold. Pre-vaccination T- 
cell responses to the W yeth strain vaccinia virus as measured by ELISPOT were 
positive in six of twelve patients (nos. 2, 4, 5, 6, 9, and 10), with frequencies 
ranging from  1:13,000 to 50,000. After vaccination, the IFN-y-producing T-cell 
frequency to the vaccinia vector increased by approximately two-fold
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(frequencies 1:2,000-10,000) compared with pre-vaccination levels in all 
patients, except no. 4. No positive IFN-y responses were detected against the 
Vero lysate control. The increase in anti-vaccinia responses post-vaccination 
indicated that the patients were able to respond to the vaccinia vector 
component of the vaccine TA-HPV after vaccination.
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Figure 5-5. Vaccination induced immunity against the vaccinia vector. Pre- and post­
vaccination peak antibody and T-cell response  above background to the vaccinia vector were 
detected in patient serum  and PBMC sam ples taken prior to vaccination (day 0) and at days 28, 
56 and 84 post-vaccination. P eak  serum  antibody (IgG) responses were m easured by ELISA 
pre-vaccination (triangle) and post-vaccination (square). Frequency of IFNy-producing T-cells 
responding to vaccinia vector w as m easured by ELISPOT in pre-vaccination (light bar) and 
post-vaccination (dark bar) patient PMBC.
5.3.4.2 Pre-vaccination HPV 16-specific immune responses.
Pre-existing HPV 16-specific immunity was detected in six of the ten patients 
(nos. 2, 4, 5, 7,10, and 12; Table 5-2), all of whom showed reactivity within the
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HPV 16 E6 protein. Three subjects (nos. 4, 5 and 7) also dem onstrated HPV 16 
E7-specific T-cells.
5.3.4.3 Vaccine-induced HPV 16-specific immune responses.
TA-HPV-induced HPV 16 E6 and E7-specific T-cell immunity was analyzed by 
the stimulation of PBMCs w ith a set of overlapping peptides covering the 
complete amino acid sequence of the E6 and E7 proteins (section 2.2.5.3 and 
Figure 5-6a). From ten of twelve patients, enough material was available to 
study the HPV 16-specific im m une response before vaccination as well as four 
a n d /o r  eight weeks after vaccination w ith TA-HPV (Table 5-2). Upon 
vaccination, four patients (nos. 1, 4, 6, and 10) did not m ount an increased 
response to the HPV 16 peptide pools. Two of these patients (nos. 1 and 10) also 
showed no clinical reduction in the size of the lesion(s). Importantly, HPV 16 
E6- and E7-specific T-cells were specifically enhanced after vaccination in six of 
the ten patients tested (nos. 2, 3, 5, 7, 11 and 12; Table 5-2 and Figure 5-6b). In 
one case (no. 3) the T-cell response was focused to one peptide pool, whereas in 
the rem ainder (nos. 2, 5, 7,11 and 12), T-cell reactivity was detected against two 
or three different peptide pools. All patients reacted to the positive memory 
recall mix. In addition, PBMCs were stim ulated with six CTL epitopes 
identified within HPV-16 E6/E7 and chosen for their ability to bind MHC class 
I molecules of HLA-A*0201-positive individuals (Kast et al, 1994; Ressing et al, 
1995). Of the ten patients typed as HLA-A2 (Table 5-1), one patient (no. 3) 
responded weakly to peptide HPV 16 E6so-88 (T-cell frequency 1/50,000). This 
response was already present before vaccination and the single injection of TA- 
HPV failed to enhance this reactivity. Two patients (nos. 7 and 12) showed an 
enhanced production of IFN-y in response to the whole HPV 16 E6 and E7 
protein as expressed in TA-CIN after vaccination with TA-HPV. No other 
patient reacted to TA-CIN either pre- or post-vaccination (Table 5-3).
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Patient Date
(weeks)
E6 
pool 1
E6 
pool 2
E6 
pool 3
E6 
pool 4
E7 
pool 1
E7
Pool
2
M R M
l 0 <1 <1 l <1 <1 <1 23
4 1 1 4 <1 1 2 49
8 NA NA NA NA NA NA NA
2 0 <1 26 <1 <1 <1 <1 100
4 1 1 3 5 <1 1 100
8 <1 26 <1 27 7 <1 100
3 0 <1 2 <1 <1 <1 <1 50
4 <1 57 <1 <1 2 <1 46
8 5 35 <1 <1 <1 <1 57
4 0 <1 6 <1 <1 <1 6 124
4 NA NA NA NA NA NA NA
8 <1 <1 <1 <1 <1 <1 103
5 0 <1 5 1 <1 10 3 119
4 <1 18 9 <1 10 14 87
8 1 86 15 <1 1 33 85
6 0 <1 <1 <1 <1 <1 <1 61
4 <1 <1 <1 <1 <1 <1 79
8 <1 1 <1 <1 4 <1 63
7 0 4 21 7 <1 5 <1 114
4 23 84 1 1 44 <1 106
8 15 66 <1 7 24 <1 91
10 0 <1 <1 1 15 1 <1 51
4 <1 0 2 7 1 1 108
8 <1 <1 <1 6 <1 <1 79
11 0 1 <1 1 <1 3 <1 63
4 <1 <1 <1 <1 9 <1 93
8 <1 <1 <1 16 <1 <1 54
12 0 4 5 13 2 4 4 104
4 84 1 42 <1 <1 <1 58
8 39 <1 17 <1 <1 <1 71
Table 5-2. TA-HPV enhanced HPV16 E6- and E7-specific immune responses. PBMC of 10 
patients were available for complete analysis of the HPV16 E6- and E7-specific T-cell response 
by IFNy- ELISPOT assay. Specific spots per 50,000 PBMC are indicated. Specific spots were 
calculated by subtracting the mean number of spots + 2xSD of the medium control from the 
mean number of spots of experimental wells. Indicated in bold are those peptide pools (and 
number of spots) to which specific T-cell frequencies were > 1/10,000 PBMC and at least 3-fold 
the pre-vaccination response, because these are considered to be vaccine enhanced. NA, not 
available for analysis. <1, no specific response to E6 or E7. MRM, memory recall mix used as a 
positive control.
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a) 20 40 60 80 100 120 140
HPV16E6
1-22 41-62 81-102 111-132
11-32 51-72 91-112 121-142
21-42 61-82 101-122 131-152
_ 7 1 * 2 _  ,.111-132 437-i58
E6 pool 1 E6 pool III
E6 pool II E6 pool IV
20 40 60 80
HPV16E7 M — S ~ 'W  — f l f u—
1-22 41-62
11-32 51-72
21-42 61-62
31-52 71-92
77-96
E7 pool I
E7 pool II
b) □
100 -
ELISPOT dem onstrated 
response to vaccination
Insufficient quantity 
or inadequate quality
ELISPOT dem onstrated 
no response to vaccination
10 11 12
Figure 6-6. V acc in e -in d u ced  im m un ity  and clinical responses
a) G ro u p s  of o v erlap p in g  p e p tid e s  u s e d  in IFN-y E LISPO T to a s s e s s  H PV -specific T- 
cell im m unity. N u m b ers  in d ica te  b eg in n in g  an d  en d  of peptide.
b) P e rc e n ta g e  red u c tio n  in m a rk e r lesion  s ize  co rre la ted  with H PV -specific T-cell 
im m unity. S u m  of w id e s t d iam e te r(s )  a t  six m o n th s show n  a s  a  p e rc e n ta g e  reduction  
c o m p a re d  w ith  th e  d ia m e te r  p re -v ac c in a tio n . In te rru p ted  red  line sh o w s  50%  
red u ctio n  in s ize . P ink b a rs  in d ica te  su b je c ts  w ho sh o w ed  vaccine ind u ced  T-cell 
r e s p o n s e  a s  a s s e s s e d  by ELISPO T.
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Table 5-3. (legend overleaf)
P a t i e n t D a te
(w e e k s )
16 E6, 
29-38
16 E6, 
59-67
16 E6, 
80-88
16 E7, 
11-20
16 E7, 
82-90
16 E7, 
86-93
TA-CIN
1 0 <1 <1 <1 <1 3 <1 3
4 <1 <1 <1 <1 7 <1 10
8 NA NA NA NA NA NA NA
12 <1 <1 <1 <1 <1 <1 3
2 0 6 <1 5 <1 3 1 <1
4 <1 <1 1 3 <1 1 2
8 1 <1 13 <1 6 <1 <1
12 <1 <1 4 <1 9 <1 <1
3 0 <1 3 24 <1 <1 <1 3
4 1 <1 <1 <1 NA 1 7
8 3 3 27 <1 <1 11 <1
12 <1 <1 7 <1 16 <1 <1
4 0 <1 <1 <1 <1 7 <1 2
4 <1 <1 1 <1 <1 <1 2
8 <1 3 1 2 <1 3 5
12 <1 <1 3 <1 <1 <1 <1
5 0 9 5 5 2 11 17 9
4 4 6 3 2 6 2 3
8 3 5 1 <1 7 9 1
12 <1 <1 <1 <1 5 4 <1
6 0 <1 3 <1 2 NA <1 5
4 <1 8 <1 2 NA 3 6
8 <1 1 3 <1 NA <1 <1
12 1 3 3 <1 NA <1 1
7 0 <1 3 1 2 <1 <1 9
4 <1 <1 3 <1 2 14 82
8 <1 <1 4 <1 <1 6 30
12 <1 1 4 <1 <1 12 44
8 0 <1 <1 3 <1 1 <1 4
4 <1 <1 <1 <1 <1 <1 1
8 <1 <1 <1 <1 <1 <1 <1
12 <1 <1 <1 <1 <1 <1 1
9 0 <1 2 2 <1 7 <1 2
4 <1 2 <1 <1 5 3 9
8 <1 <1 <1 1 4 <1 <1
12 <1 <1 <1 <1 1 <1 <1
10 0 <1 <1 <1 <1 <1 <1 7
4 <1 <1 <1 <1 <1 <1 <1
8 <1 <1 <1 <1 <1 <1 1
12 <1 <1 <1 1 <1 <1 2
11 0 <1 <1 <1 <1 <1 <1 <1
4 <1 1 1 <1 <1 5 1
8 1 1 5 1 <1 1 7
12 <1 <1 <1 <1 <1 <1 4
12 0 <1 <1 <1 <1 <1 <1 13
4 <1 <1 3 <1 <1 <1 69
8 2 <1 3 <1 <1 1 53
12 <1 <1 <1 <1 <1 <1 16
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Table 5-3. Patient immune responses to HPV 16 E6 and E7 peptides and TA-CIN protein
PBMC isolated from whole blood were cultured overnight with peptides to elicit IFNy release as 
detected by ELISPOT assay. In addition, whole HPV16 E6 and E7 protein (TA-CIN) was used 
to stimulate harvested PBMC. Specific spots per 2 x 105 PBMC are shown. Specific spots were 
calculated by subtracting the mean number of spots from 3 wells of the medium control from the 
mean number of spots of experimental wells. Values in bold are those over 20 and are taken as 
a positive response. NA, not available for analysis. <1, no specific response to peptide or 
protein.
5.4 Discussion
This chapter presents the results of a phase II clinical trial to assess the safety, 
immunogenicity and efficacy of a recom binant vaccinia vector expressing HPV 
16 and HPV 18 E6 and E7 proteins (TA-HPV) in the treatm ent of AGIN. In this 
study of twelve wom en w ith high-grade VIN and VAIN, no adverse effects of 
the vaccination were found. In general, the patients felt well w ithout definite 
evidence of pyrexia. The vaccination site was tender and uncomfortable in all 
women with duration of discomfort ranging between one and thirteen days, 
which was maximal approxim ately one week after vaccination. The vaccination 
site was dressed for a m ean duration of 25 days (range, 15-32 days) and was 
acceptable to all patients. Vulval sym ptoms were not significantly improved by 
vaccination. It may be that an  alternative reporting system, e.g., visual analogue 
scale m ight prove more sensitive in detecting symptom change. No progression 
of disease was observed in any of the twelve women during the 6 m onths after 
vaccination. In eleven women, no change in disease grade occurred, but the 
reduction in size of the m easured regions of AGIN seen in ten of the twelve 
wom en was promising. In five women, the affected areas were reduced by 
>50% of the original longest diameter, and in one patient, the lesion cleared 
completely. The lack of a placebo group in this study raises the possibility that 
this response m ight not be attributable to the vaccination. However,
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spontaneous resolution of high-grade disease (section 1.1.3.1) appears to be 
infrequent and confined to a relatively discrete population of wom en whose 
characteristics are not shared by the current cohort. Furthermore, this response 
rate is similar to that of a recently published trial using the same construct in 
which eight of eighteen patients w ith high-grade VIN showed at least a 50% 
reduction in m arker lesion size (Davidson et al, 2003a). An effective treatm ent 
that w ould compare favorably w ith the most common form of treatment, 
excisional surgery, would be one in which complete clearance occurred and in 
which recurrence was rare. The responses seen in this small group of wom en 
with diverse duration of disease and prior treatm ent do not achieve this ideal, 
although as yet, it is impossible to know  if the longer-term course of the disease 
has been influenced by the stim ulation of anti-HPV immunity. Interestingly, the 
patient who showed a complete response (no. 5) also showed resolution of 
concurrent CIN (grade I). A lthough spontaneous resolution of low-grade 
cervical disease is common (Duggan et al., 1998), persistence of her clinical 
response to twenty-four m onths after vaccination is extremely encouraging, 
especially given her prolonged (~10 year) pre-trial history of relapsing cervical 
and latterly vaginal disease. A reduction in lesion size also enabled several 
subjects to undergo relatively m inor excisional treatm ent at the conclusion of 
the study, com pared w ith the radical approach that might have been used to 
deal w ith their disease at enrolment.
The developm ent of a cell-mediated im m une response appears to be crucial to 
the control and clearance of HPV-related disease (section 1.2.2). Indeed, the 
patient w ith idiopathic CD4+ deficiency who was excluded from vaccination 
during this w ork suffers w ith the m ost extensive multifocal AGIN that the 
author has encountered. However, the precise nature of the immune response 
to HPV is still poorly understood. It has earlier been reported that women with 
HPV 16 positive cervical disease may have T-cell responses to HPV-16 E7 
peptides (Kadish et al, 1994; Boursnell et al, 1996; Muderspach et al, 2000; van 
der Burg et a l, 2001b; Kadish et al, 2002). In our patients, we found measurable 
imm une responses to at least one HPV 16 E6- or E7-peptide-pool in six of the
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analyzed wom en (60%) pre-vaccination (Table 5-2). Immunoreactivity was 
found against all HPV 16 E6- and E7-peptide-pools, but w ith slightly greater 
frequency or strength to peptides covering the central E6 region from amino 
acid 41-132. Others have suggested that T-cell responses to HPV-16 E7 peptides 
may be reduced in wom en w ith invasive cancer (de Gruijl et al, 1998; van der 
Burg et a l, 2001b) but relatively increased in persistent and especially high- 
grade cervical dysplasia (de Gruijl et a l, 1998). The low level of HPV 16 E7- 
stimulated IFN-y production by T-cells from this cohort of patients w ith VIN 3 
could reflect an apparent suppression of im m unity in chronic HPV disease or 
tolerance to 16 E7. The previously reported preponderance of immunoreactivity 
to -COOH terminal HPV-16 E7 peptides in patients w ith CIN (Luxton et al, 
1996; de Gruijl et al, 1998) or central E7 peptides in high-grade CIN and cervical 
cancer (van der Burg et a l, 2001b) was not seen in these patients w ith 
VIN/VAIN. A systemic im m une response upon vaccination was detected by 
ELISPOT assays to pooled peptides in six of the ten patient samples available 
for testing (Table 5-2 and Figure 5-6). All these six subjects showed a clinical 
response. In four wom en (40%), there was no significant increase in the num ber 
of lymphocytes producing IFN-y after exposure to viral peptides following 
vaccination compared w ith  the pre-vaccination responses. Two of these four 
women had no clinical response either, bu t the rem aining two patients showed 
a significant (>50%) reduction in m arker lesion diameter. There was no strong 
correlation between the clinical change and the observed in vitro T-cell 
response. It is possible, however, that the detection of systemic immunity to 
HPV-16 E6 and E7 peptides after vaccination may not truly reflect the intensity 
of the imm une response at the site of the disease. Nevertheless, the observed T- 
cell responses in six of eight clinical responders remain remarkable.
Other studies of vaccination as therapy for HR-HPV-associated anogenital 
disease have been reported recently. The use of DNA (Klencke et a l, 2002), 
peptides (Steller et al, 1998; van Driel et al, 1999; Muderspach et al, 2000; 
Ressing et a l, 2000; van der Burg et a l, 2001b), protein (Goldstone et al, 2000), 
recom binant virus (Borysiewicz et al, 1996; Davidson et al, 2003a), dendritic
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cells (Santin et a l, 1999) and virus-like particles (Rudolf et a l, 1999) have all 
been shown to induce an HPV-specific immune response. The developm ent of a 
cytotoxic T-cell response probably in combination w ith a T-helper cell response 
is likely to produce the best im m une attack on virally infected neoplastic cells. 
HLA class I-restricted HPV-16 E6 and E7 peptides most likely to produce a 
cytotoxic T-cell response have been defined (Kast et al, 1994; Ressing et al, 
1995). CTL responses were assessed in the current work using the ELISPOT 
technique described in detail in section 2.2.5.3. The use of well-defined minimal 
CTL peptide-epitopes in this fashion elicits strong responses from CD8+ T-cells, 
whereas CD4+ T-cell reactivity is usually weak or non-detectable because of the 
short incubation time used (van der Burg et a l, 2001b). In our patients, there 
was no stimulation of T-cell responses to these peptides after vaccination (Table 
5-3). However, the use of a restricted set of peptides to analyze CTL reactivity 
may be inadequate to perm it the detection of all CTL responses. In support of 
this testing strategy, it should be noted that eleven of twelve patients were HPV 
16-positive and that in comm on w ith the findings of previous work (Davidson 
et al, 2003b), HLA-A2 was over-represented in these patients w ith high-grade 
VIN/VAIN (10/12 patients). O ther studies of vaccination in hum ans using 
these selected peptides have suggested that patients with CIN, cervical cancer, 
and vaginal cancer are able to m ount a CD8+ T-cell response to the peptides 
(Steller et al, 1998; M uderspach et a l, 2000), although in one study, the lack of a 
peptide-specific cytotoxic T-cell response was similar to the results presented 
here (Ressing et a l, 2000).
In ten patients, T-cell responses were further assessed by ELISPOT using pools 
of 15-mer peptides spanning HPV16 E6 and E7 (Figure 5-6 and section 2.2.5.3). 
In two patients, PBMC samples were either insufficient or had deteriorated 
during storage such that further immune testing was impossible (patients 8 and 
9). In contrast to the lack of response seen using the defined CTL epitopes, an 
increased response to one or more peptide-pools following vaccination was 
seen in six of ten women tested. Work from our collaborators in Leiden 
suggests that the use of these longer peptides, which must be taken up,
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processed and presented by APCs, together with the long incubation period of 
four days used in the ELISPOT, highly favours the response of CD4+ T-cells 
(van der Burg et al., 2001b; de Jong et ah, 2002; Welters et al., 2003). These 
responses have not been previously tested in other vaccination trials in humans.
The effect of vaccination on HPV infection and HPV-associated neoplastic 
disease is less clear. In CIN, the developm ent of HPV16 E7-specific CMI has 
recently been associated w ith both disease regression and the resolution of viral 
infection (Kadish et al., 2002). Following vaccination with TA-HPV in the 
current study, the same HPV type was still detectable by PCR in abnormal 
epithelium, even in those patients w ith a significant (>50%) decrease in marker 
lesion size. However, in the one patient w ho cleared her disease (no. 5) HPV 16 
could no longer be found in the previously abnormal area of the vagina. 
Quantitative PCR to assess changes in viral load following vaccination may 
have been more informative than the qualitative PCR techniques employed to 
assess HPV status. Davidson and colleagues used real time PCR technology to 
assess viral load before and following vaccination w ith TA-HPV in high-grade 
VIN (Davidson et al., 2003a). Viral load was found to decrease following 
vaccination in six of eight patients (75%) deem ed to have a clinical response 
(>50% decrease in m arker lesion diameter). However, a decrease in viral load 
was also dem onstrated in six of the ten (60%) rem aining patients who failed to 
demonstrate a clinical response. It is therefore difficult to associate a reduction 
in viral load w ith clinical im provem ent of disease.
Only small num bers of patients w ith HR-HPV dysplasia or carcinoma have 
received vaccination as therapy, and as yet, dramatic clinical responses have not 
occurred. Borysiewicz et al. (1996) reported the use of TA-HPV in eight women 
with therapy-unresponsive cervical cancer, one of whose disease remitted. 
Although the vaccine has been used as adjuvant therapy in two small trials of 
wom en w ith CIN 3 before laser therapy and in women with early-stage cervical 
cancer before surgery, the possible effect on the disease was not evaluated 
(Adams et al., 2001). HPV peptides have been used as therapeutic vaccines in 
several small studies. In one of these, eleven women with cervical cancer and
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one w om an w ith vaginal cancer, all of whom  were of the HLA-A2 genotype, 
received im m unotherapy w ith the HPV 16 E7g6-93 peptide (Steller et al., 1998). 
None of these patients show ed a clinical response to vaccination, although two 
individuals dem onstrated induction of specific and persistent CTL responses. 
As has already been described, a second trial of TA-HPV used in the treatm ent 
of high-grade VIN has recently been published (Davidson et al., 2003a). The 
authors of this study found similar clinical response rates to those described in 
this chapter. Davidson et al. used HLA-A2 restricted peptides in an ELISPOT to 
assess HPV-specific T-cell responses. Four of seven HLA-A2 positive 
responders showed an increased CTL response following vaccination. In two of 
these cases the response w as a novel one rather than an increase in existing T- 
cell reactivity.
Another HLA-A2-restricted peptide E7i2-20 has been tested as a therapeutic 
vaccine in eighteen wom en w ith HPV 16-positive high-grade intraepithelial 
neoplasia of the cervix (n =16) or vulva (n=2) ( M uderspach et al, 2000). Seven 
of these wom en also received the same HPV 16 E7 peptide, E786-93 used by 
Steller and colleagues (Steller et al., 1998). There was observed im provement of 
disease in terms of partial (6/18) or complete (3/18) clearance of affected areas 
w ith im provem ent only occurring in wom en w ith CIN. Ten of sixteen women 
tested had induction of E7 immunoreactivity as assessed by IFN-y release and 
chromium release assays. The combination of these two HPV 16 E7 peptides, 
E7n-2o and E786-93, has also been tested as therapy in nineteen women with late- 
stage HPV 16-positive cervical cancer who were HLA-A*0201-positive (van 
Driel et al., 1999). The vaccination was well tolerated but produced no clear 
effect on disease course. A third type of vaccine tested in hum an disease has 
recently been reported (Klencke et al., 2002). Plasmid DNA encoding the amino 
acids 83-95 of HPV 16 E7 was used as a vaccine in patients with AIN. Three of 
ninteen treated individuals were found to have changed from high- to low- 
grade AIN, whereas in the remainder, the disease did not change.
Ideally, therapeutic vaccination for HPV-associated AGIN would have an 
efficacy that induces complete disease regression without recurrence. To
227
Therapeutic vaccination in AGIN
produce such an effect, the immune response should be readily induced and 
m aintained and m ust be able to produce a potent cytotoxic or delayed type 
hypersensitivity response against epithelial cells harboring the viral DNA. The 
developm ent of a therapeutic vaccine to combat this virally driven disease is 
still some way from producing these aims. However, when interpreted w ith the 
results of other studies of therapeutic vaccination, the work presented in this 
thesis suggest that stim ulation of the imm une response in HR-HPV-infected 
individuals may be able to produce at least a partial effect on neoplastic disease. 
Improvements in vaccine design and delivery as well as techniques to optimize 
immune responses w ithin the diseased epithelium  may ensure that therapeutic 
vaccination becomes an effective treatm ent choice for HPV-associated AGIN.
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Chapter 6 Summary, conclusions and future directions
The diagnosis of VIN does not inevitably lead to the development of vulval 
SCC. However, a review of the available evidence w ould suggest that, at least 
for some individuals, the condition is pre-m alignant in nature (section 1.1.3). 
Despite the potential for investigation and intervention at this earlier stage, the 
viral, genetic and immunological events that occur during vulval oncogenesis 
have been poorly understood. Previous studies have concentrated on defining 
changes associated w ith SCC lesions, the end-point of vulval oncogenesis. In 
contrast, the current w ork has focussed on the potentially pre-invasive 
intraepithelial lesion and provides insight into both the pathophysiology and 
potential im m unotherapy of HPV-related vulval neoplasia. It is hoped that a 
better understanding of VIN will allow for more effective, individualised 
treatment of wom en who suffer w ith this often distressing condition.
6.1 VIN shows a strong association with HR-HPV infection
The cohort of wom en involved in the current w ork appears to be typical of 
those suffering with VIN and vulval SCC. Many women with VIN suffer 
recurrent or relapsing disease. The finding that two-thirds of the patients with 
VIN were under the age of fifty years w ould appear to support the stance that 
an increasing proportion of w om en w ith VIN are young (Jones et al, 1994; 
Herod et al, 1996; Joura et a l, 2000). The strong association between HPV 
infection and high-grade VIN was confirmed in the current work. 
Unfortunately, the low incidence of HPV-negative disease has limited the 
ability of this w ork to establish differences between individuals w ith HPV- 
positive and HPV-negative VIN and therefore this aim has not been achieved. 
However, the high incidence (>90%) of HPV infection in VIN found both in this 
work and by others (van Beurden et al, 1995; van Beurden et al, 1998a) may 
indicate that such differences are unlikely to be of clinical relevance and it may 
therefore be more productive to focus future efforts on defining different 
clinico-pathological subgroups within the cohort of patients with HPV-positive
229
Conclusions and future directions
VIN. Rather than m aking the absolute division between HPV-positive and 
HPV-negative cases, it may be more informative to consider viral load as 
assessed by real-time PCR. Indeed, for cervical disease, viral load has been 
proposed as a predictor for the developm ent of future HSIL (Josefsson et al., 
2000; Ylitalo et ah, 2000) and copy num ber of HPV 16 DNA and RNA may 
correlate directly w ith the grade of SIL as assessed by cervical cytology (Wang- 
Johanning et ah, 2002). The detection of m ultiple HPV infections was limited by 
the typing methodology chosen (section 1.1.4.1.1). However, in keeping with 
the findings of others, there was a preponderance of HPV 16 infection in cases 
of VIN (~94%; section 3.3.1). This is a HR-HPV type with a proven role in the 
development of carcinoma of the cervix (Bosch et ah, 2002). The strong 
association between VIN and HR-HPV provides a plausible mechanism for 
oncogenesis in the vulva and lends support to those who, like the author, feel 
that VIN is a potentially pre-m alignant condition (section 1.1.3). The data are 
not however strong enough to claim a causal relationship between HPV and 
vulval neoplasia.
6.2 VIN is associated with transcriptionally active HR-HPV
RNA ISH using digoxigenin-labelled riboprobes was successfully used to 
demonstrate transcriptionally active HPV 16 in VIN lesions as well as both 
vulval SCC and histologically 'norm al' vulval skin (section 3.3.3). The pattern of 
viral gene transcription did  not allow the selection of a potentially high-risk 
group of patients w ith VIN and this aim was not therefore acheived. Specimens 
tended to be either 'positive' or 'negative' for most of the transcripts studied. 
The various methodological issues that may explain this finding have been 
discussed at length in Chapter 3. The use of more sensitive methods such as 
radio-labelled riboprobes or tyram ide signal amplification for future studies 
may allow differentiation between sub-groups of VIN lesions in terms of 
differentiating patterns of viral transcription.
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6.3 Viral integration appears to occur early in the development 
of HPV-related vulval malignancy
Transcriptionally active HPV was dem onstrated in histologically normal vulval 
skin before the onset of dysplasia. HPV may therefore be im portant in vulval 
oncogenesis at an early stage. The effects of cellular factors and host responses 
on viral transcription m ay be crucial in the containment of such infections. Viral 
integration has been proposed as a m ethod by which HPV transcription may 
become de-regulated. Following integraton, the resultant preponderance of 
transcripts from the high-risk ORFs increases the capacity of the HPV to 
produce immortalisation and malignancy (Schwarz et al., 1985; Cripe et ah, 1987; 
Romanczuk et al., 1992). Integration, as represented by the loss of the E2 signal 
at PCR, was dem onstrated in approxim ately half the HPV-positive VIN 
samples studied (section 3.3.1). The limitations of this methodology to assess 
integration have been described in Chapter 3 and it is likely that this method 
will underestim ate the true extent of viral integration in VIN. It w ould appear 
that, like viral transcription, HPV integration occurs at an early rather than late 
stage in the developm ent of HPV-related vulval malignancy. This hypothesis 
would be in keeping w ith recent in vitro work using the W12 cell line, in which 
viral integration was show n to precede the development of high-level 
chromosomal instability (Pett et a l, 2004). Given the relatively high frequency of 
HPV integration in VIN lesions, the detection of integrants may prove to be of 
limited value in the defining subsets of VIN at particular risk of progression to 
carcinoma. The use of techniques such as APOT (Klaes et al, 1999) to detect 
transcriptionally active integrants, m ight be of more prognostic significance 
than simply dem onstrating viral integration within a specimen.
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6.4 Chromosomal alterations in VIN occur in a non-random 
fashion and the nature of CNIs observed may contribute to 
the progression of intra-epithelial iesions
The consequence of HR-HPV infection w ith viral transcription and integration 
would appear to be the production of an environment that favours the 
acquisition of genetic damage. W hilst a limited num ber of abnormalities were 
seen in low-grade disease, the use of CGH to screen VIN biopsies has revealed 
high-grade VIN (VIN 2-3) to be a genetically unstable lesion, w ith CNIs 
commonplace (section 4.3). There is m uch uncertainty regarding the diagnosis 
and clinical significance of low-grade VIN. Certainly, where CNIs are 
concerned, this thesis provides a genetic basis upon which to consider moving 
from a three-tier to a two-tier classification system (section 4.3.3.4), especially 
with the im provements in pathological classification that such a system affords 
(Preti et al., 2000). Of the few abnormalities seen in low-grade lesions, gain of 
the telomeric end of lp  m ay confer a selection advantage that assists the 
progression to high-grade VIN. The nature of the common CNIs observed 
within the high-grade VIN lesions was comparable to those seen in high-grade 
CIN (section 4.3.3.1). In particular, several gains that have been proposed as 
potential m arkers of invasive potential in cervical neoplasia were also 
demonstrated in a subset of high-grade VINs. Gain of 3q was seen in eight 
individuals w ith high-grade VIN and associated w ith loss of 3p suggestive of 
isochromosome form ation in five cases. CNIs affecting this region are thought 
to be of particular relevance in the formation of HPV-positive SCCs of the 
genital tract (section 4.4). Interestingly, two of the subjects in whom  gain of 3q 
was dem onstrated w ithin an area of VIN had associated invasive lesions. The 
implications of the high-level gain of 5p found in one case of high-grade VIN 
have been discussed and the localised region of CN gain affecting l l q  lends 
support to the possible role of oncogenes such as CCND1 and EMS1 in vulval 
oncogenesis (section 4.4).
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The pattern of CNIs detected by CGH suggests that the acquisition of CNIs 
affecting chromosome 8 m ay provide a selection advantage that facilitates the 
progression of high-grade VIN lesions to SCCs. Whilst loss of 8p and gain of 8q 
were significantly more common in SCC, both were present in high-grade VIN 
lesions. The two cases exhibiting CN loss on 8p (study no's 271 and 283) were 
both thought to be at particular risk of progression, one patient being 
immunocompromised following a renal transplant and the other because there 
was an invasive lesion adjacent to the area of VIN 3. CGH data from the cervix 
have also dem onstrated CN loss in this region for both SCCs (Heselmeyer et al., 
1997b) and high-grade CIN (Kirchhoff et al., 2001). Analysis of oral SCCs 
suggests that the region contains at least two TSGs (Partridge et al., 1999).
The CNIs highlighted by this extensive CGH study of VIN should ideally be 
confirmed by interphase FISH. Microsatellite m arkers may be used to localise 
more precisely potential candidate TSGs. The functional consequence of the 
CNIs identified could be established by expression profiling. High throughput 
techniques such as the use of array technology could facilitate this future work.
6.5 The induction of CM I in individuals with VIN is both 
desirable and feasible
Progression from high-grade VIN 3 to invasive SCC is not inevitable, despite 
the frequent finding of oncogenic HPV infection and marked CNIs. It is likely 
that the host response to virally infected, dysplastic cells is crucial for disease 
containment. HLA polym orphism  has been repeatedly linked with either 
increased or decreased susceptibility to cervical neoplasia (section 1.2.2.4). We 
have recently dem onstrated similar associations with HLA polymorphisms in 
VIN (Davidson et a l, 2003b). However, individuals are not reliant solely on 
innate imm unity. The fact that high-grade VIN is associated w ith a high 
frequency of transcriptionally active HPV 16 infection (Haefner et al, 1995; 
H ording et al., 1995; van Beurden et al., 1995; Madeleine et al, 1997; van Beurden 
et a l, 1998b) provides a welcome opportunity to influence the natural history of 
the disease w ith immunotherapy. In the current work HPV was isolated from
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95% of cases of VIN. Effective prophylactic vaccination against HPV infection 
by the induction of HPV-specific antibodies is already a reality (Koutsky et al., 
2002). The limited num ber of HPV types implicated in VIN w ould make the 
choice of viral epitopes for such a vaccine m uch easier than for cervical 
neoplasia. A prophylactic vaccine that induced effective sero-immunity against 
HPV 16 alone could prevent at least 85% of cases of HPV-related VIN (Haefner 
et al., 1995; H ording et al., 1995; van Beurden et al., 1995; van Beurden et al., 
1998a; Rosenthal et al., 2001). By increasing coverage with a m ultivalent vaccine 
effective against types 16, 18, 31 and 33 almost all cases of HPV-related VIN 
could theoretically be prevented. The majority of infections are acquired 
sexually, providing a w indow  of opportunity for vaccination in childhood, 
before the onset of sexual activity. However, the vaccination of children is 
already an area of m uch controversy and there are practical, moral and ethical 
concerns about mass vaccination for a "sexually-transmitted7 disease in this age 
group. Furthermore, vertical transmission of high-risk genital HPV types does 
occur (Rice et al., 1999; Rice et al., 2000; Smith et al., 2004) and this research has 
dem onstrated infection w ith other HPV-types such as the intermediate-risk 
type 56. Therefore, prophylactic vaccination is unlikely to provide effective 
prevention against VIN in all individuals and patients will still present with 
established disease. W hilst seroconversion alone in this group is unlikely to 
cause complete disease regression, there may still be some advantage in 
inducing sero-immunity in wom en with pre-existing HPV infection. It is 
possible that the induction of mucosal antibodies may limit the spread of HPV 
to more susceptible areas of the lower genital tract e.g. the transformation zone. 
In addition, vaccination to induce hum oral immunity may help to limit cross­
infection betw een sexual partners.
The increased risk of disease progression and high incidence of multicentric 
disease in im m unocomprom ised individuals (Leckie et al., 1977; Conley et al., 
2002) w ould support the role of the host cellular immune response in limiting 
the effects HPV-related genital intraepithelial neoplasia. The work presented in 
this thesis demonstrates that vaccination of women with high-grade VIN using
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a recombinant vaccinia vaccine expressing HR-HPV E6 and E7 is both practical 
and safe. Environmental containm ent of the genetically modified vaccinia was 
achieved w ith a simple bio-occlusive dressing. No serious adverse events were 
recorded and the local reaction to vaccination only limited activity in two of the 
twelve patients vaccinated (section 5.3.2).
6.6 The induction of cellular immune responses to non- 
structural HPV 16 proteins was associated with clinical 
disease regression
Following vaccination w ith TA-HPV, there was no effect on viral transcription 
as assessed by mRNA ISH. However, a num ber of the subjects showed a partial 
clinical response, w ith one individual undergoing complete regression of her 
longstanding intraepithelial disease. The limitations in the sensitivity of the ISH 
methodology used have been highlighted previously. A quantitative 
assessment of viral copy num ber e.g. using real-time PCR technology may 
demonstrate differences in viral load (either DNA or RNA) following 
vaccination. In a similar trial, DNA copy num ber was reduced in 12/18 patients 
with VIN following vaccination w ith TA-HPV although no correlation between 
this reduction and disease regression was demonstrated (Davidson et al., 
2003a).
The current work is one of the first studies to demonstrate that the development 
of CMI to non-structural HPV proteins can be associated w ith disease 
regression and this hypothesis can therefore be accepted (sections 5.3.3 and 
5.3.4). The findings have been reproduced by other investigators (Davidson et 
al, 2003a). Previous studies have focussed on individuals with advanced stage 
carcinoma. Such patients commonly have deletions and mutations affecting 
genes involved w ith antigen processing and presentation (Brady et al, 2000; 
Evans et a l, 2001) providing a potential mechanism for viral immune evasion. A 
potential therapeutic effect in earlier stage disease may therefore be missed by 
such studies. Despite evidence from animal models suggesting that HR-HPV 
E6 and E7 provoke weak natural immune responses (reviewed by Frazer, 2004),
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these oncoproteins rem ain an attractive target for therapeutic vaccination in 
humans. Both these ORFs are consistently preserved following integration, 
itself a key step in oncogenesis and their transcription may be enhanced by this 
process (section 1.2.1.5). Certainly, integration appears to be a frequent and 
often early event in VIN and the choice of vaccination target w ould have to 
reflect this finding. In addition, naturally occurring immunity to the HR-HPV 
oncoproteins does occur and m ay confer protection against genital carcinoma. 
T-helper responses to HPV E6 are found in large num bers of healthy 
individuals (Welters et al., 2003) and are frequently absent or defective in 
cervical cancer patients (de Jong et a l, 2002). Delayed-type hypersensitivity to 
HPV 16 E7 is associated w ith clinical and cytological regression of HPV-related 
CIN (Hopfl et al., 2000). The present w ork confirms that immune responses can 
be induced to HPV 16 E6 and E7 and importantly, that vaccination may be 
therapeutic. However, the goal of an effective therapeutic vaccine for HR-HPV 
is still some way off. Most studies have concentrated on the detection of an 
immune response in the peripheral circulation. Although a response at this site 
is of interest, from a biological viewpoint, the response at the tum our site is 
certainly m ore relevant. The limited data available suggest that the frequency of 
induced CTLs is higher in the local tissues and loco-regional lym ph nodes 
(Evans et al, 1997). Such tissue specificity may well be determined early on at 
the time of antigen presentation (Mora et al, 2003) and the route of vaccine 
delivery is therefore of param ount importance. The problem of achieving tissue 
specificity other than by local adm inistration will need to be overcome. The use 
of topical im m unom odulators such as Imiquimod could assist in the 
recruitm ent of systemic, vaccine-induced CTLs to the tumour site.
Com bination vaccinations could potentially enhance the generation of HPV- 
specific CTL responses. We have recently participated in a trial of heterologous 
prime-boost im m unisation strategy. Pre-clinical studies suggested that the use 
of peptide-prim ing w ith a fusion protein (HPV 16 L2E6E7) followed by 
boosting w ith TA-HPV (recombinant vaccinia virus encoding HPV 16/18 E6 
and E7) was superior to the use of either agent in isolation (van der Burg et al.,
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2001a). However, whilst this regime induced CMI, the advantages seen in 
animal models were not replicated in hum ans and no clear relationship 
between the induction of im m unity and clinical outcome was dem onstrated 
(Smyth et al., 2004). Ensuring effective antigen presentation by delivering 
peptides packaged in antigen-presenting dendritic cells may overcome some of 
the m ethods of immune escape that are evident in HPV-related genital 
neoplasia. Whilst efforts are focussing on producing ever-greater levels of T-cell 
responses, the nature of the induced response is crucial. Multiple dose regimens 
and adjuvants have been used to produce enhanced CMI in peptide 
vaccination. However, the responses generated tend to favour the developm ent 
of a Th2 rather than the desired CTL T hl response (for review see Frazer, 2004). 
HPV appears well placed to avoid the host immune response by a combination 
of stealth and immune evasion. Choosing both the route of vaccination and 
ensuring that antigen presentation occurs w ith the correct sequence of events 
will be pivotal to generating effective responses at the tum our site.
6.7 Implications for clinical care and future clinical trials
The strong association w ith transcriptionally active HR-HPV types and the 
genetically unstable nature of the lesions studied suggests that VIN has the 
potential to progress to carcinoma. Although limited data exist regarding the 
natural history of untreated VIN lesions, these observations would suggest that 
caution is required w hen conservative m anagement protocols are adopted and 
w hen new  unproven treatm ents are introduced. During clinical trials, it would 
seem prudent to include variables such as HPV status and CNIs in the 
evaluation of therapeutic effect.
The use of CGH to study vulval neoplasia has demonstrated frequent CNIs, 
m any of which are similar to those found in CIN. The marked difference in the 
pattern and frequency of CNIs between low- and high-grade VIN lesions would 
favour the adoption of a two tier classification system, analgous to the Bethseda 
system currently in use for cervical pre-malignancy (Solomon et al., 2002). Such 
a system w ould appear biologically plausible and might well help to minimise
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differences between studies that are currently attributable to variance in 
pathological interpretation (Preti et al., 2000). The similarities dem onstrated 
between VIN and CIN suggest that novel therapeutic options defined for VIN 
are likely to be applicable to cervical disease. Vaccination would appear to be 
safe and practical and the dem onstration of a therapeutic effect in association 
w ith the induction of HPV-specific CMI is extremely encouraging to those who 
are trying to find effective new  therapies for HPV-related AGIN. Several 
potential strategies to im prove these responses have been highlighted in the 
previous section. Small phase II studies are invaluable in the early phase of 
vaccine development. However, the relative infrequency of VIN means that 
only multicentre studies are likely to generate data of sufficient pow er to guide 
clinicians in their management. It is hoped that by co-operation between 
investigators in this field, m ore rapid  progress in the understanding and 
treatm ent of this challenging condition will be made.
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